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Abstract 
Genome-scale ordered RNA structure (GORS) was first identified in 2004.  It 
refers to the presence of secondary structure throug out the length of the RNA 
genomes of certain genera of RNA virus families, as predicted by bioinformatic 
analysis.  It was also observed that the viruses containing GORS were able to 
establish persistent infections in their natural hosts, raising the possibility that 
the presence of GORS could play a role in viral avoidance of the innate immune 
system. 
 
This thesis describes the first study of GORS and its possible role in persistence.  
Two GORS viruses have been studied, equine rhinitis A virus (ERAV) and 
murine norovirus (MNV).  A 55% seroprevalence of ERAV has been 
determined in a cohort of Scottish horses indicating a wide exposure to the 
virus.  Equine faecal samples were screened for ERAV by PCR with the 
intention of identifying a virus, possibly from a persistently infected animal, 
which would not have undergone any cell culture adaptations as laboratory 
strains have.  Newly identified viruses would then b  sequenced, their secondary 
structures predicted and further studies carried out.  Unfortunately, none of the 
50 faecal samples screened were positive and clinical isolates of ERAV 
provided by the Animal Health Trust were sequenced but were identical to 
laboratory strains, so the study then focussed on MNV.  Prevalence of MNV in 
laboratory mice was determined by PCR of faecal samples to be 67%.  MNV 
was also discovered in the faeces of a pet shop mouse and a wild wood mouse 
(Apodemus sylvaticus).  The complete genomes of 4 laboratory mouse MNVs, 
the pet shop mouse and wood mouse MNVs were sequenced.  Phylogenetic 
analysis showed the wood mouse MNV had a p distance of 23% from other 
MNVs, although the laboratory mice and pet shop mouse were closely related to 
other MNVs.  Structural analysis of the genomes of 6 sequenced MNVs, 
including the wood mouse virus, showed all were GORS viruses.  A laboratory 
strain of MNV, MNV-3, was serially passaged in RAW 264.7 cells to test the 
hypothesis that in an animal with an intact immune system, there is a pressure 
for GORS viruses to maintain their genomic RNA structure as a means of 
immune avoidance, and that cell culture adaptation w uld attenuate the degree 
of secondary structure.  The complete genome of passage 33 was sequenced, 
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which revealed 7 base mutations, a mutation rate of 0.1 %, which was not 
considered significant enough to have affected the degree of secondary 
structure. 
 
In order to assess if structured and unstructured RNA behaved differently in 
cells, replication deficient RNA transcripts were made from the infectious 
clones of a panel of GORS and non-GORS viruses.  These transcripts were 
electroporated into cells and their rate of decay measured, but there was no 
difference between the GORS and non-GORS transcript.  The full length and 4 
kilobase transcripts were transfected into NIH3T3 cells and the degree of 
interferon-β induction measured by quantitative PCR and a luciferase reporter 
assay.  The IFN-β response differed across the panel of viruses, and although 
none of the GORS viruses induced strongly, the non-GORS viruses were 
variable in their ability to induce an IFN-β response, some inducing strongly, 
other not at all.  This result indicates that during exposure of viral genomes in 
the cytoplasm during infection, GORS-virus RNAs areunlikely to induce an 
interferon response, possibly contributing to their ability to persist.  It is unclear 
why some non-GORS-viruses failed to induce IFN and there are likely to be 
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Chapter 1 General introduction 
 
Genome-scale ordered RNA structure (GORS) is a phenom on first described 
by Simmonds et al. in 2004.  Using bioinformatic analysis of viral RNA 
genomes, based on energy minimising algorithms, regions of secondary 
structure were predicted.  The term “GORS” describes the occurrence of 
extensive RNA formation throughout the length of the RNA genomes in many 
families and genera of positive-sense RNA virus families.  While the high 
degree of structure in these genomes appeared to be unrelated to fundamental 
function in viral replication, there was an observed association between the 
presence of GORS and the ability of the virus to establish persistent infections.  
This thesis presents the first investigation of the biological effect of GORS by 
studying aspects of the biology of predicted GORS viruses and the interactions 
between structured and unstructured viral RNA with cells. 
 
1.1 Caliciviridae 
The Caliciviridae are a family of non-enveloped, single-stranded, positive-sense 
RNA viruses.  Members of this family cause a range of human and veterinary 
diseases.  There are four genera within the family, each named after a typical 
member of the genus (Green t al., 2000); the four genera are:  
 
i)  Vesivirus  e.g. Vesicular exanthema of swine virus, Feline calicivirus 
ii) Lagovirus e.g. European brown hare syndrome virus, Rabbit haemorrhagic 
disease virus 
iii) Norovirus e.g. Norwalk virus, Murine norovirus 
iv) Sapovirus e.g. Sapporo virus 
 
Recent studies have proposed two new genera; bovine enteric virus has been 
assigned to a genus with the proposed names of Bec virus or Nabovirus (Oliver 
et al., 2006); and the Tulane virus, isolate from rhesus macaques, to a genus 




Figure 1.1  Phylogenetic trees showing calicivirus genera based on sequences alignments of: A – 
NTPase; B – polymerase; C- VP1.  The most recently designated genera, Becovirus and 
Recovirus included.  Reproduced from Farkas et al., 2008. 
 
The calicivirus virion is a small (27 - 40 nm) particle.  The name calicivirus is 
derived from the appearance of the 32 cup-shaped depressions on the surface, 
the Latin word “calyx” providing the root.  The Caliciviridae family contains a 
number of important veterinary and medical pathogens.  Feline calicivirus 
(FCV) is an important pathogen of cats, causing an upper respiratory tract 
infection with stomatitis.  Rabbit haemorrhagic disea e virus (RHDV), as the 
name suggests, causes a haemorrhagic disease in rabb ts.  Human noroviruses 
cause acute gastroenteritis and are discussed in more detail below.  The genera 
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of Caliciviridae share similar virion structures, genome arrangements and 






1.2.1 History of noroviruses 
The genus Norovirus took its name from the first discovered member of the
genus, Norwalk virus, which cause acute gastroenteritis in humans.  Before the 
discovery of the virus, episodes of acute non-bacterial gastroenteritis were 
known as “winter vomiting disease”, first described by Zahorsky in 1929.  
Throughout the 1940s and 1950s volunteer studies in the United States and 
Japan demonstrated that the disease was transmissible after administration of 
bacteria-free faecal suspensions (Reimann et al., 1945; Jordan et al., 1953; 
Fukumi et al., 1957) indicating a viral aetiology.  An outbreak of gastroenteritis 
in Norwalk, Ohio in 1968 at school affected 50 % of the pupils and teachers 
(116 / 232).  The disease had an incubation period of ~48 h and the clinical 
course lasted ~24 h.  The clinical signs of the disease were acute nausea, 
vomiting, diarrhoea and abdominal cramps.  This wasdescribed as an outbreak 
of winter vomiting disease due to its similarity to the disease described in 1929 
(Adler and Zickl, 1969).  The aetiological agent was identified by the discovery 
of a 27 nm particle, by immune electron microscopy, in the faecal filtrate of one 
of the case from the Norwalk school outbreak (Kapikian et al., 1972).  This was 
the discovery of Norwalk virus, which became the prototype member of the 
genus now known as Norovirus. 
 
1.2.2 Norovirus classification 
 
The classification of noroviruses has been determined predominantly by genetic 
analysis as, until the discovery of a cell culture system for murine norovirus 
(MNV), propagation of noroviruses in cell culture had not been possible.  
Phylogenetic analysis of the sequence of norovirus VP1 sequence divided the 
genus into five genogroups: genogroups I, II and IV contain human noroviruses, 
genogroup III contains bovine noroviruses and genogroup V contains MNV.  
Genogroup II also contains porcine noroviruses (Figure 1.1).  The genogroups 
are also divided into genotypes, also known as phylogenetic clusters (Green et 
al., 1999; Ando et al., 2000; Vinje et al., 2000; Zheng et al., 2006).   Human 
noroviruses diverge by up to 45 % at the nucleotide lev l (Zheng et al., 2006) 
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and MNVs diverge by up to 13 % at the nucleotide level that comprise a single 
genotype and genogroup (Thackray et al., 2007).  The diversity of noroviruses 
may in part be due to the fact that the RNA-dependent RNA polymerases of 
RNA viruses have no proofreading function.  It has al o been shown that 
recombination events at the overlap between ORF1 and ORF2 of MNV also 
lead to the genetic diversity of noroviruses (Worobey and Holmes, 1999; 





















































































































































Figure 1.2:  Phylogenetic tree of norovirus genus showing classification into 5 genogroups based 
on complete capsid protein (VP1) sequences.  Genogroup I contains human viruses; genogroup 













1.2.3 Norovirus virion structure 
The norovirus virion has a diameter of ~38 nm, and exhibits T=3 icosahedral 
symmetry made up of 90 dimers of the capsid protein.  The capsid structure 
contains arch-like capsomeres, creating large hollows at the icosahedral 5- and 
3-fold axes (Prasad et al., 1994; Prasad et al., 1999).  The capsid protein (VP1) 
self-assembles into virus-like particles which resemble native capsids in both 
appearance and size (Jiang et al., 1992).  The structure of this protein is 
modular, consisting of the lower shell domain (S) and protruding domain (P) 
connected by a flexible hinge.  The protruding domain is then split further into 
the central stem domain (P1) and distal globular domain (P2).  It is the 
protruding domains that make up the arch-like structures, with the S domain 
acting as an icosahedral scaffold (Chen et al., 2006).  Katpally et al showed that 
the protruding domain is lifted off the shell by ~16Ǻ and rotated in a clockwise 
direction by 40°, forming new interactions at the base of P1, creating a cage-like 
structure that engulf the shell domains (Katpally et al., 2008).  The amino acid 
sequence of the S domain is relatively conserved throughout the noroviruses, 
whereas the P2 domain is the most variable, indicating its role in receptor 
binding and antigenicity (Prasad et al., 1999; Nilsson et al., 2003; Tan et al., 
2003). 
 
1.2.4 Norovirus genome structure 
Norovirus has an RNA genome of ~7.5 kilobases, the genome is a positive-
sense, single-stranded RNA molecule.  The genome contains 3 well-defined 
open reading frames (ORF), and a fourth of uncertain function has recently been 
postulated in MNV, but not in human, bovine or porcine noroviruses (Thackray 
et al.2007),.  The 5’ end of the genome is covalently bound to a viral protein 
called the VPg protein.  ORF1 encodes a large polypr tein which is 
subsequently cleaved by viral proteases into the non-structural (NS) proteins 
(Liu et al., 1996; Blakeney et al., 2003; Sosnovtsev et al., 2006).  ORF2 encodes 
the major capsid protein, also known as the viral potein VP1 which makes up 
the S and P domains (Jiang et al., 1990; Prasad et al., 1999).  ORF3 encodes the 
small basic protein, VP2, which appears to have a role in the stability of the 
virion (Bertolotti-Ciarlet et al., 2003; Glass et al., 2000).  ORF 2 and 3 are 
thought to be encoded by a sub-genomic RNA.  There is also a 3’ untranslated 
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region in noroviruses, consisting of a stem loop of 47 nucleotides and a poly(A) 





Figure 1.3: Genome of MNV showing ORF1, the sub-genomic ORF2 and ORF3 
with putative ORF4 and proteins encoded.  Taken from Thackray et al., 2007. 
 
 
1.2.5 Norovirus attachment and cell entry 
Noroviruses are usually transmitted orally, and the virions are acid-stable which 
enables them to pass through the stomach and cause enteritis in humans.  
Human noroviruses have been shown to bind histo-blod group antigens and to 
carbohydrate antigens in the gut, specifically Lewis type antigens (Hutson et al., 
2003).  The part of the capsid that interacts with the cellular receptor has also 
been shown to be the hyper variable P2 domain (Lochridge et al., 2005).  
Recently it has been reported that the receptor for MNV has been identified as 
ganglioside-linked terminal sialic acid moieties on murine macrophages (Taube 
et al., 2009).  After attachment of the virus and entry into cells the genome must 
be uncoated.  Bhella et al showed that the capsid of feline calicivirus (FCV) (a 
member of the genus Vesivirus of the family Caliciviridae) underwent a 
conformational change induced by binding to its cellular receptor (Bhella et al., 
2008).  FCV, however, has also been shown to enter cells by clathrin-mediated 
mechanism in acidified endosomes (Stuart and Brown, 2006), whereas MNV 
entry into permissive macrophages and dendritic cells is pH independent (Perry 




1.2.6 Calicivirus / Norovirus replication 
As noroviruses have proven difficult to grow in cell culture until the recent 
success in growing MNV in RAW264.7 cells, much of what is known about 
calicivirus replication has come from work on FCV.  This section will discuss 
calicivirus replication based on work on FCV and MNV.  As single-stranded, 
positive-sense RNA viruses, calicivirus RNA acts as a messenger RNA when 
released into cells.  The RNA is translated by using the cellular machinery for 
the creation of progeny virus particles which are th n released from the cell.  
Unlike other families of RNA viruses, viruses of the family Caliciviridae have 
neither a long 5’ UTR, with highly structured regions such as internal ribosome 
entry sites (IRES), nor a 5’ 7-methylguanosine cap with which to interact with 
host ribosomes.  The VPg protein at the 5’ end of the genome has been shown to 
bind to translation initiation factors in infection by Norwalk virus 
(Daughenbaugh et al., 2003) FCV (Goodfellow et al., 2005; Chaudhry et al., 
2006) and MNV (Daughenbaugh et al., 2006).  MNV1 VPg, for example, was 
co-precipitated with eIF4GI and eIF4E from infected murine macrophages 
(Daughenbaugh et al., 2006).  Translation of the genome produces a large 
polyprotein.  This protein then undergoes proteolytic cleavage by a virus-
encoded protein called 3C-like proteinase (3CL Pro), this process produces the 
non-structural proteins.  In the MNV polyprotein there are five cleavage sites in 
the ORF1 protein: 341E/G342, 705Q/N706, 870E/G871, 994E/A995 and 117Q/G1178.  
These cleavages produce six mature non-structural proteins: NS1-2 (Nterm), 
NS3 (NTPase), NS4 (3A-like), NS5 (VPg), NS6 (Pro) and NS7 (Pol) 
(Sosnovtsev et al., 2006). 
 
 
Figure 1.4: Diagram of MNV polyprotein including cleavage sites and non-
structural proteins of ORF1.  Taken from Sosnovtsev et al., 2006. 
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RNA replication then occurs by the action of the RNA-dependent RNA 
polymerase.  This takes place from the polyadenylated tail of the 3’ end of the 
genome which creates a negative-sense strand of RNA, the reverse complement 
of the genomic RNA.  In cells infected with FCV it has been shown that there 
are two double-stranded RNA molecules corresponding to the genomic (8.2 kb) 
and sub-genomic (2.4 kb) RNAs.  The negative strands then act as a template for 
the production of progeny genomic RNAs (Neill and Mengeling, 1988).  FCV 
viral RNA replication is associated with host cell membranes (Green et al., 
2002).  The positive-strand subgenomic RNA then acts s a template for the 
translation of ORF2 and ORF3, producing the major capsid protein VP1, and the 
small basic protein VP2.  As noted above, the capsid roteins undergo self-
assembly very readily to produce virus-like particles, giving an indication to 
how the virus particles assemble.  The packaging signal for norovirus RNA may 
be found in the non-structural region of the genome, or that the non-structural 
proteins, or even VPg, may be necessary for packaging of RNA (Asanka et al., 
2005).  Recent work has revealed that MNV-1 replication is associated with 
cellular membranes similar to many other RNA viruses; MNV-1 replication 
complexes have been identified in a perinuclear locati n involving membranes 
derived from the endoplasmic reticulum, Golgi and endosome (Hyde et al., 
2009).  It has been suggested that caliciviruses induce cells to undergo apoptosis 
as a means of releasing progeny virus.  Another featur  of MNV-1 infection of 
RAW264.7 cells, is that it is able to inhibit the expression of the antiapoptotic 
protein survivin, and that there was an increase in l vels of caspase-3, a factor 
involved in the execution of cellular disassembly.  Changes were also noted in 
the nuclear chromatin and DNA fragmentation, other ma kers of apoptosis (Bok 
et al., 2009).  These observations support the theory that noroviruses are able to 
use apoptosis as a mechanism for virus release. 
 
1.2.7 Norovirus infections of humans 
Norovirus infections in humans affect people of all ages (Rockx et al., 2002) 
and can occur all year round, but there is a cold weather peak in incidence 
(Mounts et al., 2000).  The illness in humans is generally a mild, acute onset 
gastroenteritis characterised by nausea, vomiting, diarrhoea and abdominal 
cramps.  Vomiting is the predominant clinical sign n children over 1 year old, 
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and diarrhoea is the main feature in children under 1 year and adults (Kaplan et 
al., 1982).   The cause of the clinical disease typically l sts 2-3 days, although 
this may be longer during hospital outbreaks (Lopman et al., 2004).  
Transmission is by the faecal-oral route, by aerosolisation of viral particles from 
infectious vomit or person-to-person contact.  These routes of transmission 
enable the rapid spread of norovirus during outbreaks in enclosed environments 
such as hospitals, schools and cruise ships (Widdowson et al., 2005; Becker et 
al., 2000; Gunn et al., 1980).  Outbreaks usually begin after exposure to 
contaminated food or water (Kaplan et al., 1982b).  Spread of the virus is made 
easier by the fact that it has a very low infectious dose, and the probability of 
infection of a single Norwalk virus particle estimated to be close to 0.5 (Teunis 
et al., 2008), the prolonged viral shedding after resoluti n of clinical signs and 
the stability of the viral particle in high concentrations of chlorine (Duizer et al., 
2004).  Immunity to norovirus has been demonstrated in volunteer studies, but it 
is short-lived (6-12 weeks), and subjects were susceptible to infections when 
challenged 2-3 years later (Parrino, et al., 1977).  Susceptibility to norovirus 
infection is determined by the presence of specific human histo-blood group 
antigen (HBGA) receptors.  These are present in the gut which is the presumed 
site of virus replication (Lindesmith et al., 2003; Hutson et al., 2004). 
 
1.2.8 Noroviruses in animals 
Since their recognition as significant human pathogens, noroviruses have also 
been detected in other species, such as cattle, pigs and mice.  Norwalk-like virus 
genes were discovered in the caecal contents of healthy pigs in Japan in 1998.  
There was 58.2 % to 59.9 % similarity between Norwalk virus and those 
detected in the pigs, and the new viruses were placed in the norovirus genogroup 
II (Sugieda et al., 1998).  Small, round viruses were first identified n the UK by 
electron microscopy in calf diarrhoea in 1978 (Woode and Bridger, 1978) and in 
Germany in 1980 (Gunther and Otto, 1987). The German virus, known as Jena 
virus, was sequenced in 1999 and was shown to have a markedly similar 
genome organisation to Norwalk virus, and phylogenetic studies of the RNA 
polymerase sequence placed it with other noroviruses (Liu et al., 1999; van Der 
Poel et al., 2000).  Bovine noroviruses were later classified as genogroup III 
(Liu et al., 1999; Oliver et al., 2003).  Porcine noroviruses appear to cause only 
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sub-clinical infections (Wang et al., 2007) but are relatively prevalent, 17 % - 20 
% (Reuter et al., 2007; Wang et al., 2006).  Porcine noroviruses are often 
monitored due to their genetic relatedness to human noroviruses and potential 
for zoonotic spread (L’Homme t al., 2009).  Bovine noroviruses are associated 
with diarrhoea in gnotobiotic calves (Woode and Bridger, 1978) although their 
impact in the wider cattle population is not clear.  A recent study has shown the 
prevalence in Belgium to be 7.5 % by faecal RT-PCR (Mauroy et al., 2009). 
 
1.2.9 Murine norovirus 
Murine norovirus was first described by Karst et al. in 2003.  It was observed 
that laboratory mice deficient in the recombination-activating gene 2 (RAG2) 
and signal transducer and activator of transcription 1 (STAT1) (RAG/STAT-/- 
mice) would sporadically succumb to an unknown pathogen.  RAG2 plays an 
essential role in the development of T and B lymphoid cells and their diversity 
of cell surface receptors, enabling them to recognise umerous pathogens; thus 
it plays a crucial role in the development of adaptive immunity (reviewed by 
Sobacchi et al., 2006).   These mice were severely immunocompromised and the 
infection would produce meningoencephalitis, cerebral vasculitis and 
pneumonia.  The pathogen was more virulent in mice which were deficient in 
the interferon (IFN) αβ and interferon γ receptors.  The aetiological agent was 
suspected to be viral as it could be passed through a 0.2 µm filter.  Rational 
difference analysis was carried out and the sequences obtained were similar to 
calicivirus genomes (Karst et al., 2003).  The ability of this virus to cause 
disease was then tested in mice which had normal expression of STAT1 but 
were deficient in RAG1 or RAG2.  The mice were inoculated by intracranial, 
intranasal and peroral routes, but 90 days later a significant number of mice had 
not succumbed to the infection.  The RAG-/- mice in fact became persistently 
infected, indicating that T and B cell adaptive immunity was not necessary for 
protection against the lethal disease.  It was hypothesised that the innate immune 
system was primarily responsible for protection against the virus.  Mice with 
various parts of the innate immune system, IFNαβ and IFNγ receptors, protein 
kinase RNA-activated (PKR) or inducible nitric oxide synthetase (iNOS), 
knocked out were challenged again with the virus.  Mice with IFNαβ and IFNγ 
receptors knocked out were 10,000 fold more susceptibl , showing that 
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interferons were essential for resistance (Karst et al., 2003).  Macroscopic 
pathological changes present in the affected RAG/STAT-/- mice included 
splenomegaly and multifocal pale foci on the liver.  Hepatitis ranging in severity 
from mild to severe has been described consisting of focal to diffuse 
inflammatory infiltrates of mononuclear cells and neutrophils.  Focal interstitial 
pneumonia, consisting of macrophages within the alvolar air-spaces and walls, 
was seen in some mice but was usually mild.  Immunohist chemistry against an 
MNV antigen identified infected cells to be those of macrophage or dendritic 
cell type in the liver (Kupffer cells), red pulp ofspleen, intestinal lamina propria 
and mesenteric lymph nodes (Ward et al., 2006).  Infection in 
immunocompetent mice occurs, with MNV-1, which has been shown to 
replicate and disseminate to various parts of the body.  Histological examination 
of normal mice infected with MNV1 has revealed: mild enteritis consisting of 
increased numbers of granulocytes; the spleens showed red pulp hypertrophy 
and white pulp activation at 72 hours post infection.  MNV-1 was shown to be 
present in the spleen, lung, liver and lymph nodes.  The function of STAT1 is to 
inhibit viral replication and thus the prevention of virus-induced apoptosis 
resulting in little spread of the virus, resulting i  the absence of clinical disease 
in immunocompetent mice (Mumphrey t al., 2007; Perdue t al., 2007). 
 
After the discovery of MNV-1, further MNVs were discovered and described.  
In 2006, Hsu et al. described the identification of MNV-2, MNV-3 and MNV-4.  
Immunocompetent mice from geographically separate laboratories in the United 
States were euthanased and their mesenteric lymph nodes (MLN) screened for 
MNV by a multiplex fluorescent assay.  MLN material was inoculated onto 
permissive cells and 3 novel strains of MNV were isolated.  It was also shown 
that these novel strains persisted in mice as MNV was detected in faeces by RT-
PCR for up to 8 weeks post-infection, whereas MNV-1 only produced a 
transient infection which was quickly cleared (Hsu et al., 2006).  Further 
characterisation of the novel MNVs, from comparison of full length nucleotide 
sequences, showed that despite their different biological behaviours they had a 
high degree of sequence homology with MNV-1, but not with human or bovine 
noroviruses (Hsu et al., 2007).  Thackray et al. in 2007 conducted a study into 
MNV diversity by sequencing the complete genome of 21 novel MNVs and 
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compared them to the 5 sequences published at that ime.  They discovered 15 
distinct strains of MNV, with up to 13 % divergence at the nucleotide level.  
These 15 strains, however, made up a single genogroup, genotype and serotype; 
there was also evidence of recombination within ORF2 in several of the MNV 
genomes (Thackray et al., 2007).  The study of MNV, and of noroviruses in 
general, was made easier with the development of a cell culture system which 
could support the growth of MNV.  Efforts had been made to cultivate human 
noroviruses in the laboratory but were unsuccessful (D izer et al., 2004).  The 
observation that MNV had been identified in the macrophage/dendritic cells in 
the liver, spleen and small intestine lead to the att mpt to grow MNV in this cell 
type.  Bone marrow derived macrophages and bone marrow derived dendritic 
cells were inoculated with MNV-1 stock, derived from the brains of the mice 
that had originally lead to the discovery of MNV (Karst et al., 2003).  MNV-1 
had a marked tropism for both cell types as infection produced cytopathic effect 
in both.  The cell line RAW 264.7, a macrophage cell line transformed by 
Abelson leukaemia virus (Raschke et al., 1978), was found to support MNV 
replication with visible CPE and plaque formation (Wobus et al., 2004).  This 
cell line has since become the standard means of growing MNV in laboratories.  
A further advance in the study of noroviruses has been the development of 
reverse genetics system for MNV.  In 2007, Ward et al described the recovery 
of infectious MNV after the baculovirus delivery ofMNV cDNA into human 
hepatoma cells using an inducible DNA polymerase promoter (Ward et al., 
2007).  Chaudhry et al. also demonstrated the recovery of genetically defined 
MNV using the fowlpox virus T7 RNA polymerase system (Chaudhry et al., 
2007).  The ability to manipulate the MNV genome in future will surely reveal a 
great deal about norovirus replication and pathogenesis. 
 
1.2.10 Immunity to noroviruses 
The identification of MNV in RAG/STAT-/- mice and subsequent studies lead to 
the conclusion that the innate immune system was primarily responsible for 
protection against fulminate clinical disease associated with MNV infection 
(Karst et al., 2003; Mumphrey et al., 2007).  A functional innate immune system 
does not protect the mice from infection though, as several strains of MNV have 
been shown to infect mice sub-clinically and to persist in immunocompetent 
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hosts (Hsu et al., 2006).  These observations are consistent with the clinical 
course of human norovirus infections i.e. acute onset and short duration.  The 
rapid resolution of the disease suggests that an adptive immune response would 
not have time to have been invoked to play a role in the course of the disease; 
however, adaptive immunity does have a role to play in clearing the norovirus 
infection.  Since MNV-1 infections of RAG-/- mice, which have impaired 
adaptive immunity but unaffected innate immunity, did not succumb to clinical 
disease, but had higher levels of viral RNA in lung, liver, spleen, proximal 
intestine, brain, blood and faeces 90 days after peroral inoculation (Karst et al., 
2003).  The conclusion was that the adaptive immune system is necessary for 
the clearance of MNV. 
 
The innate immune system will be discussed in more detail later in this 
introduction.  Briefly, it consists of the detection of pathogen-associated 
molecular patterns by cellular receptors which lead to the production of type I 
interferons (IFN-αβ).  The pattern recognition receptors (PRR) that initiate the 
response to viruses include: toll-like receptor 3 (TLR3) and the Rig-I-like 
helicases, RIG-I and MDA-5 (Takeuchi and Akira, 2007).  IFN-αβ then acts in a 
paracrine fashion, binding to its cellular receptors and act via the JAK-STAT 
pathway to upregulate the expression of numerous genes which collectively 
produce the antiviral state.  The antiviral moleculs include: protein kinase R 
(PKR), 2’ 5’oligoadenylate synthetase (OAS) and ISG15 (reviewed by Randall 
and Goodbourn, 2008).  The pathogenicity of MNV-1 in STAT-/- mice 
demonstrates how significant this system is in protecting mice from disease.  As 
MNV has a tropism for cells of the macrophage/dendritic cell lineage, a study 
was conducted by McCartney et al. in 2008 in which bone marrow derived 
dendritic cells (BMDC) from wild-type, TLR3-/- and MDA5-/- mice were 
infected with MNV-1.  They showed that MDA-5 recognises MNV-1 which 
stimulates the production of type I IFN, along with IL-6, MCP-1 and TNFα.  
The MDA-5-/- cells had a severe deficit in IFN production, although MDA-5-/- 
mice were still able to clear MNV-1 infection.  It was concluded that MDA-5 is 
the predominant sensor in BMDCs, but that other sensors may play a role in 
other cell types which are important during infection of an animal.  It was also 
suggested that the 5’ VPg is essential for MDA-5 recognition of MNV-1 
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(McCartney et al., 2008).  Changotra et al have recently elucidated part of the 
mechanism by which the IFN response is able to abrogate MNV infection.  They 
have shown that there is an IFN-mediated blockage to MNV-1 replication after 
virus entry and genome uncoating, but before the translation of the non-
structural polyprotein.  The most likely explanation was considered to be that 
the production or accumulation of the non-structural polyprotein is being 
prevented by an IFN-induced product.  They have also shown that PKR is not a 
requirement for type I IFN-induced block to virion production.  A possible 
mechanism for the IFN antiviral effect is that it affects the association of the 
VPg with the cellular translation machinery, leading to a failure to translate viral 
genomes (Changotra et al., 2009). 
 
Antibodies generated against noroviruses have been shown to recognise epitopes 
on the protruding domain (P2) of the VP1 protein which contain conserved 
amino acids sequences across human, murine, bovine and porcine noroviruses 
(Lochridge et al., 2005).  A single amino acid substitution in the P2 domain of 
MNV was actually sufficient for escape from antibody neutralisation (Lochridge 
et al., 2007).  A recent study in which mice were infected with a high dose of 
MNV-1, followed by a secondary challenge 6 weeks later, revealed that there 
was no protection from a homologous virus (Liu et al., 2009).  Although the 
antibody response did not prevent disease in the rechall nged mice, a memory 
immune response was elicited as the virus was cleared more quickly on the 
second infection.  The reasons for the lack of protection are not clear, although it 
could be due to inappropriate tolerance of the virus or a direct result of the 
infection of antigen presenting cells inhibiting their function (Liu et al., 2009).    
 
Recent studies into the effectiveness of vaccines against MNV have revealed 
more information about the nature of the adaptive immune response.  Chachu et 
al. have recently demonstrated that vaccination by oral administration of live 
MNV-1 virus produced a long lasting immunity, up to 24 weeks post treatment.  
It was demonstrated that for that for vaccination t be effective the presence of 
CD4 T cells, CD8 T cells and B cells were necessary, nd that the MNV VP1 
protein contains epitopes for each cell type.  The molecule perforin, a product of 
CD8 cytotoxic T cells was found to be important in the clearance of the virus 
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(Chachu et al., 2008).  This study was conducted in MNV-1, which s not a 
persistent strain; it is unclear whether this vaccine s effective in persistent 
strains of MNV.  Another recent study by LoBue et al., has shown that 
norovirus-like particles with alphavirus adjuvant particles, when administered to 
mice, produced cross-reactive and receptor-blocking a tibodies, and protection 
against infection with heterologous MNVs (LoBue et al., 2009).   
 
The study of the role of the adaptive immune system in human norovirus 
infections has provided a picture of the nature of the response.  Due to the 
historical difficulty in growing noroviruses in cell culture, human norovirus 
studies have often relied on clinical material from outbreaks or volunteer 
studies.  Acute norovirus gastroenteritis in humans is characterised by an 
infiltration of mononuclear cells into the jejunum, a transient circulating 
lymphopaenia and the presence of serum antibody (Dolin et al., 1975; Dolin et 
al., 1976).  Prevalence of norovirus antibodies in humans has been shown to be 
high in many countries (reviewed by Lopman et al., 2002), e.g. 2,382 of 3,250 
English serum samples (72.3 %) were seropositive (Gray et al., 1993).  
Rechallenge studies to determine if the antibody response was protective against 
future infection produced a picture whereby some people develop a short-term 
immunity to rechallenge with the same agent, whereas others are protected for 
up to 42 months later (Parrino et al., 1977; Blacklow et al., 1979).   
 
The cytokine responses to norovirus infections have be n described in human 
norovirus infections.  A study of a natural outbreak of human norovirus 
demonstrated increased levels of IL-2 and IFN-γ in faecal samples, suggesting a 
Th1 immune response (Ko et al., 2006).  Similarly, a volunteer study with Snow 
Mountain virus, a human norovirus, also stimulated he production IL-2 and 
IFN-γ (Lindesmith et al., 2005).  These cytokine profiles are consistent with the 
observation that the cytotoxic T cell system is important in the clearance of 
MNV-1 (Chachu et al., 2008).  There is still much to learn about the exact 
nature of the adaptive immune response to noroviruses in the way in which 
humoral and cell mediated immunity interact, and how s me strains of MNV are 





1.2.11 Diagnosis of noroviruses 
Early in the history of norovirus diagnosis the most reliable method was to 
administer faecal filtrates to volunteers.  Noroviruses were first identified by the 
use of electron microscopy and immune electron microscopy (Kapikian et al., 
1972).  Other diagnostics test followed in the following years: 
radioimmunoassay (Greenberg and Kapikian, 1978), enzyme immunoassay 
(Herrmann et al., 1985) and Western blot (Hayashie et al., 1989), which 
detected either norovirus antigen or antibody.  With the cloning and sequencing 
of the Norwalk virus genome (Xi et al., 1990; Matsui et al., 1991) molecular 
diagnostic techniques were described.  Noroviruses w re detected in human 
stool samples by PCR (Jian et al., 1992; Moe et al., 1994; Le Guyader et al., 
1996; Atmar et al., 2001; Vinje et al., 2003).  Real-time PCR was developed to 
detect and quantitate Norwalk virus in stools (Richards et al., 2004; Kageyama 
et al., 2003; Pang et al., 2004).  The same diagnostic methods have been 
extensively used to detect the noroviruses of other sp cies  
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1.3 Viruses and innate immunity 
The innate immune system of vertebrates consists of barriers protecting the body 
from microbial attack.  These barriers may be anatomical e.g. the epidermis of 
the skin, or the cilia of the respiratory epithelium or based on secretions e.g. 
mucosal immunity associated with various epithelial linings and gastric acid 
secretions.  The response of the innate immune system against invading 
pathogens is on-specific and often leads to the activation of the complement 
system and acute inflammation.  Cells of the innate immune system include 
dendritic cells and tissue macrophages; these cellsproduce many cytokines, 
including interferons (IFN), are able to present antigens to lymphocytes and in 
so doing link the innate immune system to the adaptive.  In order to respond to 
pathogens, the innate immune system is able to recognise pathogens that have 
invaded the host.  Pathogens are recognised by pathogen associated molecular 
patterns (PAMPs) by cellular pattern recognition receptors (PRRs) (Kindt et al., 
2007).  PAMPs are molecular patterns present in pathogens but are usually 
absent from the host.  It is the recognition of dsRNA, the most important PAMP 
produced during replication of RNA viruses, which will be discussed in relation 
to the relationship between the presence of GORS in viral genomes and the 
ability of those viruses to persist.  This discussion will focus on the IFN-β 
system as the detection of dsRNA leads to the production of IFN-β via PRRs 
such as toll-like receptor -3, RIG-I and MDA5 during viral replication, which 
leads to the establishment of the anti-viral state.  I  has been hypothesised that 
GORS leads to persistence by enabling the avoidance of r cognition of viral 
RNA by the PRRs. 
 
1.3.1 Introduction to interferon system 
Type I interferons (IFN), also known as IFN-αβ, were discovered by Isaacs and 
Lindenmann in 1957.  They are produced in response to viral infection.  Type II 
interferon, IFN-γ is secreted by T cells and natural killer cells (NK cells).  Type 
III IFNs have been recently described and consist of IFN-λ1, -λ2 and λ3 that are 
inducible by viral infection and produce an antiviral state, similar to type I IFN 
(Kotenko et al., 2001); they are also known as IL-29, IL-28A and IL-28B 
(Sheppard et al., 2003).  The production of IFN is stimulated by the recognition 
of pathogen associated molecular patterns (PAMPs) by cellular pattern 
 20 
recognition receptors (PRRs); these receptors activate signal transduction 
pathways resulting in the production of IFNs. There are many molecules 
displayed or produced by pathogenic organisms which are considered to be 
PAMPs, and lead to the induction of IFN.  The IFN then acts through cellular 
receptors, via a signal transduction pathway to induce the transcription of 
numerous IFN-stimulated genes (ISG)s which collectiv ly produce the antiviral 
state.  The ISGs act in a variety of ways to inhibit viral replication and, 
ultimately, prevent disease (Reviewed by Randall and Goodbourn, 2008).  This 
review of the interaction between viruses and IFN-α/β system will pay particular 
attention to RNA viruses (although DNA virus examples of certain features will 
be used where appropriate), describe the detection of viral PAMPs, in particular 
double stranded RNA (dsRNA), the pathways involved in IFN induction and 
transcription of the ISGs, the nature of the antiviral state and various strategies 
employed by RNA viruses to avoid detection and inhibit those cellular 
pathways. 
 
1.3.2 Detection of viral PAMPs 
RNA viruses induce an IFN response, largely by their production of dsRNA.  
Studies on the induction of IFN by synthetic polynucleotide complexes revealed 
polyinosinic polycytidylic acid (poly I:C), a dsRNA homologue, to be a potent 
inducer of IFN (Field et al., 1967).  It was later demonstrated by work on 
defective interfering particles of vesicular stomatitis virus (VSV), in which a 
single molecule of dsRNA was presumed to be formed, that the dsRNA induced 
IFN, whereas conventional particles containing ssRNA did not (Marcus and 
Sekellick, 1977).  This work indicated that dsRNA, which is produced by 
viruses during their replication, was the most important viral inducer of IFN 
(Marcus, 1983). 
 
Viral dsRNA may be detected via endosomal delivery o  within the cell 
cytoplasm.  The toll-like receptors (TLRs) are a family PRRs; TLR3 has been 
demonstrated to be a receptor for dsRNA, and that is activation results in the 
induction of IFN (Alexopoulou et al., 2001).  Before stimulation, TLR3 is 
localised to the endoplasmic reticulum, but then moves to the endosome 
containing dsRNA.  The recognition of dsRNA requires an acidic pH within the 
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endosome (de Bouteiller et al., 2005).  TLR3 has also been identified on the cell 
surface of a human fibroblast cell line, enabling the extracellular detection of 
dsRNA and IFN induction (Matsumoto et al., 2002).  As well as IFN induction, 
dendritic cells that have phagocytosed other virus infected cells contain TLR3 
that is able to detect viral dsRNA; the cells are activ ted and induce a cytotoxic 
T cell response (Schulz et al., 2005).  Studies of TLR3 knockout mice have 
revealed that it is an essential part of the mouse’s ability to resist infection with 
some viruses e.g. murine cytomegalovirus (although a DNA virus, it is assumed 
to produce dsRNA as a result of bidirectional transcription) (Tabeta et al., 2004) 
whereas it appears not to have the same role in other viral infections e.g. 
lymphocytic choriomeningitis (LCMV) virus, VSV and reovirus (Edelmann et 
al., 2004).  These studies showed that although TLR3 is an important receptor 
for viral dsRNA in some viral infections, there must still be other systems 
operating in the induction of IFN by other viruses, which will be described later. 
 
TLR3 induces IFN via a signal transduction pathway.  After detection of 
dsRNA, TLR3 undergoes a tyrosine phosphorylation, accompanied by 
dimerization (Sarkar et al., 2004).  The phosphorylated TLR3 then recruits toll-
interleukin (IL)-1 domain adaptor inducing IFN-β (TRIF)  which results in the 
activation of two cascades that result in IFN induction (Hoebe et al., 2003; Jiang 
et al., 2004).   
 
The first cascade, the NF-κB branch, begins with the association of TRIF with 
tumour necrosis factor receptor-associated factor 6 (TRAF6) the receptor-
interacting protein 1 (RIP1) (Sato et al., 2003; Meylan et al., 2004; Cusson-
Hermance et al., 2005).  TRAF6 functions with the ubiquitin conjugating 
enzyme Ubc13 to catalyze the synthesis of unique lysine-linked polyubiquitin 
chains (Deng et al., 2000) which bind to TAK1-binding proteins 2 and 3 (TAB 2 
and 3) and activate transforming growth factor β-activated kinase 1 (TAK1).  
Polyubiquitinated RIP1 is able to recruit IKK through the binding between the 
polyubiquitin chains and the NF-κB essential modifier (NEMO), which is a 
regulatory subunit of the IKK complex (Ea et al., 2006).  As a result of the 
creation of a TRIF-RIP1-TRAF6-TAB-TAK1 complex, TAK1 phosphorylates 
and activates IKK (Wang et al., 2001), leading to the phosphorylation of IκB, its 
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degradation and release of NF-κB from its bound, inactive form (Baeuerle and 
Baltimore, 1988) which migrates to the nucleus (Randall and Goodbourn, 2008). 
 
The second branch, after TRIF, is the IFN regulatory factor 3 (IRF3) pathway.  
As well as TRAF6, TRIF also recruits TRAF3, and they ave distinct functions 
(Häcker et al., 2006).  The modulator of TRAF3 signalling is TANK (Li et al., 
2002), which interacts with TANK-binding kinase 1 (TBK1) and IκB kinase 
(IKK) (Pomerantz and Baltimore, 1999) which are essential parts of the IRF3 
signalling pathway (Fitzgerald et al., 2003) as they can phosphorylate the C-
terminal part of IRF3 and are important in activation (Zhang et al., 2009).  Two 
recently described adaptor proteins have also been d scribed as having a role in 
IRF3 activation, they are NK-κB-activating kinase-associated protein 1 (NAP1) 
and similar to NAP1 TBK1 adaptor (SINTBAD) (Sasai et al., 2004; Ryzhakov 
and Randow, 2007). 
 
TLR3 is not involved in the detection of all RNA viruses, as not all viruses are 
detected intraendosomally.  The detection of intracytoplasmic dsRNA which 
leads to IFN induction is via two cytoplasmic RNA helicases.  Retinoic acid 
inducible gene I (RIG-I) was identified as an essential regulator for dsRNA 
induced signalling in 2004 (Yoneyama et al., 2004) and the related protein 
melanoma differentiation-associated gene 5 (MDA-5) was also first described in 
2004 (Andrejeva et al., 2004).  Both RIG-I and MDA-5 have been shown to 
respond to the synthetic dsRNA analogue poly I:C (Rothenfusser et al., 2005; 
Yoneyama et al., 2005; Gitlin et al., 2006) although more recent work has 
shown that RIG-I is selectively activated by viral RNA transcripts and MDA-5 
by poly I:C (Kato et al., 2006).  It has been shown that the ligand which RIG-I 
recognises is the 5’ triphosphate group, which is present in many viral RNAs, 
and is therefore recognized as non-self (Hornung et al., 2006; Pichlmair et al., 
2006).  The presence of cap structures or a VPg on the viral RNA means there is 
no 5’ triphosphate group to be detected.  This is one reason that different viruses 
are detected preferentially by each of the two helicases e.g. MDA-5 detects 
picornaviruses whereas RIG-I detects influenza viruses and Japanese 
encephalitis virus (Kato et al., 2006).  Another difference in the nature of 
dsRNA molecules detected by RIG-I and MDA-5 are lengths of dsRNA, with 
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MDA-5 detecting long dsRNA, >1 kb, whereas RIG-I has been shown to detect 
short (<1 kb) RNAs (Kato et al., 2008).  RIG-I and MDA-5 have a similar 
structure, they have C-terminal domains (CTD), a DEx /H-box helicase and an 
effector domain called the caspase recruitment domain (CARD).  The CTDs of 
both RIG-I and MDA-5 are responsible for the recognitio  of dsRNA (Cui et al., 
2008; Li et al., 2009).   The CARD is the effector domain, after activation it 
interacts with a mitochondrial adaptor protein which has been given several 
names: CARD adaptor IFN-β (Cardif) (Meylan et al., 2005), virus-induced 
signalling adaptor (VISA) (Xu et al., 2005), mitochondrial antiviral signalling 
protein (MAVS) (Seth et al., 2005) or IFN-β promoter stimulator protein (IPS-
1) (Kawai et al., 2005).  Both RIG-I and MDA-5 use this same adaptor r tein 
in their signalling pathways (Kumar et al., 2006).  During its activation, RIG-I 
undergoes ubiquitination by tripartite motif-contaiing 25 (TRIM25) which is 
essential for its IFN induction capability, although this is not true of MDA-5 
(Gack et al., 2007).  Another difference between the two helicases is in their 
regulation in the cell; MDA-5 in under the regulation of dihydroxyacetone 
kinase (DAK), of previously unknown function, whereas RIG-I is not (Diao et 
al., 2007). 
 
A third helicase, related to RIG-I and MDA-5 is LGP2; unlike the other two, 
LGP2 has no CARD domain and was initially described as a negative feedback 
regulator of IFN induction, by sequestering dsRNA (Rothenfusser et al., 2005; 
Yoneyama et al., 2005).  It was subsequently shown that LGP2-/- mice showed 
markedly different antiviral responses, being resistant to VSV, but having a 
deficient IFN response to encephalomyocarditis virus (Venkataraman et al., 
2007).Recent work has shown that the CTD of LGP2 is able to bind to the blunt 
ends of dsRNA, and the authors speculate that RIG-I binds to the 5’ triphosphate 
groups in a similar way, and that LGP2 may regulate RIG-I through a direct 









Figure 1.6 RIG-I and MDA-5 signal transduction pathway; from Randall and Goodbourn, 2008 
 
1.3.3 IFN induction pathways 
IFN-β is induced by the activation of IRF3 and NF-κB.  IRF3 is activated by the 
phosphorylation, by IKK and/or TBK1, of the Ser/Thr residues in the C-terminal 
domain, resulting in its dimerization, cytoplasm-to-nucleus translocation, 
interaction with co-activators CBP/p300 and association with DNA (Panne et 
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al., 2007; Dragan et al., 2007; Sato et al., 1998; Lin et al., 1998).  NF-κB is 
maintained in its inactive form by being bound to IκB (Baeuerle and Baltimore, 
1988), which is ubiquitinated and degraded, allowing free NF-κB to translocate 
to the nucleus (Chen, 2005; Wullaert t al., 2006; Hayden and Ghosh, 2004).  
The transcriptional activation of the IFN-β gene is dependent on the assembly of 
a complex consisting of the transcription factors ATF-2/c-Jun, IRF3, NF-κB the 
high-mobility group chromatin-associated protein (Y) HMGI(Y)); this complex 
is called the enhanceosome (Maniatis et al., 1998; reviewed by Merika and 
Thanos, 2001).  These factors cooperate to bind to a DNA site and activate the 
expression of the IFN-β gene (Panne t al., 2004).  Although the enhanceosome 
is formed, the consensus view is that it is only the binding of IRF3 and/or IRF7 
which is truly indispensable for IFN-β induction and that the other elements may 
not be necessary in certain cell types (Randall and Goodbourn, 2008).  During a 
viral infection, the production of IFN-β leads to the production of other 
transcription factors that may have positive or negative regulatory effects.  IRF1 
and IRF2 have been identified as an activator and repressor of IFN genes 
respectively (Kawakami et al., 1995).  Low levels of IFN-β can act in an 
autocrine or paracrine way to stimulate the expression of IRF7 and IRF5 which 
act as a positive feedback and amplify the IFN respon e, an example of this is 
the role of fibroblast IFN-β in the induction of IFNs in peripheral tissues (Marie 
et al., 1998; Sato et al., 1998; Erlandsson et al., 1998; Paun and Pitha, 2007).  In 
fact, IRF7 can be considered the master regulator of IFNαβ expression as IRF7-/- 
are unable to express IFNαβ genes at all upon viral infection (Honda et al., 
2005). 
 
1.3.4 Signalling responses to IFN 
The cell surface receptor for IFN was first described y Friedman in 1967, but it 
was not until 1990 that the first IFN receptor identified was cloned (Uze t al., 
1990).  When a second receptor molecule was cloned in 1994 (Novick et al., 
1994) the genes were designated IFNAR1 and IFNAR2 (reviewed by de Weerd 
et al., 2007).  Each subunit interacts with a member of the Janus activated kinase 
(JAK) family; IFNAR1 is associated with tyrosine kinase 2 (Tyk2) and IFNAR2 
associates with JAK1 (Darnell et al., 1994; Ihle, 1995).  A ligand-dependant 
rearrangement and dimerization leads to activation of the JAKs (Platanias, 
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2005).  There are many genes induced by IFNs (Der et al., 1998), but the most 
important antiviral signalling pathways activated are the signal transducer and 
activator of transcription (STAT) pathways, which were first described in the 
1990s (Schindler et al., 1992; Fu et al., 1992; Silvennoinen et al., 1993).  The 
ligand-induced dimerization of the receptor and phosphorylation of tyrosine 
sites on the cytoplasmic tail of the receptor creates a docking site for the SH2 
domains of the STATs (Greenlund et al., 1994; Darnell, 1997).  Tyk2 then 
phosphorylates STAT2, and JAK1 phosphorylates STAT1, and the two 
phosphorylated STATs form a heterodimer (Randall and Goodbourn, 2008).  
After stimulation of the pathway, STAT2 which normally is constantly shuttling 
between the nucleus and cytoplasm, is only imported into the nucleus; this 
results in the STAT1-STAT2 heterodimer accumulating in the nucleus 
(Banninger and Reich, 2004; Frahm et al., 2005).  The heterodimer then 
interacts with IRF9 in the nucleus, leading to the cr ation of IFN-stimulated 
gene factor-3 (ISGF3) heterotrimer which binds to the IFN-stimulated response 
element (ISRE) (Tang et al., 2007).  The complex is activated by acetylation of 
all three components of the complex by CREB-binding protein (CBP), 
previously recruited by the IFNR2.  The ISGF3 complex then regulates antiviral 








Figure 1.7 IFN effector transduction pathway; from Randall and Goodbourn, 2008 
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1.3.5 IFN effector mechanisms 
1.3.5.1 Antiviral state 
As a result of the action of IFN the genes that are expressed result in the cell 
going into what is known as the antiviral state.  Several hundred genes have 
been identified, but there are several important gees that have been studied in 
depth and their actions elucidated. 
 
1.3.5.2 PKR 
dsRNA-dependant protein kinase (PKR) is an IFN induce  molecule first 
described by Metz and Esteban in 1972.  PKR is a protein with dsRNA-
dependant kinase activity but exists in a latent sta e (Garcia et al., 2006).  It is 
activated after recognising and binding dsRNA (Clemens, 1997); due to 
structural constraints, it is only able to detect dsRNA molecules of greater length 
than 30 bp (Manche et al., 1992).  After binding dsRNA, PKR undergoes 
various conformational changes and homodimerises, bcoming active in the 
process.  The homodimer is further stabilised by autophosphorylation (Dey et 
al., 2005).  PKR is activated in several other conditions: by TLRs, by growth 
factors and cytokines and in response to cell stress (Garcia et al., 2006).  PKR is 
a member of a family of kinases called the eukaryotic initiation factor 2- (eIF-
2α) specific kinases (de Haro et al., 1996), which inhibit the function of eIF-2α 
and therefore inhibit protein synthesis (Rhoads, 1993).  The ability of PKR to 
detect long viral dsRNAs and inhibit cellular protein synthesis means that it also 
inhibits viral protein synthesis.  PKR is also able to phosphorylate the NF-κB 
inhibitor IκB-α, removing the inhibition and therefore promoting the further 
induction of IFN-β.  The actions of PKR on both eIF-2α and NF-κB have also 
been shown to be mediators in apoptosis (Lee and Esteban, 1994; Gil et al., 
1999). 
 
1.3.5.3 2’5’ OAS 
The discovery of the 2’5’-oligoadenylate synthetase (2’5’OAS) system and its 
association with the activation of the latent RNase (RNase L) took place in the 
late 1970s (Hovanessian et al., 1977; Clemens and Williams, 1978).  As one of 
the many ISG (3), dsRNA stimulation of OAS leads to the generation of short 
(trimer, tetramer, pentamer) 5’phosphorylated, 2’5’-linked oligoadenylates (2-
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5A) from ATP (Kerr and Brown, 1978; Minks et al., 1979).  2-5A is degraded 
very quickly by 2’phosphodiesterase (2’PDE) and 5’phosphatases (Kubota et
al., 2004).  The most important function of 2-5A is it activation of RNase L in 
response to IFN during viral infection, but also as p rt of cellular RNA stability 
(Zhou et al., 1993).  RNase L cleaves on the 3’ side of UN sequences in RNA 
molecules, particularly UA, UU and UG sequences, but m ch less so after CA 
or AC (Wreschner et al., 1981; Floyd-Smith et al., 1981).  The RNase L enzyme 
consists of an ankyrin repeat domain, which constitutes the 2-5A binding site, a 
kinase-like domain and the RNase domain (Hassel et a ., 1993; Tanaka et al., 
2004).  In the absence of 2-5A, RNase L exists as amonomer which has no 
ribonuclease activity (Dong and Silverman, 1995) due to the repressing effects 
in the last three ankyrin-like repeats (Dong and Silverman, 1997).  It is thought 
that 2-5A binding causes a conformational change in RNase L, releasing the 
inhibitory effects of the ankyrin repeats, forming dimers and unmasking the 
ribonuclease domain, leading to the ability to cleave RNA (Dong and Silverman, 
1997; Dong et al., 2001).  The role of the 2’5’OAS/RNase L system in antiviral 
defences is illustrated by the fact that RNase L-/- mice have an increased 
susceptibility to infection with the picornaviruses ncephalomyocarditis virus 
(EMCV) and Coxsackievirus (Zhou et al., 1997; Flodström-Tullberg et al., 
2005) or the flavivirus West Nile virus (Samuel et al., 2006).  Some viruses, 
however, have evolved mechanism to avoid the antiviral effects of RNase L; for 
example in reovirus infection, PKR and RNase L are involved in shutoff of 
cellular translation, which are actually beneficial to the growth of some reovirus 
strains (Smith et al., 2005).  Other aspects of the antiviral effects of the system 
are that it is able to induce apoptosis of infected c lls via a mitochondrial 
pathway (Zhou et al., 1997; Castelli et al., 1998a;1998b) and that it induces the 
transcription of other genes that suppress virus replication (Malathi et al., 2005). 
 
1.3.5.4 Mx 
Mx was discovered after an inbred strain of mouse was described as being 
unusually resistant to influenza A virus (Lindenmann, 1962).  It was later found 
that the resistance observed was due to a single gen , the Mx1 gene (Reeves et 
al., 1988).  It was later discovered that many of the commonly used inbred 
mouse strains had non-functional Mx (Staeheli et al., 1988).  A second Mx gene, 
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Mx2, was identified which also contained mutations in BALB/c and CBA mice 
(Staeheli and Sutcliffe, 1988).  Mx proteins are GTPases related to dynamins 
(Staeheli et al., 1993), they are able to form trimers, self-assembl  into rings that 
tabulate lipids and localises to the smooth endoplasmic reticulum ( Melen et al., 
1992; Accola et al., 2002).  The mechanism(s) by which Mx effects its antiviral 
properties are still being investigated.  A physical nteraction between Mx and 
the viral nucleocapsid of Thogoto virus has been demonstrated (Kochs and 
Haller, 1999) as well as human Mx being able recognise bunyavirus  capsid 




The ISG15 gene was first cloned in 1986 from IFN trea ed human Daudi cells 
(Blomstrom et al., 1986).  It was classified as a ubiquitin homologue and a novel 
mechanism for response to IFN in 1992 (Loeb and Haas, 1992).  Ubiquitin is a 
molecule that tags proteins and labels them for degradation or modifies their 
functions (Liu et al, 2005).  Ubiquitins require a ubiquitin-activating enzyme 
(E1), a conjugating enzyme (E2) and sometimes a ligase (E3) (Reviewed by 
Kerscher et al., 2006).  It has been shown that ISGylation is similar to 
ubiquitination in that is has a specific E1-like activating enzyme, UBE1L (Yuan 
and Krug, 2001).  Two E2-like conjugating enzymes have also been discovered, 
namely UbcH8 (Zhao et al., 2004) and UbcH6 (Takeuchi et al., 2008).  These 
enzymes activate and conjugate ISG15 to specific protein targets and modulate 
their activity, rather than marked them for degradation as in ubiquitination 
(Zhao et al., 2004; Harty et al., 2009).  Similar to ubiquitin, ISGylation is also 
reversible e.g. the enzyme UBP43 cleaves only ISG15 (Catic et al., 2007; 
Malakhov et al., 2002).  Many targets for ISGylation have already been 
identified, including members of the antiviral IFN systems: PKR, MxA, HuP56, 
RIG-I and STAT1 (Zhao et al., 2005; Giannakopoulous et al., 2005; Takeuchi 
and Yokosawa, 2008).  ISG also enhances the innate immune response by 
subverting the ubiquitin mediated degradation of IRF3, thereby providing a 
positive feedback mechanism (Lu et al., 2006).  ISG15 is also able to enhance 
the signalling of NF-κB; by conjugating with protein phosphatase 2C beta, 
which normally suppresses NF-κB (Takeuchi et al., 2006).  In addition to its 
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ubiquitin-like role, ISG15 is also secreted as a cytokine as a response to IFN, but 
its exact extracellular functions are unclear (D’Cunha et al., 1996).  Its role in 
antiviral defence mechanisms has been demonstrated by studies which have 
shown increased susceptibility to various virus infections e.g. influenza, Sindbis 
and herpes viruses (Lenschow et al., 2007), although the antiviral state induced 
by VSV and LCMV was not affected in the absence of ISG15 (Osiak et al., 
2005).  Two other related proteins are ISG54 and ISG56.  They inhibit 
translation by interacting with the eIF3 complex (Guo et al., 2000; Terenzi et 
al., 2005).   
 
 
1.3.5.6 PML nuclear bodies 
Promyelocytic leukaemia nuclear bodies (PML NBs) are small nuclear sub-
structures which have been linked to a variety of cellular processes, including: 
sensing DNA damage and cellular stress (Dellaire and Bazett-Jones, 2004), 
apoptosis (Bernardi and Pandolfi, 2003), senescence (Bischof et al., 2002), 
ubiquitination (Anton et al., 1999) and the IFN response to viral infection 
(Regad and Chelbi-Alix, 2001).  PML NBs have been shown to be induced by 
IFN (Chelbi-Alix et al., 1995) and to reduce gene expression in the human 
foamy virus (Regad et al., 2001), and inhibits the replication of influenza virus 
and VSV (Chelbi-Alix et al., 1998).  The absence of PML in mice rendered 
them more susceptible to LCMV and VSV (Bonilla et al., 2002).  In the case of 
poliovirus, infection leads to PML activation of the p53 gene, which leads to 
apoptosis (Pampin et al., 2006). 
 
1.3.5.7 Adenosine deaminases (ADARs) 
The RNA-specific adenosine deaminase (ADAR) was discovered when an 
enzyme, able to unwind dsRNA, was also shown to convert adenosine residues 
to inosine residues (Bass and Weintraub, 1988).  In human cells there are two 
forms of ADAR1 (Patterson and Samuel, 1995), a constitutively expressed 110 
kDa protein (ADAR1-S) and an IFN inducible 150 kDa protein (ADAR1-L) 
(George and Samuel, 1999; Kawakubo and Samuel, 2000).  ADAR1-L was 
shown to be >70 fold more active than ADAR1-S in assay  with substrates 
edited in either the nucleus or cytoplasm, and also with substrate generated 
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during viral replication (Wong et al., 2003) leading to the suggestion that 
ADAR was part of the antiviral innate immune system.  The A-to-I domination 
is a form of genetic recoding and is found in multiple sits in viral RNA.  Inosine 
is recognised as guanosine by ribosomes and transcribi g polymerases, this 
leads to A-to-G transitions in the edited strand and therefore to U-to-C 
transitions in cRNA; A-to-G hypermutation has been observed in the genome 
choriomeningitis virus for example (Zahn et al., 2007).  A-to-I hypermutations 





Viperin (virus inhibitory protein, endoplasmic reticulum-associated, interferon-
inducible) is a cytoplasmic protein, induced by IFN that was first identified in 
human cytomegalovirus infection (Chin and Cresswell, 2001).  It has since been 
shown to have antiviral activity against hepatitis C virus (Helbig et al., 2005), 
influenza virus (Wang et al., 2007), HIV (Rivieccio et al., 2006) and 
alphaviruses (Zhang et al., 2007).  Viperin localises to the cytoplasmic faces of 
the endoplasmic reticulum (Hinson and Cresswell, 2009); it has been shown to 
inhibit the release of influenza virus from the plasma membrane of cells by 
interacting with farnesyl diphosphate synthase (FPPS) leading to altered 
membrane fluidity by affecting the formation of lipid rafts, affecting the release 
of the virus (Wang et al., 2007). 
 
1.3.5.9 Apoptosis 
IFN is also able to induce a cell to undergo apoptosis; if an infected cell is 
forced into programmed cell death it can help to remove a source of infection to 
the remainder of the animal.   There are various pathw ys by which IFNs may 
act to induce apoptosis: activation of the STAT pathway can induce the 
expression of caspase 1 (Chin et al., 1997), and it has been shown that IFN-γ 
can induce Fas, which acts through Fas ligand to cause apoptosis (Dai and 
Krantz, 1999).  PKR has been shown to play a role in virus induced apoptosis 
e.g. VSV (Gaddy and Lyles, 2007).  It is the role of PKR in the phosphorylation 
of eIF-2α that mediates apoptosis (Srivastava et al., 1998; Gil et al., 1999; 
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Scheuner et al., 2006).  dsRNA generated during viral infections can, 
independent of protein synthesis, induce apoptosis by the activation of caspase 8 
(Iordanov et al., 2005).  The tumour suppressor gene, p53, is also involved in 
IFN signalling; IFN induces the transcription of p53 and this response has been 
observed in virally infected cells (with VSV) leading to apoptosis (Takaoka et
al., 2003; Munoz-Fontela et al., 2005).  The mechanism by which virus 
infection and IFN induction leads to upregulation of p53 have been shown to be 
a physical association between PKR and p53, resulting in a functional 
interaction (Cuddihy et al., 1999).  As has been stated previously, the 
2’5’OAS/RNase L system also plays a role in the induction of apoptosis 
(Castelli et al., 1998). 
 
1.3.5.10 Cell-cycle arrest 
IFNs have been shown to arrest cell growth via a STAT mediated induction of 
cyclin-dependant kinase inhibitor p21 (Chin et al., 1996).  For this reason, IFNs 
have been used as anti-cancers agents (reviewed by Ferrantini et al., 2007).  A 
family of IFN-inducible proteins, the p200 family also affect the cell cycle.  
HIN-200 is a nuclear protein that regulates cell differentiation through its 
mediation of the cell cycle (Dawson and Trapani, 1996). 
 
1.3.5.11 Immunomodulation 
IFNs play a role in the transition from innate immunity to adaptive immunity; 
IFN-αβ are able to upregulate of class I major histocompatibility complex 
(MHC-I) and elements of the antigen-presenting machinery (reviewed by Le 
Bon and Tough, 2002).  IFN-αβ produced by virus infected cells also has a role 
in the maturation of dendritic cells (Le Bon et al., 2003) and potentiates the 
clonal expansion and survival of CD8+ T cells responding to a specific antigen 
(Tough et al., 1996).  IFN can also induce the production pf IL-15 which is 
central to the proliferation and survival of T cells (Boyman et al., 2007) and 




Figure 1.8 IFN effector mechanism pathways; from Randall and Goodbourn, 2008 
 
 
1.3.6 Viral strategies for avoidance of IFN system 
Viruses have developed throughout evolution various means by which to avoid 
the IFN response. There are five main strategies for circumventing the innate 
immune response: 
i)  Interference with host-gene expression 
ii)  Minimising IFN production by limiting production of PAMPs 
iii)  Inhibition of IFN signalling 
iv)  Inhibition of IFN induced enzymes 
 
1.3.6.1 Interference with host-cell gene expression 
There are many viruses that are able to inhibit cellular protein expression, often 
with the result of circumventing the IFN response.  Bunyamwera virus (BUNV) 
non-structural proteins have been shown to target th  RNA polymerase II in 
mammalian cells; this possibly leads to a lytic infection as opposed to the 
persistent infection seen in BUNV infection of insect cells (Thomas et al., 
 35 
2004).  An advantage to the virus is that inhibiting cellular protein synthesis will 
also reduce the production of IFN, but the cell may die soon after infection, 
giving the virus less time to manipulate the cell or establish persistent infections 
(Randall and Goodbourn, 2008).  Table 1.1 shows viruses that avoid the IFN 
system by global inhibition of host cell gene expression. 
 
Virus Mode of action Reference 
Polio virus Viral proteases cleave: 
 eIF4-G; 
 Poly (A) binding protein  
 TAT box-binding protein  
 
Etchison et al., 1982  
Joachims et al., 1999  
Clark et al., 1993 
Foot-and-mouth disease 
virus 




Kirchweger et al., 1994 
Belsham et al., 2000 
VSV M protein inhibits host-cell 
transcription and translation 




transport and translation of 
capped mRNAs. 
Porter et al., 2006 
Theiler’s murine 
encephalomyelitis virus 
L protein interacts with Ran-
GTPase and interferes with 
nucleocytoplasmic trafficking 
Delhaye et al., 2004 
Influenza A virus NS1 protein inhibits processing 
and export of cellular mRNAs 
Fortes et al., 1994 
Bunyamwera virus NSs protein inhibits RNAP II 
to inhibit host cell transcription 
Thomas et al., 2004 
Rift valley fever virus NSs protein inhibits host cell 
transcription by interacting 
with transcription factor TFIIH 
Bouloy et al., 2001 
Eastern equine 
encephalitis virus 
Capsid protein nsP2 inhibits 
cellular transcription 
Aguilar et al., 2007 
 
Table 1.1: Viruses that avoid the IFN system by globa  inhibition of host cell gene expression 






1.3.6.2 Minimizing IFN production 
In order to minimise the production of IFN, viruses have evolved replication 
strategies which minimize the production of PAMPs; they have achieved this 
by: 
i)  Controlling virus transcription and translation to minimize the production of 
PAMPs. 
ii)  Encapsidating RNA 
iii) Protecting the 5’ triphosphate group from RIG- 
iv)  Integrating their genomes into host chromosomes 
v)  Hiding PAMPs from cellular receptors 
(Randall and Goodbourn, 2008) 
 
As dsRNA is one of the most important PAMPs in viral infections, many viruses 
have developed means of binding or sequestering it.  The reovirus protein σ3 is 
able to inhibit the activity of PKR by binding dsRNA (Imani and Jacobs, 1988), 
a similar mechanism has been shown for the core protein σA of the avian 
reovirus (Martinez-Costas et al., 2000).  The porcine group C rotavirus NSP3, 
which shares homology with dsRNA-binding proteins, also bind dsRNA and 
inhibit PKR (Langland et al., 1994).  Other viral genes that encode proteins that 
have dsRNA sequestering properties include the E3L gene of vaccinia virus 
(Chang et al., 1992), the VP35 of Ebola virus (Cardenas et al., 2006), the SM 
protein of Epstein-Barr virus (Poppers et al., 2003), the pTRS1 of human 
cytomegalovirus (Hakki and Geballe, 2005), the m142 and m143 proteins of 
murine cytomegalovirus form a homodimeric complex that is also able to bind 
dsRNA (Child et al., 2006; Valchanova et al., 2006), the Erns glycoprotein of 
bovine viral diarrhoea virus (BVDV) has dsRNA-bindig activity and RNase 
activity (Iqbal et al., 2004).  The dsRNA binding ability of influenza A virus 
NS1 protein has also been shown to inhibit the 2’5’OAS/RNase L pathway (Min 
and Krug,. 2006), prevent the activation of IRF3 (Talon et al., 2000) and is also 
able to inhibit the action of PKR by binding directly o it (Li et al., 2006).  
Viruses have developed the ability to avoid detection by directly inhibiting the 
cytoplasmic PRRs.  The V protein of paramyxoviruses inhibits MDA-5 activity 
(Andrejeva et al., 2004), although RIG-I is unaffected (Childs et al., 2007).  The 
paramyxovirus Sendai virus C protein can also block RIG-I (Strahle et al., 
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2007).  Influenza A virus NS1 protein, however, inhibits RIG-I (Guo et al., 
2007) by forming a complex between NS1, RIG-I and Cardif/IPS1 (Mibayashi 
et al., 2007). 
 
In addition to preventing the detection of dsRNA by TLR3, RIG-I or MDA-5, 
viruses have also evolved various means to inhibit the signalling cascade 
emanating from the cellular PRRs.  Hepatitis C virus (HCV) NS3/4A is a 
protease that cleaves the TLR adaptor protein TRIF (Li et al., 2005).  Vaccinia 
virus proteins A52R and A46R are able to target multiple adaptors in the IFN 
signalling pathway including IRAK2, TRAF6, MyD88 and TRIF leading to a 
reduction in IFN production (Stack et al., 2005; Harte et al., 2003).  
Plasmacytoid dendritic cells (pDCs) are able to detect viruses without being 
directly infected, recognition of ssRNA viruses is through TLR7 after transport 
of dsRNA replicatory intermediates through the cytoplasm to the lysosome by 
autophagy.  Autophagy is a cellular system for the degradation of proteins in 
lysosomes, and has been shown also to target intracellular pathogens (Lee t al., 
2007; reviewed by Kirkegaard et al., 2004; Schmid et al., 2006).  It is also 
required for the production of IFN by pDCs (Lee t al., 2007).  Macroautophagy 
is induced by phosphorylated eIF2α, a result of the action of PKR and therefore 
part of the IFN response (Talloczy et al., 2002).  Several RNA viruses have 
hijacked the system for their own advantage though e. . mouse hepatitis virus 
(Prentice et al., 2004), poliovirus (Suhy et al., 2000) and equine arteritis virus 
(Pedersen et al., 1999) are able to assemble their replication complexes at 
double-membraned vesicles which are reminiscent of autophagosomes (Schmid 
et al., 2006).  The limiting of IFN production is achieved through the Atg5-
Atg121 conjugate, a regulator of autophagy, which directly associates with the 
CARD of RIG-I (Jounai et al., 2007).  
 
Other parts of the transduction cascade are also targeted by viruses, including 
inactivation of Cardif/VISA/MAVS/IPS-1, inhibition of IRF-3, inhibition of 
IKK complexes, inhibition of NF-κB and interference with the IFN-β promoter; 
the strategies for minimizing IFN production are summarized in table 1.2.  It is 
notable that certain viruses e.g. vaccinia virus and HCV, act in more than one 
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location in the IFN production cascade, as well as other parts of the IFN system 
to be discussed later. 
 
 
Virus (protein) Mode of action Reference 
Bovine viral diarrhoea virus (Erns) Degradation of dsRNA Iqbal et al., 2004 




Influenza A virus (NS1) 
Epstein-Barr virus (US11) 
Human cytomegalovirus (TRS1) 
Ebola virus (VP35) 
Murine cytomegalovirus 
(m142/143) 
Sequestration of dsRNA Chang et al., 1992 
Imani and Jacobs, 1988; 
Martinez-Costas et al., 2000 
Langland et al., 1994 
Talon et al., 2000 
Poppers et al., 2000 
Hakki and Geballe, 2005 
Cardenas et al., 2006 
Child et al., 2006 
Hepatitis C virus (NS3/4a) 
Vaccinia virus 
Inhibition of TLR signalling Li et al., 2005 
Harte et al., 2003 
Paramyxoviruses (V) 
Influenza A virus (NS1) 
Inhibition of RIG-I / MDA-
5 
Andrejeva et al., 2004 
Guo et al., 2006 
Mibayashi et al., 2006 
Hepatitis C virus (NS3/4a) 
 
Inactivation of Cardif / 
VISA / MAVS / IPS-1 
Li et al., 2005 
Borna disease virus (P) 
Vaccinia virus (N1) 
Interferes with VAK Unterstab et al., 2005 
DiPerna et al., 2004 
Rabies virus (P) 
Hantavirus (G1) 
Human herpes virus-6 (E1) 
Rotaviruses (NSP1) 
Bovine viral diarrhoea virus (Npro) 
Classical swine fever virus (Npro) 
Human papillovirus 16 (E6) 
Herpes simplex virus (ICP0) 
Bovine herpes virus 1 (bICP0) 
Thogoto virus (ML) 
Bovine respiratory syncytial virus 
Human respiratory syncytial virus 
SARS corona virus 
 
Inhibition or degradation of 
IRF-3 
Brzozka et al., 2005 
Alff et al., 2006 
Jaworska et al., 2007 
Graff et al., 2007 
Hilton et al., 2006 
Bauhofer et al., 2005 
Ronco et al., 1998 
Lin et al., 2004 
Saira et al., 2009 
Hagmaier et al., 2004 
Bossert et al., 2003 
Spann et al., 2005 
Kopecky-Bromberg et al., 
2007 
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Human papillovirus (E7) 
Hepatitis C virus (core) 
Vaccinia virus 
Adenovirus (E3) 
Interferes with the IKK 
complex 
Spikovsky et al., 2002 
Joo  et al., 2005 
DiPerna et al., 2004 
Friedman and Horwitz, 
2002 
African swine fever virus 
(A238L) 
Vaccinia virus (N1) 
Myxoma virus (MNF) 
Inhibition of NF-κB Powell et al., 1996 
Shisler and Jin, 2004 
Camus-Bouclainville, 2004 
Human herpes virus 8 (IRF 
orthologues) 
Interfere with IFN-β 
promoter activation 
Offermann, 2007 
Semliki Forest virus (NSP2) Inhibits IFN production, 
uncertain mechanism 
Breakwell et al., 2007 
 




Figure 1.9  Viral strategies for evasion of detection and induction of IFN-β; from Randall and 
Goodbourn, 2008 
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1.3.6.3 Inhibition of IFN signalling 
Viruses have also evolved mechanisms to counter the IFN signalling cascades, 
reducing the production of antiviral products and preventing the generation of 
the antiviral state.  Viruses from many families and genera have evolved these 
mechanisms, and many viruses are able to interfere with multiple parts of the 
signalling cascade.  Examples of mechanisms of counteracting IFN signalling, 
and the viruses that produce them, include: sequestration of IFN, by 
orthopoxvirus IFN-α/β binding proteins for example (Alcami et al., 2000; 
Colamonici et al., 1995); down regulation of IFN receptors by human herpes 
virus 8 (Li et al., 2007); interference with IFN receptor activity bythe NS5 
protein of Japanese encephalitis virus (Lin et al., 2004, 2006).  The STATs are 
often the targets of viral evasion strategies: parainfluenza 5 targets STAT1 for 
degradation (Horvath, 2004), but type 2 targets STAT2 (Ulane and Horvath, 
2002); mumps virus targets STAT1 and STAT3 (Ulane et al., 2003; Kubota et 
al., 2005); the V and P proteins of Nipah and Hendra viruses sequester STAT1 
and STAT2 (Rodriguez et al., 2002; Rodriguez, 2003); rabies virus protein P 
forms an inactive complex with STAT1 and STAT2 (Brzozka et al., 2006); 
HCV core protein prevents the phosphorylation of STAT1 (Lin et al., 2006); 
SARS coronavirus can inhibit the nuclear transport of STATs.  IRF-9 is another 
target, the E7 protein of human papillomavirus interacts with IRF-9 (Barnard 
and McMillan, 1999; Barnard et al., 2000).  Table 1.3 summarizes the viruses 
and mechanisms that inhibit IFN signalling. 
 
Virus  Mode of action Reference 
Vaccinia virus Sequestration of IFN Alcami et al., 2000 
Human herpes virus 8 Downregulation of IFN receptor Li et al., 2007 




Murine polyoma virus 
Measles virus 
Mumps virus 
Herpes simplex virus 
Human papillomavirus 18 
Interference with JAK kinases Lin et al., 2004 
Ho et al., 2005 
Best et al., 2005 
Miller et al., 1998 
Weihua et al., 1998 
Yokota et al., 2003 
Kubota et al., 2002 
Chee and Roizman, 2004 
Li et al., 1999 
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Parainfluenza virus 2 
Parainfluenza virus 5 
Mumps virus 
Newcastle disease virus 
Respiratory syncytial virus 
Sendai virus 
Herpes simplex virus 
Degradation / loss of STAT Ulane and Horvath, 2002 
Ulane and Horvath, 2002 
Kubota et al., 2001 
Huang et al., 2003 
Ramaswamy et al., 2004 
Garcin et al., 2002 










Hepatitis B virus 
Vaccinia virus 
Mapuera virus 
Sequestration of STATs or 
altering phosphorylation of 
STATs 
Rodriguez et al., 2002 
Rodriguez et al., 2003 
Palosaari et al., 2003 
Nanda and Baron, 2006 
Lin et al., 2006 
Paulus et al., 2006 
Brzozka et al., 2006 
Garcin et al., 1999, 2000 
Look et al., 1998 
Christen et al., 2007 
Najarro et al., 2001 
Hagmaier et al., 2007 
Ebola virus 
SARS corona virus 
Inhibition of STAT trafficking Reid et al., 2006 
Frieman et al., 2007 
Human papilloma virus 16 
 
Herpes simplex virus 
Hepatitis C virus 
 
Hepatitis B virus 
 
Human herpes virus 8  
Adenovirus 
SARS corona virus 
 
Dengue virus 
Herpes simplex virus 
Interference with IRF-9 Barnard and McMillan, 
1999 
Yokota et al., 2004 
Bode et al., 2003 
Duong et al., 2006 
Christen et al., 2007 
Fernandez et al., 2003 
Rezaee et al., 2006 
Leonard and Sen 
Kopecky-Bromberg et al., 
2007 
Munoz-Jordan et al., 
2003 
Chee and Roizman, 2004 
 
Table 1.3:  Viruses that inhibit IFN signalling (Adapted from Randall and Goodbourn, 2008) 
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1.3.6.4 Inhibition of IFN induced enzymes 
The interferon stimulated genes that give rise to the antiviral state are also 
targets for viruses to circumvent the IFN response.  There are examples of viral 
mechanisms of avoiding the effects of PKR, 2’5’-OAS, I G 15 and PML 
nuclear bodies.  The sequestering of dsRNA is not oly effective in preventing 
the induction of IFN, as has been described, but also prevents the activation of 
PKR, 2’5’-OAS and ADAR.  Apart from dsRNA, PKR also has dsRNA 
independent cellular activators, PKR associated activator (PACT) in humans 
(Patel and Sen, 1998), and the murine homologue RAX (Ito et al., 1999).  The 
presence of PKR in the cell as part of a stress response may be the reason that 
viruses have evolved mechanisms against PKR specifically, mechanisms 
include: RNA inhibitors, viral RNAs that bind to PKR in competition with 
dsRNA; direct interaction of a viral protein with PKR; eIF2α homologues that 
act as pseudo-substrate competitive inhibitors; degradation of PKR and eIF2α 
phosphatases.  Table 1.4 summarizes the viral anti-PKR mechanisms. 
 
 
Virus (protein) Mode of action Reference 
Hepatitis C virus (RNA) 
Human immunodeficiency 
virus 
RNA inhibitors Vyas et al., 2003 
Gatignol et al., 1991 
Hepatitis C virus (NS5A) 
Vaccinia virus (E3L) 
Human herpes virus 8 (vIRF-
2) 
Influenza viruses (p58) 
PKR interaction / binding Taylor et al., 1999 
Romano et al., 1998 
Burysek and Pitha, 2001 
Tan et al., 1998; Lee et al., 
1992 
Vaccinia virus (K3L) 
Human immunodeficiency 
virus (tat) 
eIF2α homologues Beattie t al., 1991 
Endo-Munoz et al., 2005 
Poliovirus PKR degradation Black et al., 1993 
Herpes simplex virus (γ134.5) eIF2α phophatase Chou et al., 1995 
 
Table 1.4:  Viral anti-PKR mechanisms (Adapted from Langland et al., 2006) 
 
As has been stated, the action of 2’5’-OAS is reduc by the sequestration of 
dsRNA, but some viruses have evolved a specific anti-OAS strategy.  Human 
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immunodeficiency virus 1 (HIV-1) and encephalomyocarditis virus (EMCV) 
induce the production of RNase L inhibitor (RLI) (Martinand et al., 1998; 
1999).  Inhibition of ISG15 has been shown influenza B NS1 protein by 
preventing its interaction with the El ligase (Yuan d Krug, 2001).  The 
adenovirus E4orf3 protein has been shown to interact with PML nuclear bodies 
and induce a morphological change (Doucas et al., 1996). 
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1.4 RNA stability 
The genomes of positive-sense RNA viruses are equivalent to cellular mRNAs 
in that they are released into the cell to be translated by ribosomes.  In the cell, 
control of mRNA degradation is an important factor in the regulation of gene 
expression and many of the enzymes and pathways have been described over 
recent years (reviewed by Garneau et al., 2007).  Cellular mRNAs have 7-
methylguanosine caps at their 5’ ends, and a poly(A) tail at their 3’ ends.  In the 
majority of mRNAs, the degradation process begins with shortening of the 
poly(A) tail followed by either degradation in a 3’-5’ direction by a 10-12 
subunit complex of exonucleases called the exosome; r the 5’ cap is removed 
and the RNA degraded by 5’-3’ exoribonucleases, such as Xrn1 (Houseley et 
al., 2006; Garneau et al., 2007).  The first step, deadenylation, is carried out by 
the nucleases PAN2 and CCR4; PAN2 initiates deadenylation followed by 
CCR4-mediated shortening of the poly(A) tail (Yamashita et al., 2005).  
Structures known as P bodies play a role in mRNA control, they are sites where 
the fates of mRNA molecules in determined (Eulalio et al., 2007).  These 
granular structures contain factors associated with translation initiation 
(Ferraiuolo et al., 2005), deadenylation (Cougot et al., 2004), decapping (Sheth 
and Parker, 2003), decay by 5’-3’ exonucleases (Bashkirov et al., 1997) and 
nonsense-mediated decay (NMD) (Sheth and Parker, 2006).  P bodies are 
dynamic and represent only active mRNA decay sites; they disappear when not 
active (Cougot et al., 2004).  Endonucleases cleave RNA molecules to produce 
multiple fragments which are then susceptible to exnucleases (Garneau et al., 
2007).  It has been shown that the protein Argonaute 2, part of the RNA-induced 
silencing complex (RISC), cleaves RNA as part of the s ort interfering RNA 
(siRNA) mechanism (Liu et al., 2004).  These mechanisms also make up a 
system of mRNA surveillance by detecting aberrant RNAs.  Nonsense-mediated 
decay detects premature termination codons, non-stop decay degrades mRNAs 
lacking a stop codon and no-go decay detects stalled ribosomes on an mRNA 
(Garneau et al., 2007).  There are various mRNA stability elements that control 
mRNA decay.  One of the most important is the AU-rich element (ARE), often 
found in the 3’ untranslated region of the molecule.  The AREs are able to 
recruit the mRNA-decay machinery  through various ARE-binding proteins such 
as AU-rich binding factor-1 (AUF1), tristetraprolin (TTP) and KH splicing 
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regulatory protein (KSRP) that interact with various decay factors (Garneau et 
al., 2007). 
 
RNA viruses that deliver their genomes into cells must be able to avoid 
degradation by the cellular ribonucleases in order to establish infection in a cell.  
This may be achieved by shielding the RNA physically from RNA decay 
machinery, or by modulating the decay machinery (Sokoloski et al., 2006).  
Many RNA viruses have been shown to form membrane-bound vesicles during 
replication flaviviruses and noroviruses, for example (Uchil and Satchianandam, 
2003, Hyde et al., 2009).  Viruses may also produce ribonucleoproteins (RNPs) 
which may regulate the RNA decay mechanisms.  The 3’ UTR of hepatitis C 
virus (HCV) binds to the cellular HuR protein, conferring protection against 
exonucleases (Spangberg et al., 2000).  Some viral RNAs have no cap, so would 
be vulnerable to degradation by ribonucleases.  Poliovirus, which is not capped, 
produces the protein 2Apro which is able to cleave parts of the cap-binding 
complex and the poly(A)-binding protein (PABP), whic  plays an important role 
in initiation of translation in eukaryotic cells (Joachims et al., 1999).  The 2’5’-
OAS/RNAse L system has already been described as an IFN stimulated 
mechanism in which RNase L degrades viral and cellular RNAs.  This system 
may also play a role in regulation of cellular mRNA activity (Bisbal and 
Silverman, 2007).  There is more to be learned about the interaction of viral 
RNAs with cellular degradation mechanisms, but these interactions may play a 
role in viral persistence.  One of the examples given above, HCV, is one of the 
best characterised persistent viruses which has evolved many means of avoiding 
various parts of the cells defences; there may be similar strategies in many other 
viruses. 
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1.5 Persistent infections 
Persistent infections are a feature of many viral diseases.  In order for a 
persistent infection to be established, viruses have to adopt a replication strategy 
that allows them to continuously reside in cells intead of killing them, and to be 
able to evade the innate and/or adaptive response so as not to be cleared from 
the body (reviewed by Oldstone, 2006; 2009).  Whilst many viruses become 
persistent through their ability to evade host defences, it must be remembered 
that non-persistent viruses have developed mechanisms to evade cellular 
defences too over the course of their evolution. 
 
Hepatitis C virus (HCV) is one of the best characterized persistent infections 
and will be briefly summarized here.  HCV is able to produce a persistent 
infection by various immune evasion mechanisms.  The NS3/4A protein is able 
to disrupt RIG-I signalling which prevents activation of the IRF-3 or NF-κB 
arms of the IFN-B induction pathway (Foy et al., 2005).  HCV proteins are also 
able to inhibit IFN-α/β signal transduction through the JAK-STAT pathway by 
blocking the binding of STAT transcription factors to the ISG promoters.  This 
happens through the action of protein phosphatase 2A which produces 
hypomethylated STAT1 which then associated with PIAS1, an inhibitor of 
STAT DNA binding (Heim et al., 1999; Blindenbacher et al., 2003; Duong et 
al., 2004).  HCV core protein has also been shown to i duce the expression of 
the suppressor of cytokine signalling -3 (SOCS3) (Bode et al., 2003).  HCV 
protein NS5A also has a role in IFN antagonism; it is able to induce the 
expression of interleukin 8 (IL-8) which is associated with reduced 2’5’OAS 
activity (Khabar et al., 1997).  HCV protein E2 can inhibit the kinase activity of 
PKR and block its inhibitory effect on protein synthesis (Taylor et al., 1999).  
Ribonuclease L, the effector enzyme of the 2’5’OAS pathway, selectively 
cleaves RNA at UA and UU dinucleotides, but HCV has evolved to have a 
relative lack of these dinucleotides (Han et al., 2004).  Another aspect of HCV 
evolution that may enable it to evade immune system and become persistent is 
that it exists as a population of closely related yt divergent genomes, known as 
quasispecies.  This genetic variability may play a role in protecting the virus 
from innate or adaptive immunity (Farci and Purcell, 2000).     
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The cells of the innate immune system include dendritic cells and natural killer 
(NK) cells.  Dendritic cells act as antigen presenting cells in peripheral tissues; 
they load antigenic peptides onto major histocompatibility complex (MHC) 
class I and II molecules and present them to T lymphocytes, thus initiating the 
adaptive immune response (reviewed by Guermonprez et al., 2002).  Different 
populations of dendritic cells express different receptors, so are able to detect 
different microbes (Kadowaki et al., 2001).  Plasmacytoid dendritic cells (pDC) 
produce large amounts of IFN-αβ on viral stimulation and promote the function 
of NK cells, B lymphocytes, T lymphocytes and myeloid dendritic cells 
(McKenna et al., 2005).  As they play such an important role in the interface 
between innate and adaptive immunity, they are often targets for persistent 
viruses (Liu et al., 2009).  In persistent infection of mice with lymphocytic 
choriomeningitis virus (LCMV), the pDCs lose their ability to secrete high 
levels of IFN-αβ which in turn, reduces the stimulation of NK cells; as a 
consequence, mice are less able to mount a response t  subsequent infection 
with murine cytomegalovirus (Zuniga et al., 2008).  It has also been shown that 
measles virus and LCMV both inhibit the development a d expansion of DCs 
through the generation of IFN that acts through a STAT2 dependant mechanism 
which has antiproliferation and antidifferentiation effects on DCs (Hahm et al., 
2005). 
 
Although some viruses are counteracted predominantly by the innate immune 
system, complete clearance of the virus from the body ften depends on the 
action of the adaptive immune system e.g. MNV, see above.  Viruses may also 
establish persistent infections by evading the adaptive immune system.  Studies 
on LCMV by Oldstone and colleagues demonstrated that viruses and antibodies 
circulate as immune complexes (Oldstone and Dixon, 1968).  These immune 
complexes are infectious and may contribute to the maintenance of persistent 
infections and allow the virus to infect different cell types (Oldstone, 2006).  
Viruses can also alter the processing and migration of their peptides in antigen 
presenting cells (Oldstone, 2009). Foot-and-mouth-disease virus (FMDV) 
infections may be persistent in some of the species it nfects.  FMDV persists in 
the pharynx of cattle (Zhang and Alexandersen, 2004), and can be detected in 
the African buffalo for up to 5 years (Hedger, 1972).  The precise mechanism is 
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still unclear, although it is likely that CD8 T cells activation is suppressed 
(Alexandersen et al., 2002).  Table 1.5 shows a selection of known persistent 
viruses described in the book Persistent Viral Infections, edited by Ahmed and 
Chen, 1999, with brief notes on the mechanism by which they may become 
persistent taken from each chapter and the most recent references. 
 
 
Persistent Virus Mechanism of immune 
evasion / establishment of 
persistence 




 Grovit-Ferbas et al. 
Human T cell leukaemia virus Integration of proviral DNA 
into host genome 
Kashanchi et al. 
Hepatitis B virus Neonatal tolerance, failure of 
clearance by T cells; T cell 
hyporesponsiveness 
Chisari and Lai; Billerbeck et 
al., 2007 
Hepatitis C virus Multiple evasion strategies Walker; Gale and Foy, 2005 
Polyomavirus Not fully understood Lukacher; Comoli et al., 
2008 
Papillomavirus Tolerance of viral antigens; 
inhibition of IRF-3 
Frazer and Dunn; Ronco et 
al., 1998 
Adenovirus E3 proteins migrate to 
membrane, protect infected 
cells from CTL response, also 
bind to MHC molecules 
Lukashok and Horwitz; 
Fessler et al., 2004 
Varicella-zoster virus Downregulation of MHC class 
I, upregulation of MHC class 
II 
Arvin; Abendroth and Arvin, 
2001 
Cytomegalovirus Downregulation of HLA class 
I and II; protein US3 delays 
maturation of MHC I 
Soderberg-Naucler et al.; Liu 
et al., 2009 
Epstein-Barr virus Modulates cytokine balance 
and apoptotic signals 
Hutt-Fletcher; Ohga et al., 
2002 
Herpesviruses 6,7,8 Binding immunoglobulins, 
inactivating antigen presenting 
pathways 
Meng and Pellett 
Measles virus V protein targets STAT-2 Schneider-Schaulies et al.; 
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Ramachandran et al., 2008 
Visna virus Integrate genome into host 
DNA 
Chebloune et al. 
Feline leukaemia virus Integrate genome into host 
DNA 
Rohn and Overbaugh 
Murine adenovirus Reduction in MHC class I Smith and Spindler 
Bovine papillomavirus E2 protein ensure tethering of 
viral genomes to host 
chromosomes for persistence 
of viral episomes 
Campo; You et al., 2004 
Theiler’s murine 
encephalomyelitis virus 
Restricted expression of viral 
genes, infection of microglial 
cells, suppression of MHC; L 
protein inhibits transcription 
of IFN genes. 
Tsunoda and Fujinami; 
Ricour et al., 2009 
Mouse hepatitis virus Cytotoxic lymphocyte escape 
mutations 
Stohlman et al.; Kim and 
Perlman, 2003 
Borna disease virus Low productivity by control 
of viral gene expression; 
inhibition of NF-κB; P protein 
interacts with TBK1 




Impairment of CTL response Buchmeier and Zajac; 
Wherry et al., 2003 
Bovine diarrhoea virus Envelope glycoprotein inhibits 
IFN expression; inhibits 
induction of apoptosis 
Akkina; Matzener et al., 
2009; Schweizer and 
Petehans, 2001 
 
Table 1.5  A selection of persistent viral infection with mechanisms of persistence; adapted from 
Persistent Viral Infections, edited by Ahmed and Chen, 1999. 
 
Several of the viruses referred to in table 1.5 are herpesviruses.  Herpesviruses 
are large dsDNA viruses; a feature of herpesvirus life cycles is their ability to 
become latent.  Varicella-Zoster virus (VZV) for example establishes latent 
infections in sensory ganglia; the linear DNA genomes assume a circular 
conformation and there is no active viral replication until later reactivation, or 
recrudescence (Mueller et al., 2008).  Latency is distinguished from persistence 
as in latency there is no viral replication, whereas in persistent infection viral 
replication continues, all be it at a low level tolerated by the host. 
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1.6 Genome-Scale Ordered RNA Structure (GORS) 
 
1.6.1 RNA secondary structures in viruses 
Secondary structure in RNA molecules was first described by Fresco et al., who 
described the presence of helical regions of Watson-Crick base-pairing of 
adenine-uracil and guanine-cytosine.  They described how secondary structure 
arises from intramolecular interactions, the lateral mobility that allows RNA 
molecules to bend and form local structures such as airpins (Fresco et al., 
1960).  RNA viruses’ replication strategies often involve the use of structured 
RNA elements.  These elements may be involved in tra slation and packaging 
signals during genome encapsidation.   
 
The internal ribosome entry site (IRES) is found in the 5’ untranslated regions 
(UTRs) of picornaviruses such as poliovirus (Pelletier and Soenberg, 1988) and 
flaviviruses such as hepatitis C virus (HCV) (Tsukiyama-Kohara et al., 1992) as 
well as dicistroviruses and lentiviruses; the structural and functional diversity of 
viral IRESes has recently been reviewed by Balvay et al (2009).  The IRESes 
consist of several domains of internal base-pairing a d the formation of stem 
loops which interact with host ribosomes during transl tion of viral genomes.  
Some of the best characterised IRES structures are those of picornaviruses, 
although there is marked divergence between the IRES’s across the genera, 
reviewed by Belsham (2009).   There are two major types of picornavirus IRES, 
type I and II.  Type I IRESes have up to 14 stem-loop domains, labelled A to N 
(Jang and Wimmer, 1990), and type two have 6 stem-loops labelled I to VI 
(Harber and Wimmer, 1993).  Enteroviruses and rhinoviruses have type I 
IRESes, whereas aphthoviruses and cardioviruses have type II.  All picornavirus 
IRESes have a GNRA motif in their central domains ad  polypyrimidine tract 
20 to 25 nucleotide upstream of an AUG start codon (Balvay et al., 2009).  In 
aphthovirus, the 3’ end of their type II IRESes interacts with the eukaryotic 
initiation factors to drive translation of the viral genome (Kolupaeva et al., 
2003)   Another of the best characterised IRES’s is that of HCV; its structure 
and function are reviewed by Lukavsky (2009) but a brief summary will be 
given here.  The HCV IRES contains two major domains, II and III, and a 
smaller domain IV (Brown et al., 1992; Kieft et al., 1999).  The IRES extends 
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from residue 40 to 372 of the viral genome (Fukushi et al., 1994).  The largest 
domain, domain III, consists of branching hairpin stem-loops made up of basal, 
middle and upper parts, each of which contains further stem-loops (Brown et al., 
1992).  The function of the IRES is dependant on its secondary structure as has 
been demonstrated by mutagenesis studies (Brown et al., 1992; Fukushi et al., 
1994).  Domain III contains the regions that interact directly with eIF3 and the 
40S ribosomal subunit leading to a IRES-40S-eIF3 complex and consequent 
translation (Kieft et al., 2001). 
 
The presence of structured regions, within the coding region of viruses, that 
have a role to play in replication have also been dscribed.  In poliovirus there is 
a 61 nucleotide stem-loop, from position 4435 to 4495, which is also well 
conserved in the Enterovirus genus.  As it was required for viability it was 
named a cis-acting replication element (CRE) (Goodfellow et al., 2000).  
Similar structures have been described in enteroviruses and rhinoviruses (Xiang 
et al., 1995), foot-and-mouth disease virus (Mason et al., 2002) and the Brome 
mosaic virus (Joost Haasnoot et al.., 2002). 
 
Stem-loops may also be found in the 3’ region of viral genomes.  The terminal 
46 bases of the HCV genome were described as a stem-loop structure in 1996 
(Kolykhalov et al., 1996) which was shown to be essential for HCV infectivity 
and replication (Kolykhalov et al., 2000; Yi and Lemon, 2003).  HCV has many 
stem-loops in its coding region (Tuplin et al., 2002) one of which has been 
identified as a CRE (You et al., 2004).  A recent study has also shown that there 
is a direct interaction between the IRES in the 5’ UTR and structured elements 
in the 3’ region of the genome (Romero-Lopez and Berzal-Herranz, 2009). 
 
RNA structures also form packaging signals during ecapsidation e.g. HIV 
(Huthoff and Berkout, 2002). 
 
1.6.2 Bioinformatic prediction of RNA secondary structure 
RNA secondary structures can be predicted by use of nergy minimization 
algorithms based on dynamic programming (the development of these 
techniques is reviewed by Mathews, 2006).  The principle of these algorithms is 
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to predict the most energetically favourable structure compared to other 
potential structures.  The nearest neighbour model for predicting secondary 
structure, described by Tinoco et al. 1973, predicts free energy change at 37°C.  
An RNA molecule will exist in equilibrium between astructured and 
unstructured state.  The free energy change for a given structure quantifies its 
stability.  The structure with the lowest free energy is the most represented at 
equilibrium, and therefore the single most likely structure (Mathews and Turner, 
2006).  The nearest neighbour model is so called as it is dependant on the 
identity of the motif and adjacent base pairs (Mathews, 2006).  Algorithms were 
later developed to include the non-Watson-Crick pairing of guanine-uracil and 
to account for loop regions (Mathews et al., 2004).  Dynamic programming 
algorithms (Nussinov et al., 1980) implicitly check all the possible secondary 
structures, although they don’t actually generate them.  The first step, known as 
the fill step, the lowest free energy is determined for each fragment, starting 
with the shortest then moving to the longer fragments.  The longer fragments’ 
folding energies are determined by referring back to the energies of the short 
fragments that have been stored (Mathews and Turner, 2006).  The second step, 
known as traceback, uses the free energies to determine the exact structure that 
has the lowest free energy (Mathews, 2006).  An algorithm that is also able to 
detect pseudoknots has also been devised (Rivas and Eddy, 1999).  These 
algorithms may not produce reliably the true RNA secondary structure as in 
nature RNA molecules may have more than a single conformation and form 
suboptimal foldings.  The prediction of suboptimal foldings was described by 
Zuker in 1989.  Another method, developed by McCaskill (1990), called base-
pair partition functions, provides information about the probability of secondary 
structures.  Dynamic programming algorithms have ben used in programs such 
as MFOLD (Zuker, 2003), Pfold (Knudsen and Hein, 1999), RNAalifold 
(Hofacker et al., 2002) HotKnots (Ren et al., 2005) and RNAz (Gruber et al., 
2007).  One of the latest algorithms is UNA fold which is an integrated program 
consisting of folding simulation, hybridization and melting pathways which 
combines free energy minimization, partition function and stochastic sampling 




1.6.3 Discovery of GORS 
Genome-level ordered RNA structure was first described by Simmonds et al. in 
2004.  This study consisted of large-scale thermodynamic predictions of RNA 
secondary structures across the genomes of viruses from the families 
Picornaviridae and Flaviviridae.  The program MFOLD (Zuker et al., 1989; 
2003) was used to predict the most stable secondary structure of genomic 
fragments throughout the length of complete genome sequences of four genera 
of Picornaviridae (Enterovirus, Aphthovirus, Teschovirus and Hepatovirus) and 
four genera of Flaviviridae (Flavivirus, Hepacivirus, GBV-C-like viruses and 
Pestivirus).  The minimum free energy (MFE) of the energetically most stable 
structure, as predicted by the MFOLD algorithm, of each sequence was 
compared with the MFE of 50 randomized control sequences.  The results were 
expressed of minimum free energy differences (MFEDs) i.e. the percentage 
difference between the native sequence and the mean of the 50 randomized 
controls.  Results were also expressed as a Z score.  Th  Z score is the position 
of the MFE within a distribution of the MFEs of the randomized sequences, 
expressed as the number of standard deviations from the mean (Workman and 
Krogh, 1999).  Several randomization strategies were used in order to preserve 
certain non-random elements of the sequences such as dinucleotide frequencies.  
In viral RNA genomes the dinucleotides CG and UA are underrepresented and 
CA and UG are overrepresented (Rima and McFerran, 1997).  Randomization 
strategies that preserve non-random elements include:  
i)  Nucleotide order randomization (NOR): randomization of the sequence order. 
ii)  Codon order randomization (COS): avoids disruption of sequence order 
within codons. 
iii) Like-codon randomization (CLR): randomization of the order of codons 
encoding each amino acid but maintaining amino acidsequence. 
iv) Like-codon swap (CLS):pairwise exchange of codons specifying each amino 
acid. 
v) Dinucleotide randomization (CDR): randomization f codons with identical 
first and third bases. 
vi) Dinucleotide swap (CDS): pairwise exchange of cdons with identical first 
and third bases. 
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vii) CDLR: codon composition, order are preserved and dinucleotide 
frequencies are preserved, combines CLR and CDR. 
viii) NDS: retains regional differences in base comp sition and preserves 
dinucleotide composition. 
ix) NRR: preserves trinucleotide frequencies. 
x) NTS: preserves tetranucleotide frequencies.  
(Tuplin et al., 2002; Simmonds et al., 2004). 
 
The result was that the certain genera from Picornaviridae and Flaviviridae 
showed areas of predicted structure throughout the lengths of their genomes.  Of 
the Picornaviridae, the aphthoviruses and teshcoviruses showed extensive 
predicted structure whereas hepatoviruses and enteroviruses did not.  Of the 
Flaviviridae, HCV and GBV-C showed extensive secondary structure whereas 
flavivirus and pestivirus did not.  This phenomenon was termed genome-scale 
ordered RNA structure (GORS).    Figure 1.10 shows the predicted structure for 
fragments of the genomes of eight genera. 
Figure 1.10  The distributions of MFEDs across the genomes of genera of picornaviruses (blue) 
and flaviviruses (red); each bar represents the mean MFED of a 498 base fragment of the 
genome.  Those genera that possess GORS are Aphthovirus, Teschovirus, GBVC-like virus and 
Hepacivirus.  Adapted from Simmonds et al., 2004. 
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1.6.4 Possible roles of GORS in viral persistence 
GORS was not considered to be part of a fundamental replication strategy as 
within virus families, some genera have GORS and others do not, and 
replication strategies are usually conserved within families.  An association was 
observed, however, between the presence of GORS and the virus’s ability to 
establish persistent infections in their natural hosts.  The viruses with the highest 
MFED scores, HCV, GBV-C-like and the genus Aphthovirus are all known to 




Figure 1.11  Correlation between secondary structure and persistence.  Non-persistent viruses 
(orange) have lower % MFEDs than persistent viruses (blue).  
 
The mechanism by which GORS may enable viruses to persist is not yet clear, 
although the avoidance of the dsRNA recognition pathw ys of the innate 
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immune system by, in some way, mimicking cellular RNA structures.  It seems 
also, that GORS is an evolutionarily conserved phenomenon, as experimental 
drift of just 2 % sequence change reduced the MFED, and 10 % drift reduced 
the MFED of GORS viruses into that of non-GORS viruses, so maintaining a 
high degree of secondary structure throughout the genome must be 
advantageous for those viruses that contain it (Simmonds et al., 2004). 
 
Recent work has investigated the physical characteristics of GORS, which had 
previously been only a bioinformatically predicted phenomenon.  Probe 
hybridization was carried out on the genomes of predict d GORS viruses: HCV, 
GBV-C and MNV; and non-GORS viruses: enterovirus C,tick-borne 
encephalitis virus, rubella virus and bunyamwera virus.  The GORS genomes 
were largely inaccessible to the probes, whereas the non-GORS viruses were 
able to hybridize with the probes throughout the majority of the genome.  
Atomic force microscopy of viral RNA transcripts ofGORS and non-GORS 
viruses revealed that GORS RNA (HCV and GBV-C) appered as tightly 
compacted spheroids whereas the non-GORS viruses (poliovirus and rubella 




1.7 Project aims 
The aim of this project was conduct the first study into the role of GORS in the 
persistence of certain positive-sense RNA viruses.  There were two lines of 
investigation: 
 
i)  Study of GORS viruses - as many of the predicte-GORS viruses are difficult 
to work, e.g. hepatitis C virus (HCV) and foot-and-mouth disease virus (FMDV) 
require category 3 containment facilities, the viruses chosen for study in this 
project were ERAV and MNV.  The aim of this study was to: 
 
- determine prevalence of ERAV in horses admitted to the Equine 
Hospital, R(D)SVS 
- determine prevalence of MNV in cohorts of laboratory and wild mice 
- complete genome sequencing of novel viruses identifi d for 
phylogenetic and bioinformatics analysis 
- investigate effect of multiple passage in cell culture on the degree of 
secondary structure present in viral genomes 
 
 
ii)  Study of the effect of GORS on RNA stability and the interaction of viral 
RNA with cellular innate immunity – these studies addressed the observation 
that GORS viruses are able to establish persistent infection and tested the 
following hypotheses: 
 
- RNA transcripts of GORS virus genomes are more stable in the cell 
cytoplasm than RNA transcripts of non-GORS virus genomes. 
- RNA transcripts of GORS virus genomes induce IFN-β less strongly 
than RNA transcripts of non-GORS virus genomes. 
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Chapter 2 Material and Methods 
 
2.1.1 Cell Culture 
Cell lines used: CRE3T3 (murine fibroblast), NIH3T3 (murine fibroblast), RD 
(human rhabdomyosarcoma) cells, Vero 136 (African green monkey kidney 
epithelial cells) MDCK (Madin-Darby Canine Kidney), RAW 264.7 (murine 
leukaemic monocyte macrophage), A549n (human alveolar basal carcinoma) 
and A549NPro cells (expressing Bovine Viral Diarrhoea Virus NPro protein).  
All cell lines grow as adherent monolayers. 
 
All cell lines were maintained in sterile plastic flasks (80 cm2 surface area 
(T80)) (Nunc) at 37°C in a humidified 5 % CO2 atmosphere.  All cell lines were 
grown in Dulbecco’s modified Eagles Medium (DMEM) (Invitrogen) 
supplemented with 10 % (v / v) foetal calf serum (FCS) (Invitrogen, UK), L-
glutamine (200mM Invitrogen), penicillin (100 U / ml, Invitrogen) and 
streptomycin (100 µg / ml, Invitrogen). 
 
2.1.2 Cell Counting 
Cell lines were maintained by splitting the cell population twice a week, at 
intervals of 3 or 4 days.  At a confluency of approximately 90 % the cell 
monolayers were washed briefly with phosphate buffered saline (PBS).  To 
remove the monolayers from the flasks the majority of cell lines were incubated 
with Tryspin-ethylene diamine tetraacetic acid (EDTA) (0.05 % Trypsin, 0.53 
mM EDTA, Invitrogen) in variable conditions for each ell line until the cells 
had detached from the surface of the flask: 
RAW 264.7 Cells weakly adherent, trypsin not required as cells could 
be detached by repeated pipetting in culture medium alone 
CRE3T3 / 
NIH3T3 
Cells incubated with trypsin at room temperature for ~1 
minute 
RD  Cells incubated with trypsin at room temperature for ~2 
minutes 
Vero 136 Cells incubated with trypsin at room temperature for ~2 
minutes 
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A549n / Npro Cells incubated with trypsin at 37°C for ~2 minutes 
MDCK Cells incubated with trypsin at 37°C for up to 20 minutes 
Table 2.1  List of cell lines used in this project 
 
The trypsin was inactivated with an equal volume or xcess of 10 % FCS tissue 
culture medium.  The cells were collected by centrifugation at 478 x gravity (g) 
for 5 minutes.  The cell pellet was resuspended in 10 ml of tissue culture 
medium.  Ten microlitres of this suspension were added to a haemocytometer 
and the cells were counted; when considered necessary 10 µl of cell suspension 
were added to an equal volume of 0.4 % trypan blue (Sigma) in order to assess 
the proportion of live to dead cells.  An appropriate number of cells were added 
to a fresh flask, e.g. for most cell lines 2 x 106 cells were added to a T80 flask, 
although RAW 264/7 cells are smaller than the other cells so ~4 x 106 were 
added. 
 
2.1.3 Freezing and thawing cells 
Cells were periodically frozen and thawed as necessary.  Before freezing cells 
were grown to approximately ~80 % confluency when they were still in the log 
phase of growth.  The monolayers were washed with PBS, trypsinised where 
necessary, centrifuged, resuspended and counted as previously described.  
Freezing mix, consisting of 90 % FCS and 10 % dimethyl sulphoxide (DMSO), 
was made to allow 1 ml per vial at 2-5 x 106 cells per cryovial (Nunc).  Cells 
were then frozen at -80°C in a freezing container (Nalgene) containing 100 % 
isopropyl alcohol to ensure a cooling rate of 1°C / minute.  The cryovials were 
transferred the following day to storage in liquid nitrogen at a temperature of 
approximately -196°C. 
 
Before thawing cells, cell culture medium was warmed in a 37°C water bath and 
20 ml were pipetted into a universal tube for each vial of cells to be thawed.  
Cryovials were removed from liquid nitrogen and placed on dry ice to prevent 
gradual thawing.  The vials were then thawed rapidly in the 37°C water bath.  
Several drops of medium were added to each vial to equilibrate the osmotic 
pressure slowly.  The cells were then added to the 20 ml of medium in the 
universal and centrifuged at 359 x g for 5 minutes at room temperature.  The 
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supernatant was gently poured off, the cells resuspended in 7 ml of medium and 
added to a 25 cm2 flask (T25).  The following day the medium was changed in 
order to ensure that there was no DMSO remaining. The cells were moved up to 
the next sized flask as soon as they were growing well and had become 
confluent in the T25. 
 
 
2.2 PCR screening of ERAV and MNV 
 
2.2.1 Collection and processing of equine samples 
Samples of ~2 ml of equine blood were taken by veterinary surgeons from 
horses at the Large Animal Hospital at Easter Bush Veterinary Centre as a 
diagnostic veterinary procedure.  The blood was allowed to stand for 
approximately 30 minutes before being centrifuged at 3000 rpm for 5 minutes.  
The serum was decanted into fresh tubes and stored at -20°C at the clinical 
laboratory of the Veterinary Pathology Unit at the Easter Bush Veterinary 
Centre.   
 
Equine faecal samples were collected from the horse box s housing equine in-
patients at the Large Animal Hospital at Easter Bush Veterinary Centre.  As the 
boxes were cleaned every day the faecal samples would have been less than 1 
day old.  The faecal samples, weighing 1-3 g, were soaked in PBS at 3 ml PBS 
per 1 g faecal material for 6-8 hours with brief vortexing every 30 minutes in 
universal tubes.  The faecal suspensions were centrifuged at 4000 x g for 20 
minutes.  One millilitre of the supernatant was centrifuged additionally at 14926 
x g for 10 minutes.  The supernatant was stored at -20°C for subsequent RNA 
extraction. 
 
Isolates of ERAV and ERAV passaged from clinical samples were also kindly 






2.2.2 Collection and processing of murine faecal samples 
Mouse faecal samples were collected from thirty-nine cages in the animal unit at 
the University of Edinburgh by Mr Billy Smith.  Each tube contained faecal 
pellets from a group of in contact animals.  Up to 0.1 g of faecal material was 
suspended in 1 ml of PBS and allowed to soak for 2-3 hours.  The faeces were 
then mechanically disrupted with a pipette tip and vortexed for 2 minutes.  The 
faecal suspensions were clarified by centrifugation at 4000 x g for 20 minutes.  
The supernatants were passed through a 0.2 µm filter before being stored at -
20°C.  Murine faeces were also collected with kind permission from 
Morningside Pets, Edinburgh and processed as describ d above.  Wild house 
mice (Mus musculus) were kindly collected in standard house traps by various 
people at the University of Edinburgh.  The mice were killed under schedule 1 
of the Animals (Scientific Procedures) Act by inducing deep anaesthesia by 
exposure to gaseous halothane (Concord Pharmaceuticals Ltd) followed by 
cervical dislocation.  The mice were dissected and the faecal pellets removed 
directly from the rectum.  Faeces were then processed as described above.  
Three species of wild rodent, wood mouse (Apodemus silvaticus), field vole 
(Microtus agrestis) and bank vole (Myodes galveolus) had been trapped, 
euthanased and stored at -70°C by Anna Meredith, University of Edinburgh, 
who kindly allowed access to these animals for the collection of tissue and 
faecal samples.  Small samples of spleen and mid-jejunum were placed in 0.5 ml 
of RNA Later (Qiagen) and stored at -20°C.  Faecal samples were processed as 
described above. 
 
2.2.3 Extraction of viral RNA 
Extraction of viral RNA from faecal suspensions was carried out using the 
QIAamp Viral RNA Mini Kit (Qiagen) following the manufacturer’s 
recommended protocol.  The lyophilised carrier RNA was resuspended in the 
buffer AVE to a concentration of 1 µg / µl before adding 5.6 µl carrier RNA 
solution to 5.6 ml of the lysis buffer AVL per sample.  Carrier RNA is added to 
enhance the binding of viral nucleic acids to the Qiamp Mini membrane and to 
protect viral RNAs from degradation from any remaining RNases.  One hundred 
and forty microlitres of faecal suspension was added to 560 µl buffer AVL 
containing carrier RNA, mixed by vortexing for 15 seconds (s) and incubated at 
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room temperature for 10 minutes.  Five hundred and sixty microlitres of 70 % 
ethanol were added to each sample and mixed by vortexing for 15 s.  Six 
hundred and thirty microlitres of the solution was added to the QIAamp Mini 
column and centrifuged at 6000 x g for 1 minute, th filtrate was discarded and 
the remainder of the solution added to the column and the spin repeated.  
Buffers AW1 and AW2 were diluted with 100 % ethanol as directed.  Five 
hundred microlitres of AW1 were added to the column and centrifuged at 6000 
x g for 1 minute; then 500 µl of AW2 were added to the column and centrifuged 
at 20000 x g for 3 minutes.  The columns were placed into an RNase free tube, 
60 µl of buffer AVE added, incubated at room temperature for 1 minute before 
the RNA was eluted by centrifugation at 6000 x g for 1 minute 
 
 
2.2.4 Reverse transcription 
Reverse transcription of viral RNA into cDNA was carried out using the 
Reverse Transcription System (Promega).  5 µl of RNA were added to RNase 
free tubes and heated to 70°C for 10 minutes and placed on ice.  The following 
reaction mix was then prepared: 
 
Nuclease-Free Water    - 4.8 µl 
MgCl2, 25 mM    - 4 µl 
Reverse Transcription 10x Buffer  - 2 µl 
dNTP Mixture, 10 mM   - 2 µl 
Random Primers, 0.5 µg / ml   - 1 µl 
Recombinant RNasin Ribonuclease inhibitor - 0.5 µl 
AMV Reverse Transcriptase, 22 U / µl - 15 U / 0.7 µl 
 
15 microlitres of mix were added to the 5 µl RNA to make a 20 µl reaction 
volume.  The samples were incubated at room temperatur  for 10 minutes then 
at 42°C for 50 minutes.  The AMV reverse transcriptase was deactivated by 
heating the samples at 95°C for 5 minutes then incubated on ice for 5 minutes.  




2.2.5 Design primers for screening of ERAV and MNV 
Primers were designed for screening from consensus sequences made from 
published sequences of ERAV and MNV.  ERAV primers were designed in the 
capsid region as well as the 5’ UTR.   Screening primers were also made for 
screening wild rodent samples from a consensus sequence consisting of 
published MNV and human norovirus sequences.  Primers w re designed as a 
nested polymerase chain reaction (PCR) to increase sensitivity and specificity; 
the broad norovirus PCR was hemi-nested as the same antisense primer was 
used in both primary and secondary reactions. 
 
 














































Noro 1729 OS Sense SCCCMSTCACKCTVAAVTGTG 
Noro 2035 AS Antisense CCYTTSCCRTRNGGGGTRTT 
306 
Noro 1745 IS Sense YTGTGAYAGRATTGARAAYAAR 
Noro 2035 AS Antisense CCYTTSCCRTRNGGGGTRTT 
290 
Table 2.2  List of screening primers for ERAV, MNV and norovirus 
 
 The primers contain the following degenerate bases: 
R – A or G H - A or T or C 
Y – C or T B – G or T or C 
M  – A or C D – G or A or T 
K  – G or T V – G or A or C 
S – G or C N – A or C or G or T 
W - A or T  
Table 2.3  List of degenerate bases. 
 
2.2.6 Polymerase chain reaction (PCR) 
Polymerase chain reaction is a technique used to amplify specific DNA 
sequences from template DNA.  Sense and antisense prim rs are designed to 
anneal specifically to their corresponding DNA strands.  During the reaction the 
DNA double helix is denatured before the primers anneal.  The primers are 
extended by the action of the DNA polymerase adding complementary 
nucleotides during the extension phase.  The cycle is r peated multiple times 
creating a predominance of the specific product.   
 
The following reaction mix was prepared using a reaction buffer containing 50 
mM Tris-HCl (pH 8.5), 50 mM NaCl and 7.5 mM MgCl2; 3 mM dNTP 
(Promega); primers at 10 OD (optical density at 260nm) (Sigma) and GoTaq 
DNA polymerase (Promega): 
 
Nuclease free water    - 13.5 µl / 14.5 µl 
5x Colourless GoTaq Reaction Buffer  - 4 µl 
dNTPs, 3 mM     - 0.2 µl 
Sense primer, 10 OD    - 0.1 µl 
Antisense primer, 10 OD   - 0.1 µl 
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GoTaq DNA Polymerase, 5 U / µl  - 0.1 µl 
Template / primary PCR product  - 2 µl / 1 µl 
 
The primary PCR reaction consisted of 18 µl of mix plus 2 µl of template 
cDNA; the secondary PCR reaction consisted of a 19 µl reaction plus 1 µl of 
primary PCR product. 
 
The following PCR reaction program was run: 
 
No. of cycles Temperature (°C) Time 







1 72 5 min 
Table 2.4  Standard PCR conditions 
 
2.2.7 Agarose gel electrophoresis 
A 2 % agarose gel was made by dissolving 6 g of SeaKem LE agarose 
(Cambrex) in 300 ml of 1x TAE buffer (50x TAE buffer made by dissolving 
242g Tris base (VWR), 57.1 ml glacial acetic acid (Sigma) and 100 ml 0.5 M 
EDTA (Fisher Scientific) in 1 l of water.  The agarose was dissolved by heating 
in a microwave oven on full power for 5 minutes and allowed to cool whilst 
being mixed by a magnetic stirrer.  Thirty microlitres of ethidium bromide, at 10 
mg / ml (Fluka) were added to the gel prior to pouring into a gel tray.  After the 
gel had set it was stored at 4°C.  Nine microlitres of secondary PCR product 
were mixed with 1 µl of 10x loading dye (containing 0.1 M EDTA (Fisher 
Scientific); 0.1 % bromophenol blue (Fisher Scientific); 0.1 % xylene cyanol 
(Fisher Scientific); 1.75 M sucrose (Fisher Scientific)) and gels run at 150 V for 
30-40 minutes.  The Low Range Plus DNA Ladder (Fisher Scientific) or 100 bp 







2.2.8 PCR of two regions of MNV for phylogenetic analysis 
After screening murine samples for MNV, any PCR positive samples underwent 
further PCRs with the purpose of determining the sequence of the PCR products 
for phylogenetic analysis.  Two regions were selectd, one in the non-structural 
region, the other in the structural region and prime s designed for a nested PCR 
for each to create products of 790 and 782 bases in l ngth. 
 
Table 2.5  Primers used for PCR of two MNV sequences for use in phylogenetic analysis 
 
2.3 Sequencing of ERAV and MNV genomes 
 
2.3.1 Design of primers for complete genome sequenci g 
Primers were also designed for sequencing the length of the genomes of ERAV 
and MNV.  Primers were designed so that each PCR product would be 
approximately 800 bases long.  The sequencing reaction gives reliable 
sequences of approximately 500 bases starting from both the sense and antisense 
primers, so a product length of 800 bases ensures that there is no gap.  The 
primer set were also designed to overlap by approximately 100 bases to ensure 
agreement between the different sequencing reactions. 
 
Region Sense Start Sequence Product 
length 
L1 OS 892 TCGTGTTGAGCTGTGAYTGGAC 
NS3 OAS 1809 GRTTGGTGGTGATGATGATGAC 
917 
 IS 991 ACTGGATGATCTCYATCTTTGG 
 IAS 1781 GTCAAACATCTTCCCCTTRTTC 
790 
     
L2 OS 5973 GACMTTCACCMTGATTGAGCAG 
VP1-ORF3 OAS 6966 TGTTGATGGCRTTCTCCTGGGC 
993 
 IS 6112 GTSACCACYTTTGAGATGATYC 




Figure 2.1.  Position of primers on ERAV genome.  Red and blue lines show sets of nested primers; 
blue dots and lines represent outer primers in each set, the red lines represent inner primer sets.  The 
products of inner primer PCRs were sequenced.  
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Name Sense Start Sequence Product 
length 
UTR OS 189 CAGAGCTTCCCGGCTTTAAGGGTTAC 
 OAS 567 GTGTCGCTTYGTRAGGTTCACTCCGC 
378 
 IS 294 CTTKTCTCYYAAACAATGTTGGCGCGC 
 IAS 523 ACCATCCAGAGCAATGGCACCGGGAA 
229 
     
UTR2 OS 189 CAGAGCTTCCCGGCTTTAAGGG 
 OAS 1152 TGGTCACTCACCCAATCAATTG 
963 
 IS 348 CCTGTCATTGACTGGTCGAAGG 
 IAS 1082 GAATYCCAAGAATCTGTGTCAG 
734 
     
L OS 762 GGCAAGCTGGTTACAGCCCTGA 
 OAS 1616 CTGCATCAATTGARTTYTGGTA 
854 
 IS 835 AGCAGCAGCAGRAACGCGGGAG 
 IAS 1454 TGCCCARTGACTCAAAGTCATA 
619 
 
     
S1 OS 1200 TGTACAAAYTRTGGCAACATGG 
 OAS 2282 CAATRTAGGGCATVACCAAATG 
1082 
 IS 1357 RGGTTGGATYTGTGTYGATGAC 
 IAS 2078 CCACATCCCAKCCRTTCTTSAC 
721 
     
S2 OS 1787 ATTGARACAACNGTGGTTGGRG 
 OAS 3459 GTCTTRGTTGGTGCYCCAACMG 
1672 
 IS 1933 CACHTTYAARGTDGGYGAGTGG 
 IAS 2821 GTGRGGRGGCACAAAMGCMACC 
888 
     
S3 OS 2369 ACWGTRCCYGTGACCATGTCRG 
 OAS 3684 GCACCDGGMAGCCAATTGTARG 
1315 
 IS 2663 ATGGATGTRTCBCTCAGYGCDG 
 IAS 3459 GTCTTRGTTGGTGCYCCAACMG 
796 
     
S4 OS 2663 ATGGATGTRTCBCTCAGYGCDG 
 OAS 4307 CRACCACTCCTTCAGGSGTTTC 
1644 
 IS 3104 CCYGAYAAGCAGGTYACHAAYG 



















NS1 OS 3882 CTGGAGATGTTGAGAGCAACCC 
 OAS 4766 CATCAAAATATGTRGGGTCWGG 
884 
 IS 3944 GCMTTGTCAACRTCRCTRGGTG 
 IAS 4670 AAGATTTKCCYTGYCCTGATGC 
726 
     
NS2 OS 4517 CGCCAGTGGTTYAARGACATGC 
 OAS 5424 CTYCTRGTCATRTATGACTCCCA 
907 
 IS 4541 CAGCGTGCTCTYGCYGTGAARG 
 IAS 5405 CCCAYTTRAGATACTCTTCATG 
864 
     
NS3 OS 5139 ATGGRCAGGCTGTTAAATTGGC 
 OAS 6251 CAAGRCGAMYAACGTTGCCCTG 
1112 
 IS 5282 AARTGYWCAACTGATGAGGARC 
 IAS 6135 GCAGGTGAGCCWGCMACAATTG 
853 
     
NS4 OS 5656 GAARAATGTTCAGCCAATTGAG 
 OAS 6995 CTCTCATTGCATCAGCTGCATG 
1339 
 IS 5978 TCHCCACACCARGCACGYACTG 
 IAS 6815 GYTGCCTACCAACYACCACATG 
837 
     
NS5 OS 5978 TCHCCACACCARGCACGYACTG 
 OAS 7380 AARGTSACCTCYGAAAGCGTTC 
1402 
 IS 6722 AAAGATGAGATYCGCCCACTTG 




Figure 2.2.  Position of primers on MNV genome.  Red and blue lines show sets of nested primers; blue 
dots and lines represent outer primers in each set, th  red lines represent inner primer sets.  The 




Name Sense Start Sequence Product 
length 
5’ OS 1 GTGAAATGAGGATGGCAACGCC 
 OAS 727 TAGAGATCTTCGCCCTCTTCAG 
726 
 OS 1 GTGAAATGAGGATGGCAACGCC 
 IAS 407 CTCYYTTGCATCCATRGCGTCC 
406 
     
NS1-2.1 OS 58 GCAAAAACAAAAAGGCTTCATC 
 OAS 1139 CGAGTTGGTGGAGGCGAGCTTG 
1081 
 IS 100 GAGCACCTAGCCTTCTCTCTTC 
 IAS 407 CTCYYTTGCATCCATRGCGTCC 
307 
     
NS1-2.2 OS 100 GAGCACCTAGCCTTCTCTCTTC 
 OAS 1264 ATGACAGCCTGCTCCATGTTGG 
1164 
 IS 599 GTTGAGGAAGTGYGTTGGCATG 
 IAS 1139 CGAGTTGGTGGAGGCGAGCTTG 
540 
     
NS3.1 OS 892 TCGTGTTGAGCTGTGAYTGGAC 
 OAS 2136 ARTCATAGACCTTGTTYTGGAG 
1244 
 IS 991 ACTGGATGATCTCYATCTTTGG 
 IAS 1781 GTCAAACATCTTCCCCTTRTTC 
790 
NS3.2 OS 991 ACTGGATGATCTCYATCTTTGG 
 OAS 2212 ATCGCTGCCATCTTGTACCARG 
1221 
 IS 1674 GGCATGGACAAYGTGGTGAAGG 
 IAS 2136 ARTCATAGACCTTGTTYTGGAG 
462 
     
NS4 OS 1674 GGCATGGACAAYGTGGTGAAGG 
 OAS 3018 CAACACGGGACCAGATGGARAC 
1344 
 IS 1961 CTACAGCCACATCAAYTTCATC 
 IAS 2587 TCCTCAAAGAGRTCAAAGGCAC 
626 
     
NS5 OS 1961 CTACAGCCACATCAAYTTCATC 
 OAS 3638 CCAGAACATGGTCTTGGTGATC 
1677 
 IS 2391 TGTGTCAGRAGGATYAAGGAGG 









NS6 OS 2391 TGTGTCAGRAGGATYAAGGAGG 
 OAS 4268 ATCCATGTGGTAYCTGAARTTG 
1877 
 IS 2732 CAAGTACTCCATTGATGAYTAC 
 IAS 3638 CCAGAACATGGTCTTGGTGATC 
906 
     
NS7.1 OS 2732 CAAGTACTCCATTGATGAYTAC 
 OAS 5067 CATCCTCATTCACAAAGACTGC 
2335 
 IS 3423 TAYAAGAARGGAAACACCTGGG 
 IAS 4268 ATCCATGTGGTAYCTGAARTTG 
845 
     
NS7.2 OS 3423 TAYAAGAARGGAAACACCTGGG 
 OAS 5455 TGGGAAAATAGGGTGGTACAAC 
2032 
 IS 4099 TYTGGGGCTCTGAYCTTGGCAC 
 IAS 5067 CATCCTCATTCACAAAGACTGC 
968 
     
VP1.1 OS 4840 CAGGACAYGCTCAGAGACCCTC 
 OAS 6085 TCTCRGTCTGSACCTCGATCTC 
1245 
 IS 4919 TGTGGCTTCCCGGGTCTCCAAG 
 IAS 5455 TGGGAAAATAGGGTGGTACAAC 
536 
VP1.2 OS 4919 TGTGGCTTCCCGGGTCTCCAAG 
 OAS 6616 AGCTGACGACCTCAAAGAAGCC 
1697 
 IS 5334 TGCCCACCTCTCAGCCATGTAC 
 IAS 6085 TCTCRGTCTGSACCTCGATCTC 
751 
     
VP1.3 OS 5334 TGCCCACCTCTCAGCCATGTAC 
 OAS 6717 CACCTCCAATCGCTCCRAARAG 
1383 
 IS 5973 GACMTTCACCMTGATTGAGCAG 
 IAS 6616 AGCTGACGACCTCAAAGAAGCC 
643 
     
ORF3.1 OS 5973 GACMTTCACCMTGATTGAGCAG 
 OAS 7224 GRGACCAGGAACCTCCACGAAG 
1251 
 IS 6112 GTSACCACYTTTGAGATGATYC 
 IAS 6894 AAGAGTTGGYTTGGAGCTGCTG 
782 
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ORF3.2 OS 6112 GTSACCACYTTTGAGATGATYC 
 OAS 7321 TCTCTTCCAACCTATGCCCTGC 
1209 
 IS 1 6765 TCARAACCTTCAGGCAAATAAC 
 IAS 7224 GRGACCAGGAACCTCCACGAAG 
459 
     
3’ OS 6765 TCARAACCTTCAGGCAAATAAC 
 OAS 7366 GCAGTAAGCAGAAATCATTTTC 
601 
 IS 6957 CCAGGAGAAYGCCATCAACATC 
 OAS 7366 GCAGTAAGCAGAAATCATTTTC 
409 
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2.3.2 Sequencing reaction 
For sequencing reactions, the following reaction mix was assembled: 
 
Nuclease free water    - 17 µl 
Sense or antisense primer, 10 OD  - 1 µl 
Big Dye (Applied Biosystems)  - 1 µl 
PCR product     - 1 µl 
 
 
The following reaction was carried out: 
 







Sequencing reaction conditions 
 
The products of the sequencing reaction were sent to The Gene Pool, The 
University of Edinburgh School of Biological Sciences.  Sequence data were 
returned in the form of a chromatogram, which could be visualized using 
Chromas Lite (www.technelysium.com.au), and an accompanying file 
containing a sequence readout.  The sequence files were converted into a 
FASTA format and imported into Simmonics v1.73 for analysis and editing; 
sequence files were checked against the chromatogram for accuracy.  Published 
sequences of ERAV and MNV were also imported in FAST  format from 
NCBI Entrez Nucleotide (www.ncbi.nlm.nih.gov/sites/entrez) for use in helping 
to construct received sequences and generating phylogenetic trees. 
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2.3.3 Genome sequencing of a novel norovirus 
 
During screening of wild rodent faecal samples with the degenerate norovirus 
primers a positive result was seen in one sample from a wood mouse (Apodemus 
silvaticus).  A PCR reaction was carried out with each of the MNV primer sets 
along the full length of the genome.  Three primer s ts gave a positive result, 
these products were sequenced which gave sequence data at positions 991 – 
2587 and 5476 – 5954.  In order to complete the rest of the genome sequence, 
specific primers were designed from the newly acquired sequences to enable 
approximately 500 more bases to be sequenced.  New primers were designed 
and a combination of specific primers and MNV primers were used in the PCRs 
and sequencing reactions until the gap in the between the two originally 
sequenced parts of the genome had been closed.  To sequence the regions 
between the original sequences and the 5’ and 3’ ends of the genome specific 
primers were designed and used with a range of MNV primers in nested PCRs.  
Sequences obtained from these reactions could likewise be used to design 
further specific primers to sequence the length of the entire genome.  The 
primers designed specific to the novel norovirus are named “Aponoro” followed 
by the position on the genome and sense: 
 
Aponoro 433 AS 434-413 CTCAAGAATGGATCCAACCTTG 
Aponoro 1110 S 1110-1131 TTCTGAGACTCTTGGGAGGAAG 
Aponoro 1342 S 1342-1363 TTCCTTAAAGCCCTTGATGATG 
Aponoro 1566 AS 1566-1545 CAGATTCTGGCAAAACCAAGTC 
Aponoro 1679 AS 1679-1658 TCATCCCATACAACAACTCTGG 
Aponoro  1868 S 1868-1889 TGACTTTTTGGTCTACGCTGAG 
Aponoro 2030 AS 2030-2009 GTGTTTCCTTGTCGGTCAAAAC 
Aponoro  2198 S 2198-2219 TCCCTTGGTATAAGATGGCAAC 
Aponoro  2452 S 2452-2473 ACTGATGTGGTGTCAACTGTCC 
Aponoro  2802 S 2802-2823 TTTGAAGAAATGTTTGGTGACG 
Aponoro  3263 S 3263-3284 CTCTGGAGAGATGCTTGCTTTG 
Aponoro  4754 AS 4754-4733 ACCGAACTGGTCACCAACTATC 
Aponoro   5295 AS 5295-5274 AATCTCACCTGGGGTATTTCTG 
Aponoro  5565 S 5565-5586 GTGGCATGCTACTCAAGATCAG 
Aponoro 5648 S 5648-5669 ATGAGTCATTTGTGGTGTCTGG 
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Aponoro  5670 AS 5670-5649 ACCACAAATGACTCATCACCAG 
Aponoro  5700 AS 5700-5721 ACAGCAGGCCTCGATAGTCGTC 
Aponoro 7150 S 7150-7171 TGGTTGCTCGCTCTGTGGACAC 
Table 2.8  Primers specific for Apodemus MNV. 
 
The following primer sets were used in the PCR reactions followed by the 
sequencing reaction of positives and analysis as decrib d.  Multiple 
combinations of Aponoro and MNV primers were used to maximise the chance 
of a positive PCR result which would lead to a product that could be sequenced.  
Table x shows the primer sets used in the nested PCRs used for the generation of 











MNV 1 MNV 1 Apo 433 Apo 1566 




Apo 1566 Apo 1679 
MNV 991 MNV 1674 MNV 2136 MNV 2212 
Apo 1342 Apo 1868 Apo 2288 Apo 2288 
MNV 1674 MNV 1961 MNV 2587 MNV 3018 






Apo 2802 Apo 5275 
MNV 3018 
Apo 5700 
MNV 4840 MNV 5334 MNV 6085 MNV 6616 








Apo 5565 Apo 5648 MNV 7356 MNV 7356 
Table 2.9  Primer sets fro complete genome sequencing of Apodemus MNV, a mixture of 
specific Apodemus MNV and MNV 
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2.4 Phylogenetic analysis 
Phylogenetic trees are a graphic representation of ev lutionary relationships 
between genetic sequences within or between species.  Phylogenetic trees were 
constructed from novel and previously published MNV sequences by neighbour 
joining using the Jukes-Cantor model with pair-wise d letion for missing 
nucleotides in Mega 4 (Mega 4.0.1, Tamura, Dudley, Nei, and Kumar 2007).  
Pairwise distances were also calculated by Mega 4.   
 
 
2.5 Prediction of folding free energy and RNA structure prediction 
RNA secondary structure prediction along the length of the genome was carried 
out on 4 complete MNV genomes from laboratory mice, one full length genome 
from the pet shop mouse and the full length genome f the wood mouse MNV.  
The degree of secondary structure along the genome was also predicted for 
MNV1-4 taken from GenBank. Folding free energy calculations were made 
using UNAFold (http://dinamelt.bioinfo.rpi.edu/refs.php; Markham, N. R. & 
Zuker, M. (2008)).  Minimum free energy differences (MFED) were calculated 
by comparing the MFE of the native sequence to 50 randomised control 
sequences retaining the same nucleotide composition.  This determines the 
degree of secondary structure dependent on sequence order.  The sequence 
randomisation algorithm used was NDR which preserves dinucleotide 
frequencies.  The genome was divided in fragments of 300 bases, starting at 
position 58, spaced at intervals of 9 bases.  This created 776 overlapping 
fragments for which the MFEDs were calculated in both the sense and antisense 
directions.  Sequence randomisations were carried out using internal functions 










2.6 Virus growth and titration 
   
Virus   Cell type grown in 
Murine Norovirus (MNV) RAW cells 
Equine Rhinitis A Virus (ERAV) Vero136 cells 
Canine Calicivirus (CaCV) MDCK cells 
Semliki Forest Virus A7 (74) (SFV) CRE3T3 or NIH3T3 cells 
Echovirus 11 (E11) RD cells 
Theiler’s Murine Encephalomyelitis 
Virus (TMEV) 
CRE3T3 or NIH3T3 cells 
Table 2.10  Viruses used in this project and cell lines grown in 
 
2.6.1 Infection of cells with virus and creation of virus stocks 
 
To create a stock of each virus it was necessary to grow them up in cell culture.  
Viruses were generally grown up in a T175 flask or a T80 flask depending on 
the amount of material and the titre of the virus.  Cells were grown to a 
confluency of approximately 70 %.  Virus was added to the cells in a small 
volume of cell culture medium e.g. 10 ml in a T175 flask or 4 ml in a T80 flask.  
The cells were incubated with the virus in the incubator at 37°C for 1 hour.  Cell 
culture medium was then added to the flasks up to 50 ml in a T175, up to 18 ml 
in a T80.  The flasks were returned to the incubator nd observed for signs of 
cytopathic effect (CPE).  Cytopathic effect is the morphological change the cells 
undergo as a result of virus infection; it is often identified by the appearance of 
cell rounding, shrinkage, detachment from the flask nd lysis.  Dead cells may 
be seen floating within the culture medium.  RAW cells have a round 
morphology but CPE is still easily identifiable by other morphological changes 
such as cell shrinkage.  Virus was harvested from the cell culture medium at the 
time of marked CPE but before large numbers of cells died.  The medium was 
aspirated from the flasks and transferred to universal tubes.  The medium was 
clarified by centrifugation at 1328 x g for 20 minutes at 4°C.  The supernatant 




2.6.2 Titration of viruses 
Viruses were titrated by using an endpoint method.  A 96-well plate (Nunc) was 
prepared with 5 x 105 cells per well in a volume of 200 µl with all cell types 
except for RAW cells which were seeded at 1 x 106 cells per well.  Plates were 
left overnight to allow cells to adhere to the wells.  Eight serial 10-fold dilutions 
of each virus were made by adding 300 µl of each dilution to 2.7 ml of 2 % FCS 
cell culture medium.  The medium was aspirated from the plate and 200 µl of 
each dilution was added to an entire row of the plate resulting in each of the 
eight dilutions being added to twelve wells.  Plates were incubated at 37°C for 
1-2 days and monitored for CPE and/or cell death.  Tissue culture infective dose 
50 (TCID50) was calculated using the Reed-Muench method (Reed and Muench, 
1932; as described in Fundamental Virology, Ed. D. Knipe and P. Howley; 
Chapter 1, A. Levine).  The number of infected and uninfected wells were 
counted and recorded.  A cumulative total of infected wells from the highest 
dilution to the lowest was created, as was a cumulative total of uninfected wells 
from the lowest dilution to the highest.  A ratio was calculated to determine 
percentage of infected wells for each dilution.   The dilution at which 50 % of 











The result of the equation gives the proportionate distance between the two 
dilutions that gave a percentage infection either side of 50 %.  The distance 
between the dilutions is calculated by using the following equation: 
 
(log dilution above 50%) + (proportionate distance x log dilution factor) = log 
TCID50 
 
The reciprocal of the TCID50 is used to express the virus titre as TCID50 / unit 





2.6.3 Virus neutralisation assay 
The equine serum samples were tested for the presenc  of antibody against 
ERAV by a virus neutralisation assay.  Vero 136 cells were seeded into a 96-
well plate at a density of 5 x 105 cells per well in a volume of 200 µl.  The 
equine sera were diluted to 1:40, 1:160, 1:640 and 1:2560.  Mixed with each 
serum dilution was ERAV at a titre of 102 TCID50 / ml (the highest dilution that 
produce 100 % infected wells during virus titration).  A positive control 
consisted of virus mixed with equine serum known to contain anti-ERAV 
antibodies (kindly provided by Tobias Tuthill); negative controls consisted of 
virus with no serum and uninfected cells.  Each plate consisted of the four 
dilutions of each serum plus virus added to 2 wells.  The results, i.e. wells 



















1:160             
1:640             
1:2560             
1:10240             
1:160             
1:640             
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2.6.4 MNV passage 
In order to assess the effect of multiple passage of MNV3 on its genome a 
system was established to serially passage the virus at high and low 
multiplicities of infection.  RAW cells were seeded in a 12-well plate (Nunc). 
Wells for the first passage were seeded at 5 x 105 cells per well for infection the 
following day; wells for the second passage were seeded at 3 x 105 cells per well 
for infection after 3 days.  MNV virus stock was used; at high multiplicity of 
infection (moi) 400 µl of virus stock was added to the cells, at low moi 40 µl of 
virus were added to 360 µl of medium before being added to the cells, and mock 
cells had 400 µl of cell culture medium alone added.  The virus was incubated 
with the cells for 1 hour then was removed and 1.5 ml of 2 % FCS medium was 
added.  After 2 days the 400 µl of medium from the high moi infection and 40 
µl of medium from the low moi infected cells were taken and the previously 
prepared wells infected in the same way.  The remainder of the medium from 
the each passage was stored at -80°C.  MNV3 was passaged thirty-three times.  
Passages 10, 20 and 33 were sequenced at the 2 parts of the genome used 



















2.7 Creation of RNA transcripts 
 
2.7.1 Plasmids used in the generation of RNA transcripts 
RNA transcripts of viral genomes from a panel of GORS and non-GORS viruses 
were made for use in RNA stability and interferon induction experiments.  
Viruses used were GB Virus-C (GBVC), hepatitis C virus JFH-1 GND (HCV), 
murine norovirus 1 (MNV1), pea enation mosaic virus (PEMV), bunyamwera 
virus (BV), poliovirus (PV), rubella virus (RV), Semliki Forest virus (SFV).  
RNA transcripts were made from the following full-length clones kindly 
provided by other collaborators.   
 
pHGV (Iowan) (GBVC) Jack Stapleton (University of Iwa) 
pJFH-1 GND (HCV) John Mclauchlan (MRC Virology 
Unit) 




Eugene Ryabov, (University of 
Warwick) 
pT7RiboBUNL (+) (BV) Richard Elliott  (University of St. 
Andrews) 
pJM1 (Mah) (PV) David Evans (University of 
Warwick) 
pRobo502 (RV) Teryl Frey (Georgia State University) 




Pablo de Felipe (St. Andrews) 









2.7.2 Generation of RNA transcripts from plasmids 
 
Full length and truncated RNA transcripts were made by Dr Matthew Davis.  
Briefly, each plasmid was linearised with the approriate restriction enzyme 
(Davis et al. 2008).  The DNA was then extracted by phenol-chloroform 
extraction and ethanol precipitated.  As the purpose f generating the RNA 
transcripts for these studies was to study the effects of viral RNA within cells in 
the absence of viral replication, several of the DNA clones were digested with 









GBV-C MluI 8862/9395 533 
HCV EcoRV 9236/9678 442 
PV PvuII 7055/7440 385 
TMEV RsrII 6724/8101 1377 
RV BamHI 9174/9762 588 
Table2.12  Restriction enzyme used to truncate plasmids 
 
The other transcripts were made untruncated as MNV was replication 
incompetent, SFV consisted only of the non-structural genes and the BV 
transcript consisted only of the L segment.  In vitro transcription was undertaken 
using the Megascript T7/SP6 kit (Ambion). 
 
2.7.3 Enzymatic treatment of RNA transcripts 
The RNA stability study was designed to measure the rat  of degradation of 
RNA transcripts after electroporation into cells.  As the rate of decay was 
measured by quantitative real-time PCR, it was essential to ensure that there was 
no plasmid DNA remaining.  The transcripts were therefore incubated with 0.5 
µl Turbo DNAse (Megascript Kit, Ambion) and 0.3 µl of the restriction enzyme 






2.8 RNA stability study 
 
2.8.1 Electroporation of cells 
Two large flasks (T175) of NIH3T3 cells were grown to near confluence.  The 
cells were trypsinised and resuspended in 10 ml of cell culture medium; the cells 
were then counted.  The cells were centrifuged at 544 x g for 5 minutes.  The 
cell pellet was resuspended in 10 ml chilled PBS.  The cells were washed in 
diethylpyrocarbonate (DEPC)-treated PBS and spun a further two times.  After 
the last spin, the cell pellet was resuspended at a concentration of 2 x 107 cells / 
ml in 400 µl per electroporation.  Then 400 µl cells were transferred to a bijou 
tube (Sterilin) and chilled on ice for 5 minutes.  Five micrograms of each RNA 
transcript GBVC, HCV, MNV, BV, PV and TMEV, were added to each bijou, 
mixed, and then transferred to a chilled electroporati n cuvette (Bio-Rad).  The 
cells were electroporated by using the following settings on a Gene Pulser Xcell 
(Bio-Rad) eletroporator on the pre-set Mammalian 3 setting: pulse type – 
exponential decay; capacitance - 500 µF; PC - ∞ Ω; voltage – 160 V; cuvette – 
0.4 cm; cell volume – 100 µl.  Cells were then transferred to a 12 well plate at 2 
x 105 cell per well.  Cells were collected at 4 hours (h), 24 h, 48 h, 72 h and 96 
h.  The cells were washed with PBS before being trypsinised with 100 µl of 
trypsin to remove the cells.  The cells were spun at 478 x g for 5 minutes, the 
supernatant discarded and the cell pellets frozen at -80°C. 
 
2.8.2 Extraction of total cellular RNA 
 
Total cellular RNA was extracted using the RNEasy Mini Kit (Qiagen).  Briefly, 
before starting 2-mercaptoethanol (2-ME) (Sigma) was added to Buffer RLT at 
a ratio of 10 µl 2-ME in 1 ml RLT to denature cellular RNases.  The cell pellets 
were defrosted at room temperature then disrupted by the adding of 350 µl of 
Buffer RLT and mixing by pipetting.  The disrupted cells were transferred into a 
QIAShredder (Qiagen) and centrifuged at full speed for 2 minutes.  The volume 
of the lysate was measured and the same volume of 70 % ethanol (VWR) was 
mixed with it.  This was transferred to the RNEasy spin column and either the 
spin protocol or vacuum protocol followed.  In both cases the lysate was passed 
through the column, the column was then washed with700 µl Buffer RW1 and 
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two washes with 500 µl of Buffer RPE.  The column membrane was then dried 
by centrifugation at 8000 x g for 2 minutes.  The RNA was eluted in 40 µl of 
RNase free water by centrifugation at 8000 x g for 1 minute.  RNAs were stored 
at -80°C.  Reverse transcription was carried as described previously. 
 
 
2.8.3 Quantitative real-time PCR 
Quantitative real-time PCR is a technique very similar to standard PCR in which 
specific regions of DNA are amplified by the annealing of specific primers to 
sense and antisense strands of DNA followed by extension by Taq polymerase 
so that a specific product is generated.  In order to visualise the generation of 
product the dye SYBR Green is used which binds to double stranded DNA and 
fluoresces brightly at λ = 522 nm.  The real-time machine (Corbett Research) is 
able to detect the level of fluorescence at each cyle of the PCR reaction which 
is recorded by computer software.  The software plots a graph of fluorescence 
against cycle number.  Analysis of data after the run has finished enables the 
user to determine the cycle number at which production of specific product has 
become exponential by crossing a threshold, giving a Ct value.  In order to 
quantify DNA concentrations in samples, standard curves are made consisting of 
serial dilutions against which sample concentrations can be calculated. 
 
The following reaction mix was assembled including a reaction buffer (Roche) 
(containing 500 mM Tris/HCl, 100 mM KCl, 50 mM (NH4)2SO4, 20 mM 
MgCl2, pH 8.3), 3 mM dNTP, primers 10 OD, FastStart Taq DNA polymerase 
(Roche) and SYBR Green I (Invitrogen) diluted 1:1000 in DMSO (Sigma). 
 
Nuclease free water   - 14 µl 
Buffer, 10x conc with 20 mM MgCl2 - 2 µl 
dNTP, 3 mM    - 0.4 µl 
Sense primer, 10 OD   - 0.2 µl 
Antisense primer, 10 OD  - 0.2 µl 
SYBR Green    - 1 µl 
FastStart Taq DNA Polymerase - 0.2 µl 
Template    - 2 µl 
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Primers were designed, for each of the viruses usedto make the RNA 
transcripts, to result in a short product, 100-250 base pairs, which is the optimal 
size in real-time.   
 
Name Sense Start Sequence Product 
length 
GBV-C S 131 AGGGTTGGTAGGTCGTAAATCC 
 AS 366 TGGTCAAGAGAGACATTGAAGG 
235 
     
HCV S 339 CCATGAGCACAAATCCTAAACC 
 AS  502 CTCCGAAGTTTTCCTTGTCGTG 
163 
     
MNV caps S 5275 ACCCCAGGTGAAATACTGTTTG 
 AS 5452 TGGGAAAATAGGGTGGTACAAG 
177 
     
E11 UTR S 302 CAACCCCAGTGTAGATCAGGTC 
 AS 481 AGTTAGGATTAGCCGCATTCAG 
179 
     
TMEV 
UTR 
S 545 AAGACAGGGTTATCTTCACTCC 
 AS 762 TGCCTTTGTGTGGTCGCTACAG 
217 
Table 2.13  Primers used in RNA stability study 
 
The following program was set. 
No. of cycles Temperature (°C) Time 







1 94 20 s 
Melt Ramps from 65-94 
0.3° each step 
20 s 1st step 
1 s per step for remaining steps 





2.8.4 Creation of standard curves for stability study 
Each of the transcripts used in the study was normalised to 1 µg / µl which was 
designated as concentration 100.  Serial ten-fold dilutions in 0.25 µg / ml DNA 
from herring testes (Sigma) were then made from 10-1 – 10-9.  These RNAs then 
underwent reverse transcription, 5 µl RNA in 20µl reaction volume under 
previously described conditions.  Standard curves wre created by running each 
dilution in duplicate on the real-time PCR machine which also established the 
limit of detection.  During experiments standards were run alongside sample 
cDNAs.  As the sample total cellular RNAs had been tr ated in an identical way 
it was possible to determine the concentration of each viral RNA transcript 
present at each time-point. 
 
 
2.9 Four kilobase transcripts  
 
2.9.1 Creation of 4 kb RNA transcripts 
The interferon induction study consisted of transfecting RNA transcripts into 
cells and measuring induction of interferon beta (IFN-β) by quantitative real-
time PCR indicating the level of IFN-β mRNA present in the cell.  These 
experiments were carried out using the long (full length or truncated) transcripts 
made by Dr Matthew Davis as previously described, and 4 kilobase (kb) 
transcripts.  These 4 kb transcripts were made to es ablish that any differing 
ability of GORS and non-GORS viruses was due to their tendency to form 
secondary structure alone, and not as a consequence of transcript length or of 
proteins translated from the RNAs after transfection.  The long transcripts were 
of differing lengths and some of them contained IRES’s within their 5’ UTRs: 
GBVC, HCV, PV, and TMEV. The 4 kb transcripts were made by designing 
primers to amplify a region of the genome beyond the 5’ UTR of those viruses 
containing one.  The viruses not containing a UTR included were MNV, BV, 
SFV and PEMV2.  The sense primers contained the T7 promoter sequence at the 





Name Position Product 
size 
Sequence (T7 sequence in bold) 
T7-HCV S T7+594 TAATACGACTCACTATAGGGGGCCCCTATATGGGAATGAG 
 




T7-GBVC S T7+563 TAATACGACTCACTATAGGGTCCTTCTGCTCCTTCTCGTG 
 




T7-MNV S T7+147 TAATACGACTCACTATAGGGTTACATGACCCCTCCTGAGC 
 




T7-BV S T7+165 TAATACGACTCACTATAGGGTATTTTGGTCGGGAGCTTTG 
 




T7-PV S T7+850 TAATACGACTCACTATAGGGTCAGCTAGTAACGCGGCTTC 
 




T7-SFV S T7+167 TAATACGACTCACTATAGGGAGGTGGAGTCATTGCAGGTC 
 




T7-TMEV S T7+1163 TAATACGACTCACTATAGGGATGGTTCCCTACGGACCTTC 
 




T7-PEMV S T7+200 TAATACGACTCACTATAGGGGGAGTGCAACCTCCTTATCC 
 




Table 2.15  Primers used to create 4 kb transcripts, wi h T7 sequence attached to sense primers 
 
 
2.9.2 Four kilobase PCR 
The 4 kb PCR products were made from 100 ng of the full length clones; the 
following reaction mix was prepared: 
 
Nuclease free water    - 37.2 µl 
5x Colourless GoTaq Reaction Buffer  - 10 µl 
dNTPs, 3 mM     - 0.8 µl 
Sense primer, 10 OD    - 0.4 µl 
Antisense primer, 10 OD   - 0.4 µl 
GoTaq DNA Polymerase, 5 U / µl  - 0.2 µl 
Template, 100 ng (plasmid 100ng / µl) - 1 µl 
 
The PCR reaction was run under the following conditions: 
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No. of cycles Temperature (°C) Time 







1 72 5 min 
Table 2.16  4 kb PCR conditions 
 
Ten microlitres of the PCR products were run on a 1 % agarose gel to check that 
each band was a single band of the correct size. 
 
2.9.3 Gel purification of 4 kb PCR products 
The PCR products were gel extracted to isolate the 4 kb product.  This 
minimised the risk that there would be any contamination of the subsequent in
vitro transcription reaction with the original template plasmid, ensuring that only 
the 4 kb product would be transcribed into a 4 kb RNA transcript.  The 
remainder of the PCR products, 40 µl, were run in a 1 % agarose gel for 1 hour 
to allow the bands to move apart making them easier to identify and cut.  The 
bands were cut using a clean scalpel blade and placed in 1.5 ml tubes 
(Eppendorf).  The gel extraction was carried out using the QIAquick Gel 
Extraction Kit (Qiagen) following the manufacturer’s instructions.  Briefly, 600 
µl buffer QG was added to the tubes containing the gel fragments, they were 
incubated at 50°C for 10 minutes with frequent mixing by vortexing until the 
gels had dissolved.  One volume of isopropanol (Sigma-Aldrich) was mixed 
with the samples and added to the QIAquick spin columns.  The columns were 
centrifuged at 17900 x g and the flow-through discarded.  A further 0.5 ml of 
Buffer QG was added to the column which was spun again, then 0.75 ml of 
Buffer PE was added to the column which was spun again.  The flow-through 
was discarded and the column spun again for another 1 minute to completely 
remove residual buffers from the membrane.  DNA waseluted in 30-40 µl of 
Buffer EB.  Gel extracted products were run on a 1 % agarose gel to ensure the 
4 kb products had been preserved in the eluted DNA. 
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2.9.4 Second PCR and PCR purification 
The gel extracted 4 kb PCR products were then used a  the template for a 
second round of PCR using the same sets of primers under the same conditions 
to increase the yield.  The PCR product was run on a 1 % agarose gel.  In order 
to create a clean product to be used in the in vitro transcription reaction the PCR 
product was purified by using the QIAquick PCR Purification Kit (Qiagen) 
following the manufacturer’s protocol.  Briefly, 5 volumes of Buffer PB were 
added to the PCR samples and mixed and transferred to the QIAquick columns.  
The columns were centrifuged at 17900 x g for 1 minute and the flow-through 
discarded.  The column was washed by adding 0.75 ml of Buffer PE and 
centrifuged for 1 minute; the column was centrifuged for a further minute to 
remove any residual buffers.  The DNA was eluted in 30-50 µl of Buffer EB.  
The eluted DNA was run on a 1 % agarose gel. 
 
2.9.5 DNA Precipitation 
In order to concentrate the DNA further it was precipitated in ethanol.  Two 
volumes of ethanol, 0.1 x volumes of 5M sodium chloride (NaCl) and 1 µl of 20 
mg /ml glycogen (Roche) were added to the DNA.  TheDNA was precipitated 
on ice on 30 minutes then centrifuged at full speed on a bench top centrifuge at 
4°C for 30 minutes.  The supernatant was removed and 500 µl of 70 % ethanol 
added to the tube containing the pellet.  The tube was centrifuged at full speed 
for 15 minutes at 4°C.  The supernatant was removed and the pellet air dried at 
room temperature for 5 minutes.  The DNA was resuspended in 12 µl nuclease 
free water. 
 
2.9.6 Determination of nucleic acid concentration 
Concentration of DNA or RNA was determined by using the NanoDrop 1000 
Spectrophotometer (Thermo Fisher Scientific).  Absor ance measured at 260 
nm was used to calculate DNA / RNA concentration expr ssed in ng / µl. 
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2.9.7 In vitro transcription 
In vitro transcription was carried out using the Megascript T7 kit (Ambion) 
following the manufacturer’s protocol.  Briefly, a 20 µl reaction was assembled 
consisting of 2 µl of each of the 4 nucleotides soluti ns (ATP, CTP, GTP, UTP), 
2 µl 10x Reaction Buffer and 2 µl of Enzyme Mix.  A mass of 500 – 800 ng of 
the purified PCR product containing the T7 promoter s quence was added in a 
volume of 8 µl of nuclease free water.  The reaction was incubated for 5 hours 
or overnight at 37°C.  After the incubation 1 µl of TURBO DNAse was added to 
the reaction mix and incubated at 37°C for 15 minutes to remove template DNA. 
 
2.9.8 RNA Cleanup 
The RNA was cleaned up using the RNEasy Mini Kit (Qiagen) following the 
manufacturer’s RNA Cleanup protocol.  Briefly, the RNA solution was made up 
to 100 µl with nuclease-free water; and 350 µl Buffer RLT added.  To the RNA 
was added 250 µl 100 % ethanol and mixed, the sample was then transferred to 
the RNEasy Mini spin column.  The column was centrifuged at 8000 x g for 15 
seconds (s) and the flow-through discarded.  The column was washed by adding 
500 µl Buffer RPE and centrifuging for 15 s followed by a second wash and 
centrifugation for 2 min.  RNA was eluted in 40 µl nuclease free water.  RNA 








2.9.9 Calculation of RNA copy number 
RNA copy numbers were calculated by using the following equations based on a 
single nucleotide of RNA having a molecular mass of 330 and a 4 kb transcript 
length: 
Transcript length x 330 = transcript molecular mass 
4000 x 330 = 1.32 x 106 


















The same equation was used to calculate the mass of a single copy of the full 
length or truncated transcripts according to transcript length.  The mass of single 
copies of DNA molecules e.g. PCR products was determined using the same 
equation based on a single DNA base pair having a molecular mass of 650. 
 
2.9.10 Phosphatase treatment 
To remove 5’ phosphate groups from the RNA transcript a phosphatase 
treatment was carried out using Antarctic Phosphatase (New England Biolabs).  
One µg of RNA was mixed with 1 µg of 10 x Reaction Buffer and 1 µl of 
enzyme in 10 µl reaction volume.  The reaction was incubated at 37°C for 15 
minutes then inactivated at 65°C for 5 minutes.  TheRNAs were then visualised 
on an agarose gel to ensure they had not degraded during the phosphatase 
treatment. 
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2.10 Interferon induction study 
2.10.1 Transfection of RNA transcripts 
Twelve well plates were prepared with NIH3T3 cells and A549n cells at a 
seeding density of 1 x 105 cells per well.  The RNA transcripts to be transfected 
were diluted to the appropriate concentrations and kept on ice.  Lipofectamine 
2000 (Invitrogen) was added to GIBCO Opti-MEM (Invitrogen) at a ratio of 1-2 
µl Lipofectamine 2000 mixed in 100 µl Opti-MEM per transfection.  The RNA 
transcripts were also diluted in 100 µl Opti-MEM per transfection and incubated 
for 5 minutes.  The RNA transcripts were mixed with the diluted Lipofectamine 
2000 and incubated at room temperature for 20 minutes.  During the incubation 
the cell culture medium was removed from the cells and replaced with 0.5 ml of 
2 % FCS medium.  After the incubation 200 µl of the complexes were added to 
the cells and the plates rocked gently by hand.  The plates were returned to the 
37°C incubator and incubated for 18 hours.  At the end of incubation the cells 
were removed, trypsinised and pelletted by centrifugation at 478 x g at room 
temperature for 5 minutes.  The cell pellets were stored at -20°C or -80°C.  Total 
cellular RNA was extracted using the RNEasy Minikit as previously described.  
The RNA concentration was determined by spectrophotome ry using the 
NanoDrop 1000 as previously described.  For each experiment the same mass of 
RNA (500 ng – 1 µg) was used as a template for revers  transcription into 









2.10.2 Quantitative real-time PCR of IFN-β and 18SrRNA 
Primers were designed for use in quantitative real-time PCR to detect murine 
IFN-β and 18S rRNA.  18S rRNA was used as the housekeeping gene as an 
internal standard as it has been recommended for use in mRNA quantification 
(Thellin et al., 1999). 
 




S 71 CACAGCCCTCTCCATCAACT 
 AS 222 GCATCTTCTCCGTCATCTCC 
151 
18SrRNA S 1577 GTAACCCGTTGAACCCCATTC 
 AS  1728 ACCATCCAATCGGTAGTAGCG 
151 
Table 2.17  Primers for murine IFN-β and 18SrRNA PCRs 




S 46 GTAGTAGGCGACACTGTTCGTG 
Homo sap 
IFN-β  




S 267 GAACTTTGACATCCCTGAGGAG 
Homo sap 
IFN-β  
AS 404 GCCAGGAGGTTCTCAACAATAG 
137 
Table 2.17  Primes for human IFN-β PCR. 
 
For use in a quantitative real-time PCR it was necessary to create a standard 
curve.  NIH3T3 cells were infected with Semliki Forest virus at moi 10 as it is 
able to induce an interferon response.  When the cells w re showing CPE, but 
before widespread cell death, the cells were collected and spun down.  The total 
cellular RNA was extracted using the RNEasy Minikit then cDNA made from 5 
µl RNA using random primers in a reverse transcription reaction.  A PCR was 
undertaken under standard conditions from 2 µl cDNA in a 20 µl reaction.  The 
PCR product was run on an agarose gel to ensure a single product of the correct 
size.  The remainder of the PCR product was purified using the QIAquick PCR 
purification kit.  The DNA concentration was determined by spectrophotometry.  
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The copy number of each PCR product was then determin d based on a DNA 
base pair having a molecular mass of 650; IFN-β and 18S rRNA PCR product 
lengths were both 151 bp. 
 
PCR product length x 650 = molecular mass 
151 x 330 = 9.815 x 104 


















Therefore, 1 ng PCR product is equivalent to 6.1 x 109 copies; 1 pg PCR product 
is equivalent to 6.1 x 106 copies.  Samples for standard curves were made by 
making serial ten-fold dilutions of these PCR products in 0.25 µg / ml herring 
testis DNA.  The real-time PCR reaction mix was made up as previously 
described.  The results were then expressed as IFN-β cDNA copy number per 
1000 copies of 18S rRNA cDNA. 
2.10.3  Luciferase reporter assay 
NIH3T3 or A549 cells were seeded into 24 well plates, as for the IFN induction 
experiments as described above, but the level of IFN induction was measured by 
the expression using the Dual-Luciferase Reporter Assay System (Promega).  
The luciferase plasmid were transfected by Lipofectamine 2000 (Invitrogen) as 
described above; p125-Luc (firefly) at 100 ng per well; pRL-CMV (renilla) at 50 
ng per well; 24 hours post-transfection of the luciferase plasmids, the RNA 
transcripts were transfected as above.  18 hours post-transfection, the cells were 
lysed with 100 µl passive lysis buffer per well; the lysates were analysed 
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immediately or the plates were frozen.  Seventy microlitres of Luciferase Assay 
Reagent II (LARII) predispensed into eppendorf tubes for each sample.  Ten 
microlitres of each lysate were added to the tubes and placed in the Glomax 
20/20 luminometer (Promega), programmed for the dual-luciferase assay, and 
the firefly activity measured.  A further 70 µl of Stop & Glo Reagent was added 
to the tubes and the renilla activity measured. 
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Chapter 3   Equine Rhinitis A Virus – prevalence 











Chapter 3  Equine Rhinitis A Virus (ERAV) 
 
3.1 Introduction 
Equine rhinitis A virus (ERAV), a virus predicted to have a genome with 
GORS, was the first virus chosen to study the possible roles of GORS.  It is a 
member of the Aphthovirus genus of the Picornaviridae family. 
 
3.1.1 Picornaviridae 
Picornaviruses are nonenveloped, single-stranded, positive sense RNA viruses.  
The family Picornaviridae consists of the following 12 genera:  
i) Enterovirus   e.g. human enterovirus, human rhinovirus 
ii Cardiovirus  e.g. Theiler’s murine encephalomyelitis virus 
iii) Aphthovirus e.g. foot-and-mouth disease virus, equine rhinitis v rus 
iv) Hepatovirus e.g. hepatitis A virus 
v) Parechovirus e.g. human parechovirus 
vi) Erbovirus  e.g. equine rhinitis B virus 
vii) Kobuvirus  e.g. Aichi virus 
viii) Teschovirus e.g. porcine teschovirus 
ix)  Sapelovirus e.g. porcine sapelovirus 
x)  Senecavirus e.g. Seneca Valley virus 
xi)  Tremovirus e.g. avian encephalomyelitis virus 
xii) Avihepatovirus e.g. duck hepatitis A virus 
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3.1.1.1 Virion structure 
Picornavirus particles are spherical, diameter of ~30 nm, consisting of a protein 
capsid surrounding a naked RNA genome.  Cardioviruses, enteroviruses, 
hepatoviruses and parechoviruses are acid stable and retain infectivity at pH 
lower than 3, whereas rhinoviruses and aphthoviruses ar  acid labile at less than 
pH 6.  Members of the latter two genera are usually found replicating in the 
respiratory system so there is no requirement to be abl  to survive the acidic 
conditions present in the stomach (Racaniello; Fundamental Virology, 4th 
Edition, Edited by Knipe and Howley, Chapter 18, 529-67).  The capsid 
consists of four structural proteins: VP1, VP2, VP3 and VP4.  These subunits 
form an icosohedral structure consisting of 60 subunits (Caspar and Klug, 1962; 
Rueckert et al., 1969).  The building block of the capsid is the protomer 
consisting of one copy each of proteins VP1-3; VP4 is an internal protein.  The 
surfaces of picornavirus capsid are variable; poliovirus and rhinovirus have 
prominent plateaus and canyons, whereas aphthoviruses and cardioviruses are 
smooth.  These features determine which structures int ract with a variety of 
host cell receptors. The RNA genome is not thought to completely fill the space 
within the capsid.  Myristic acid is a residue linked to VP4 on the interior of the 




3.1.1.2 Genome structure 
The picornavirus genome is a positive-sense, single-stranded RNA molecule so 
may be directly translated by the cellular machinery.  The 5’ end of the genome 
is covalently linked to a protein, the VPg (virion protein, genome linked) 
(Flanegan et al., 1977; Lee et al., 1977).  The VPg of FMDV is encoded by 
three genes, although it is encoded by a single gene in other picornaviruses 
(Forss et al., 1982).  At the 5’ untranslated regions (UTR) are long (100-170 
nucleotides in aphthoviruses) and contain highly structured elements.  The 
internal ribosome entry site (IRES) allows translation to occur by binding to the 
cell’s ribosome.  There are four types of IRES, types I, II, III and IV.  
Aphthoviruses and cardioviruses have a type II IRES immediately downstream 
of a poly (C) tract.  The IRES consists of a structured region predicted to contain 
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two to four pseudoknots (Escarmis et al., 1995), followed by the cis-acting 
replication element (CRE) (Mason et al., 2002), then the IRES which contains 
the stem-loops numbered 2-5 (Martinez-Salas et al., 1993).  The 3’ UTR is short 
but also contains structured elements, often a pseudoknot, which is thought to 
have a role in viral RNA synthesis (Jacobson et al., 1993).  Without the 3’ UTR 
the viruses are still infectious, but their infectivity is reduced and they replicate 




Figure 3.1:  FMDV genome taken from Domingo et al., 2002 
 
 
3.1.1.3 Attachment and cell entry of aphthoviruses 
Aphthoviruses do not have prominent peaks or canyons, but the βG-βH loop of 
the FMDV capsid protein VP1 attaches to cellular integrin receptors (Fox et al., 
1989).  There is also a heparan sulphate binding site on FMDV particles in a 
shallow depression on the surface of the virus (Fry et al. 1999).  Aphthovirus 
cell entry is achieved by receptor-mediated endocytosis, FMDV via a clathrin-
mediated mechanism (O’Donnell et al., 2008) followed by acid dependant 
uncoating (Carrillo et al., 1984; Carrillo et al., 1985).  At acidic pH, the FMDV 
capsid separates into pentamers, releasing viral RNA (van Vlijmen et al. 1998). . 
Picornaviruses use many cell surface molecules as receptors; ERAV interacts 
with sialic acid as its receptor (Stevenson et al., 2004).   
 
 
3.1.1.4 Translation of Picornavirus RNA 
Picornavirus positive-sense RNA is translated within the cell cytoplasm.  The 
viral genomes have no 5’ cap structure as they have the VPg protein.  The 
process of synthesis of plus and minus RNA strands during replication is 
initiated by uridylation of VPg (Paul et al., 2000)  A cellular enzyme unlinks the 
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VPg (Ambros et al., 1980).  All picornaviruses contain 5’ untranslated regions 
containing regions of ordered secondary structure (Rivera et al., 1988; Skinner 
et al., 1989) which are the IRESes and replication elements.  IRES mediated 
translation is stimulated by an interaction between the structured RNA and 
elements of the cellular translation machinery.  In aphthoviruses, which have a 
type II IRES, the 3’ end of the IRES interacts with eIF4G, eIF4B, eIF3 and PTB 
(Kolupaeva et al., 2003).  Translation of the RNA genome from a single open 
reading frame (ORF) produces a single polyprotein.  The polyprotein is divided 
into three regions: P1, P2 and P3.  Aphthoviruses and c rdioviruses also code a 
leader protein (L) in front of P1.  A property of the FMDV Lpro is the ability to 
cleave eIF4G which inhibits cellular translation (Devaney et al., 1988).  The 
single polyprotein is then cleaved by virus encoded proteinases.  The cleavage 
begins immediately after translation so the polyprotein does not exist in the cell 
as a single structure.  P1 is cleaved to produce the viral capsid proteins; P2 and 
P3 are cleaved to create the non-structural proteins involved in protein 
processing and genome replication.  In aphthoviruses th  VP1/2A cleavage is 
carried out by 3Cpro rather than 2A as in other picornaviruses (Palmenberg et al., 
1992).  The protein 3Cpro also carries out the cleavage between 2C and 3A.  
Aphthovirus protein 2A, although only 18 amino acids long, is still able to 
catalyze its autocleavage from 2B (Ryan and Drew, 1994).  The proteases 
initially cleave at intramolecular sites (in cis), but latterly also act at equivalent 
sites on other newly translated molecules (in trans).  In many picornaviruses 
there have also been identified cis-acting replication elements (CRE).  These are 
structured regions found within the genome at various locations in different 
viruses, some in coding regions and others in non-coding regions; these 
elements are necessary for replication (Goodfellow et al., 2000; Mason et al 
2002).  The cis-acting replication element is necessary for synthesis of the 
negative sense strand (Goodfellow et al., 2000) by templating the production of 
VPg-pUpU (Pathak et al., 2007)  During genome replication, three forms of 
viral RNA can exist: i) single stranded RNA; ii) replicative intermediate (RI) – 
full length RNA from which 6-8 strands are attached; and iii) replicative form 
(RF) – dsRNA, a full length copy of positive and negative strands.  RNA 
replication has been shown to be associated with smooth membranes called the 
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replication complex (Girard et al., 1967), under the control of the virally 








3.1.1.5 Assembly of virus particles 
After their initial cleavage, the VP0-VP3 and VP3-VP1 bonds are also cleaved 
by proteinase 3CDpro. The capsid proteins, VP0, VP1 and VP3 self-assembl by 
intra-molecular interactions (Cao et al., 2009).  Initially five protomers form a 
pentamer which are important intermediates in the assembly of picornaviruses 
(Boege et al., 1986; Rombaut et al., 1990).  Pentamers can form into 80S empty 
capsid-like particles which contain 60 copies of each protein (Kräusslich et al., 
1990), into which the RNA is inserted to produce provirions (Jacobson et al., 
1968).  The progenitor VP0 protein then cleaves intoVP2 and VP4 to form the 
virion.  The final viral particle contains only the positive sense viral RNA 
because the encapsidation process is very specific, so avoiding inclusion of 
cellular RNA or negative sense viral RNA (Nomoto et al., 1977; Novak and 
Kirkegaard).  Picornavirus infections may affect the cells by often inhibiting 




3.1.2 Equine Rhinitis A virus 
 
3.1.2.1 Clinical features and epidemiology of ERAV 
Equine Rhinitis A virus (ERAV) is a causative agent of upper respiratory ract 
infection in horses.  It was first isolated in the United Kingdom in 1962 
(Plummer, 1962) where it was described as an equine respiratory virus with 
enterovirus properties.  Cases have been reported world- ide and the virus 
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isolated in Canada (Ditchfield and MacPherson, 1965), the United States 
(Wilson et al., 1965), Italy (Flammini and Allegri, 1970), France (Brion 1966), 
Germany (Becker et al, 1974), Switzerland (Hofer et al, 1973) and Australia 
(Studdert and Gleeson 1977) .  Young animals in contact with older animals are 
the most susceptible group (Hofer t al, 1972).  The incubation period is 3-8 
days (Thein, 1978) and there is a viraemic phase of 4-5 days (Plummer and 
Kerry, 1962).  Following aerosol exposure, the virus replicates in the nasal 
epithelium before establishing viraemia.  The virus is cleared from the blood by 
an antibody response, but it persists in the pharynx.  The virus was originally 
detected in equine faeces (Plummer 1963), although it has not been isolated 
from intestinal tissue, and it may be detected for up to 4 weeks post-infection.  It 
may be that some viruses present in the pharynx are swallowed and, despite 
being acid labile, sufficient virions survive to bed tected in the faeces.  Another 
possible explanation for faecal detection is that as a consequence of the viraemia 
the enterocytes become persistently infected.  ERAV has been detected in horse 
urine for up to 146 days (McCollum and Timoney, 1992) so the urinary tract 
may be another site of persistent infection.  Clinical signs include pyrexia (41°C 
+/- 0.5°C), nasal discharge (initially serous but becoming mucopurulent), 
coughing, anorexia, pharyngitis and lymphadenitis.  Uncomplicated cases 
usually recover in 7 days, although the horses are susceptible to secondary 
bacterial infections e.g. Streptococcus zooepidemicus (Virus Infections of 
Equines, Chapter 18, M.J. Studdert).  The seroprevalence of antibodies against 
ERAV in horses in various countries has been determined e.g. 90 % in Austria 
(Kriegshauser et al, 2005), 66 % in the Netherlands (De Boer et al, 1979), 79 %, 
57 % in USA (McCollum and Timoney, 1992).  Horses appear to acquire the 
infection within the first 2 years of life and antibodies against ERAV are 









3.1.2.2 Classification of ERAV as an aphthovirus 
ERAV was previously known as Equine rhinovirus 1 (ERhV1), but its 
classification was uncertain until Wutz et al (1996) and Li et al (1996) 
demonstrated that due to its sequence homology and similar genome 
organisation it is most closely related to foot-and-mouth disease virus (FMDV), 
formerly the only member of the genus Aphthovirus in the family 
Picornaviridae.  The ability to cause a viraemia, persistent infections and broad 
cell culture host range are also more typical of aphthoviruses than other 
picornaviruses.  The most similar features between ERAV and FMDV include 
the amino acid sequence of the 2A protein which is 87.5 % identical (Li et al, 
1996) and a leader (L) protein which is similar in s ze to the FMDV Lab protein.  
ERAV and FMDV both have a type II internal ribosome entry site (IRES).  
Translation of the FMDV polyprotein is initiated from 2 different AUG codons, 
the first at the 3’ end of the IRES and the other 84 nucleotides downstream 
(Beck et al., 1983; Clarke et al., 1985) resulting in the production of 2 forms of 
the leader protein, Lab and Lb (Sangar et al., 1987).  There are also 2 start 
codons in ERAV, although they are separated by 54 nucleotides.  During 
translation of the ERAV genome however, the first site appears dominant 
resulting in an excess of Lab over Lb (Hinton et al., 2000), whereas the relative 
amounts of Lab and Lb varies between FMDV strains (Sangar et al., 1987). 
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3.2  Objectives 
1.  ERAV prevalence study by serological survey. 
 
In this study equine serum samples were collected from the clinical laboratory 
of the veterinary pathology unit at the Easter Bush Veterinary Centre, University 
of Edinburgh.  The serological survey was conducted by use of a virus 
neutralisation assay.  Based on reports of the persist nce of ERAV infections it 
was expected that there would have been marked exposure to ERAV in horse in 
Scotland. 
 
2.  ERAV prevalence study by PCR screening of faecal samples and sera 
 
ERAV causes a relatively mild upper respiratory tract infection, so it is unlikely 
that the animals admitted to the equine hospital would have been referred with 
respiratory disease due to ERAV as the primary presenting sign.  The samples 
analysed in this study were from inpatients admitted for other reasons, such as 
orthopaedic or gastrointestinal conditions.  As ERAV is a persistent virus, we 
reasoned that horse may have been exposed to ERAV and recovered clinically 
but would continue to shed virus.  This study sought to determine the level of 
ERAV detectable in faecal and serum samples. 
 
3.  Complete genome sequencing of PCR positive samples for phylogenetic 
and structural analyses. 
 
Any novel viruses discovered in the clinical samples would then undergo 
phylogenetic and bioinformatics analysis.  Bioinformatic prediction of the 
degree of secondary structure throughout the genome of ERAV revealed that the 
5’ half of the genome was predicted to be structured, but the 3’ half unstructured 
(data not shown).  We hypothesised that this uneven distribution of structure 
may have been a cell culture adaptation as sequence data are derived from 
laboratory strains, and that novel ERAVs discovered in clinical samples would 





The seroprevalence of anti-ERAV antibodies was establi hed by means of a 
virus neutralisation assay.  The results are summarised n table 3.1.  Of 53 
equine serum samples, 29 were positive, (55%).   
 
Neutralisation titre Virus No. of 





ERAV 53 22 2 7 9 11 29 55% 
Table 3.1: Neutralisation titres of 53 equine sera. 
 
The same equine sera were also screened for ERAV by PCR. The primers 
specific for the capsid and the UTR were shown to be sensitive (a ten-fold 
dilution series of cDNAs was made from RNA extracted from ERAV 
supernatant at 106 TCID50/ml; and the capsid primers detected the 10
-8 dilution, 
UTR primers detected 10-7; data not shown).  .All serum samples were negative 













Table 3.2: Result of prevalence screen of ERAV by PCR of sera and faecal samples 
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Isolates of ERAV from clinical samples were kindly provided by the Animal 
Health Trust, Newmarket.  These isolates were screened by PCR to ensure the 
presence of ERAV, and all samples were positive. 
 
 
Figure 3.3:  Gel showing result of screening with ERAV capsid primers on AHT clinical 
isolates; samples R1, 1, 2, 3 and 6 were positive wth a strong band, R1 and 1 also had a primary 






















5051/85 6 +ve 
Table 3.3: PCR result of AHT ERAV isolates. 
 
As a result of the samples R1 and 1 giving the strongest bands on the gel after 
the nested PCR these were chosen for complete genome sequencing, sequencing 
the products of a series of overlapping nested PCRs.  The result was that both of 
these samples had identical sequences to previously p b ished strains of ERAV.  
Sequences are given in appendix 1. 
 
    R1                   1                   2                     3                 4                     5                    6   
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3.4 Discussion 
ERAV, as a virus predicted to have a significant degre  of secondary structure 
over the first half of the genome was a candidate virus for the study of GORS.  
The study was conducted to determine the prevalence of ERAV in horses in 
Scotland to test the hypothesis that as viruses predicted to contain GORS are 
able to form persistent infections (Simmonds et al., 2004), and that ERAV has 
been shown to be shed persistently (McCollum and Timoney 1992), that it 
would be a highly prevalent.  This study has shown a prevalence of antibodies to 
ERAV of 55 %, which is comparable to that of other countries.  The sera 
submitted were from equine patients at the Equine Hospital, University of 
Edinburgh, which would have been treated for a wide variety of conditions.  The 
clinical history of the horse corresponding to each serum samples was not 
available, but as ERAV causes a relatively mild clini al disease it is not likely 
that the horses referred to the equine hospital would have been clinical case of 
ERAV.  The seroprevalence result of 55 % shows that a majority of horses in 
Scotland have been exposed to ERAV at some time in their lives.  The fact that 
in this study, no horses of less than 2 years of age were seropositive is also 
consistent with previous observations of age-related exposure (Studdert and 
Gleeson, 1978) which showed that 16 % of horses between the ages of 6 and 12 
months were seropositive.  The screen of each of the positive sera by PCR was 
negative however, indicating that it is highly unlikely that any of the 
seropositive horses were viraemic with ERAV. 
 
ERAV was first discovered by Plummer in 1962 in the fa ces of 13 out of 290 
horses (5 %), it was described as an equine respiratory virus with enterovirus 
properties.  Although it is now known that the virus ERAV is a member of the 
Aphthovirus genus of Picornaviridae, and cause an upper respiratory tract 
infection, it is still not certain how the virus can be detected faecally.  Theories 
include the possibility that the virus from the respiratory tract may be swallowed 
and so emerge in the faeces, although as an acid-labile aphthovirus it might not 
be expected to be able to pass through the acidic environment of the stomach.  
An alternative idea is that as the virus causes a viraemia it could potentially 
reach any part of the body and therefore be secreted in o the intestinal tract.  In 
this study faecal samples were collected from the horse boxes of 50 in-patients 
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at the Equine Hospital, University of Edinburgh and screened by PCR.  None of 
the faecal samples were positive.  The prevalence in faecal samples determined 
by Plummer i.e. 5 % is markedly below that of the seroprevalence found in this 
study and others.  A faecal prevalence of 5 % in 50 samples would have been 
given by just 2-3 positive samples, so it may be that a larger sample size was 
required.  A more sensitive detection method may also have revealed hidden 
positives. 
 
The ERAV isolates provided by the Animal Health Trust, Newmarket, were all 
detectable by PCR with the exception of one.  The almost complete genome 
sequencing was carried out in an effort to identify a new strain of the virus 
distinct from the laboratory strains and published sequences.  The hypothesis 
was that newly identified viruses from an animal would be free of cell culture 
adaptations and related sequence changes that are present in laboratory strains.  
The hope was that novel virus sequences could be analysed by bioinformatics 
structural predictions to compare the degree of secondary structure along the 
length of the ERAV genome.  The laboratory strain of ERAV shows regions of 
predicted secondary structure along the first half (5’) of the genome before 
apparently becoming unstructured towards the 3’ end.  The plan was then to 
serially passage the ERAV isolates and assess the effect of cell culture 
adaptation on the degree of secondary structure along the genome.  
Unfortunately, none of the clinical samples tested by PCR in this study were 
positive so there was no novel ERAV isolates could be o tained and the isolates 
provided by the AHT had identical sequences to the published sequences of the 
laboratory strains possibly as a consequence of contami ation. 
 
This study that the seroprevalence of ERAV in Scotland is comparable to that in 
other European countries, USA, Canada, Australia and Japan, but it did not 
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Chapter 4  Murine Noroviruses – prevalence, genomic RNA secondary 




The genus Norovirus of the family Caliciviridae consists of viruses that infect 
humans and animals.  Human norovirus infections cause mild, acute, self-
limiting gastroenteritis characterised by nausea, vomiting, diarrhoea and 
abdominal cramps (Kaplan et al., 1982).  Outbreaks typically occur in confined 
places such as cruise ships, hospitals and schools (Widdowson et al., 2005; 
Becker et al., 2000; Gunn et al., 1980).  Noroviruses have also been discovered 
in pigs (Sugieda et al., 1998), cattle (Woode and Bridger, 1978) and mice (Karst 
et al., 2003).  Bovine noroviruses are associated with darrhoea in calves 
(Woode and Bridger, 1978) whereas porcine and murine norovirus are 
subclinical in immunocompetent hosts (Wang et al., 2007; Karst et al., 2003).  
Noroviruses are classified into 5 distinct genogroups: genogroups I, II and IV 
contain human noroviruses, genogroup III contains bovine noroviruses and 
genogroup V contains murine noroviruses; the genogroups are also divided into 
genotypes (Green et al., 1999); see figure 1.1.  Murine noroviruses (MNVs) 
diverge by up to 13 % at the nucleotide level, and to date are considered to 
comprise a single genotype of genogroup V (Thackray et l., 2007). 
 
Noroviruses have a single-stranded, positive sense RNA genome of ~7.5 
kilobases.  There are 3 well characterised ORFs.  ORF 1 encodes a polyprotein 
which is cleaved into the non-structural proteins (Sosnovtsev et al., 2006).  ORF 
2, which is sub-genomic, encodes the major capsid protein VP1 (Jiang et al., 
1990); ORF 3 encodes the small basic protein VP2 which appears to have a role 
in virion stability (Glass et al., 2000).  A fourth ORF has been postulated, but is 
of uncertain function.  The 5’ end of the genome is covalently bound to the VPg 
protein and the 3’ end is an untranslated region consisting of a stem-loop and a 
poly(A) tail (Gutierrez-Escolano et al., 2003). 
 
MNV was discovered in 2003 in RAG/STAT-/- mice; these mice are severely 
immunosuppressed and the mice would die with meningoe cephalitis, cerebral 
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vasculitis and pneumonia (Karst et al., 2003).  The virus was identified as a 
norovirus and designated MNV-1.  MNV-2, 3 and 4 were subsequently 
characterised by Hsu et al in 2006 by screening mesenteric lymph nodes and 
faecal samples from laboratories across the United States.  These three new 
strains were shown to establish sub-clinical, persistent infections with prolonged 
faecal shedding, in contrast to MNV-1 (Hsu et al., 2006).  A further 21 MNVs 
were sequenced in 2007 which comprised 15 distinct strains with up to 13 % 
divergence at the nucleotide level (Thackray et al., 2007).  To date, August 
2009, there are 41 MNV complete genomes available on the NCBI Entrez 
Nucleotide database (http://www.ncbi.nlm.nih.gov/sites/entrez).   
 
MNV has also become the favoured virus to study norovirus biology as it is the 
only norovirus that is cultivatable in cell culture.  It was discovered to grow in 
the murine macrophage cell line RAW 264.7, producing CPE and forming 
plaques (Wobus et al., 2004).  This has led to the development of reverse 
genetics systems by which the virus’s replication strategies will certainly be 
further elucidated in the future (Ward et al., 2007; Chaudhry et al., 2007). 
 
MNV has also been identified as a GORS virus i.e. pr diction of secondary 
structure along the length of the RNA genome by bioinformatic analysis; the 
average MFED of MNV-1 being 6.3 %.  MNV is an ideal virus for the study of 
GORS as mice are numerous in research institutions and studies have identified 
the presence of MNV in laboratory mice in institutions around the world (Hsu et
al., 2006; Muller et al., 2007).  The observation that MNV-2, 3 and 4 caused 
persistent infection in immunocompetent hosts in 2006 agreed with the 
observation that the presence of GORS is associated with this property 
(Simmonds et al., 2004).  The cell culture system and recently developed 
reverse genetics techniques also allow passage and m ipulation of the virus.  
MNV is a virus that allows us to test hypotheses concerning the nature of GORS 








1. Prevalence study of MNV in laboratory mice and wild mouse 
populations. 
 
In this study faecal samples were collected from labor tory mice (Mus 
musculus), wild house mice (Mus musculus) the following wild rodent species: 
wood mouse (Apodemus sylvaticus), field vole (Microtus agrestis) and bank 
vole (Myodes glareolus).  The samples were screened by PCR for MNV using 
specific primers, or degenerate norovirus primers in the wild samples.  Based on 
previous reports, it was expected to identify MNV in laboratory samples; in wild 
rodents the prevalence of MNV is unknown, but it was hypothesised that a 
norovirus present in a wild population would likely to be GORS, and as GORS 
confers an evolutionary advantage in enabling the virus to persist there would be 
a similar prevalence as in mice bred in captivity. 
 
 
2. Phylogenetic analysis of novel MNVs 
 
Previous studies have shown that MNV is the only memb r of norovirus 
genogroup V, and consists of a single genotype.  The aim of our study was to 
classify MNVs identified in laboratory mice and wild mice.  To this end, regions 
of the genome were sequenced from PCR positive samples, and the complete or 
almost complete genomes sequenced from several of them. 
 
 
3. RNA structural predictions 
Using the complete or almost complete sequences of MNVs identified as well as 
selected previously published sequences, the degree of s condary structure was 
predicted along the length of the genome.  It was hypothesised that any newly 





4. MNV passage study 
We formed a hypothesis that during infection of an animal, the immune system 
exerts an evolutionary pressure and that GORS, in some way perhaps related to 
immune evasion, confers an advantage, so the degree of secondary structure is 
maintained by the virus.  We considered that in cell culture viruses are known to 
undergo adaptations, and that after serial passage the degree of secondary 
structure may decline as the virus becomes cell culture adapted.  It has been 
shown that the presence of GORS is sensitive to changes in sequence, 2 % 
sequence drift reducing the MFED, and 10 % drift undoi g the presence of 
GORS completely.  MNV-3 was therefore passaged 33 times in RAW cells at 





4.3.1 Prevalence of MNV 
Faecal samples from laboratory mice at the University of Edinburgh were kindly 
collected by Mr Billy Smith.  Access to wild rodent samples was kindly 
provided by Anna Meredith.  Other house mouse samples were provided by 
various members of the Centre for Infectious Diseases at the University of 
Edinburgh.  The pet shop mouse samples were collected from Morningside Pets, 
Edinburgh.  The faecal samples were screened by PCR using a capsid primer  
The prevalence of MNV in these various populations is ummarised in table 4.1 
 
Laboratory mice 26/39 







i) Mus musculus (House mouse) 
ii)  Apodemus sylvaticus (Wood 
mouse) 
iii)  Microtus agrestis (Field vole) 








Table 4.1  Table showing prevalence of MNV in faecal samples from 39 laboratory mice, 2 pet 
shop mice, 11 wood mice, 8 field voles and 12 bank voles.  Samples from Mus musculus were 
screened using MNV specific primers, samples from the other wild rodent species were screened 
with both MNV specific primers and degenerate norovirus primers. 
 
The MNV positive faecal samples from the laboratory mice were expected, in 
accordance with previously published studies.  The two samples from the pet 
shop were taken from different cages with a number of animals in each; both 
samples were PCR positive.  The PCR positive sample from the Apodemus 
sylvaticus is to the best of the author’s knowledge, the first identification of a 
norovirus in a wild rodent. 
 
4.3.2 Phylogenetic analysis 
After identification of PCR positive samples in the initial screening procedure, 
two regions of the genome were selected to be sequenced for phylogenetic 
analysis.  The first region, designated L1, produced an amplicon from position 
1016 – 1762 in the non-structural region of the genome; the second, designated 
L2, produced an amplicon from position 6142 – 6882.  Using these primer sets 
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in a PCR on the 26 PCR positive laboratory samples, 17 were positive for L1 
and 15 for L2.  The complete or almost complete genomes of six novel MNVs 
were sequenced: 4 laboratory MNVs designated Lab 12, Lab 17, Lab 18, Lab 
22; and the pet shop mouse MNV (PSM1), (the MNVs identified from the two 
pet shop cages had identical sequences); and the Apodemus MNV (WR960).  
The complete sequence data can be found in Appendix 1.  Phylogenetic analysis 
was carried out using Mega 4 (Mega 4.0.1, Tamura, Dudley, Nei and Kumar, 
2007).  Figure 4.1 shows a tree made from the almost c mplete nucleotide 
sequence of the 6 novel MNVs and all other previously published sequences.  
Figure 4.2 is a tree made from the almost complete amino acid sequences of the 
6 novel MNVs and published sequences.  What is notable is that the nucleotide 
and amino acid trees are very similar and that whereas the laboratory MNVs and 
pet shop MNV cluster closely together, the Apodemus MNV does not, and 
appears to be a significant genetic distance from the others.  Phylogenetic trees 
made from the nucleotide sequences of L1 and L2, figures 4.3 and 4.4, confirm 
that the majority of laboratory MNVs cluster closely with other published MNV 
sequences.  Figure 4.5 shows a phylogenetic tree made from the amino acid 
sequence of the VP1 region of selected examples of every genotype of each 
norovirus genogroup.  The position of WR960 clearly shows that it is a member 
of the MNV genogroup i.e. genogroup V, and therefor not a contaminant from 






























































































Figure 4.1  Phylogenetic analysis of nucleotide sequence by neighbour joining using the Jukes-
Cantor model with pairwise deletion, of almost complete sequences of 6 newly sequenced 
MNVs and all published sequences from GenBank.  Laboratory mouse MNVs are labelled with 





































































































Figure 4.2  Phylogenetic analysis of amino acid sequence using p distance with pairwise deletion 
of almost complete sequences of 6 newly sequenced MNVs and all published sequences from 









































































































Figure 4.3  Phylogenetic analysis of nucleotide  sequence by neighbour joining using the Jukes-
Cantor model with pairwise deletion, from position 1016 – 1762, of 19 newly identified MNVs 
and all published sequences from GenBank.  Laboratory m use MNVs are labelled with red 










































































































Figure 4.4  Phylogenetic analysis of nucleotide sequence by neighbour joining using the Jukes-
Cantor model with pairwise deletion, from position 6142 – 6882, of 17 newly identified MNVs 
and all published sequences from GenBank.  Laboratory m use MNVs are labelled with red 
dots; pet shop mouse, green; wood mouse, blue. 
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Figure 4.5  Phylogenetic analysis of the amino acidsequence of the capsid protein VP1 with 
pairwise deletion of 6 newly sequenced MNVs and select d published sequences from GenBank 
from every norovirus genotype of every genogroup.  Laboratory mouse MNVs are labelled with 


























































































































































































Genogroup II  
Genogroup I  
Genogroup V 
Gengroup III  
Genogroup IV  
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The p distances were calculated using the Simmonics sequence editing package 
of each of the novel MNVs and the average p distance of the published complete 
genome sequences.  Table 4.2 shows the p distances of the almost complete 
genome sequence of the 6 newly sequenced MNVs and the average p distance of 
all other previously published complete MNV sequences.  Table 4.3 shows the p 
distances of the amino acid sequence of the major cpsid protein VP1 of the 
same 6 novel MNVs and the average p distance of all other published MNVs.  
In both tables the p distances between the wood mouse MNV (WR960) and the 
other MNVs is higher than the p distance between the other MNVs and the 
average of the published sequences 
 
WR960 -       
Lab12 0.27 -      
Lab17 0.28 0.14 -     
Lab18 0.27 0.12 0.07 -    
Lab22 0.27 0.12 0.07 0.02 -   
PSM1 0.27 0.11 0.14 0.12 0.12 -  
Published 
(average) 
0.27 0.11 0.14 0.12 0.12 0.11 0.11 
 WR960 Lab12 Lab17 Lab18 Lab22 PSM1 Published 
(average) 
Table 4.2  Table showing p distances based on nucleotide sequence of the complete genome 
from 6 novel MNVs: WR960 (wood mouse MNV), 4 laborat ry mouse MNVs, pet shop mouse 
MNV and the average p distance of published MNVs 
 
 
WR960 -       
Lab12 0.16 -      
Lab17 0.16 0.04 -     
Lab18 0.16 0.04 0.02 -    
Lab22 0.16 0.03 0.02 0.02 -   
PSM1 0.16 0.06 0.06 0.05 0.06 -  
Published 
(average) 
0.16 0.05 0.05 0.04 0.04 0.04 0.04 
 WR960 Lab12 Lab17 Lab18 Lab22 PSM1 Published 
(average) 
Table 4.3  Table showing p distances based on amino acid sequence of VP1 protein from 6 novel 
MNVs: WR960 (wood mouse MNV), 4 laboratory mouse MNVs, pet shop mouse MNV and the 





4.3.3 MNV secondary structure prediction 
There were 26 MNV positive mice identified by PCR in the initial screening of 
laboratory mice faeces, 2 from pet shop mice and 1 from the wild rodent 
species, Apodemus sylvaticus.  Of these, the complete or almost complete 
genomes were sequenced from 4 laboratory samples, th  pet shop sample and 
the wild rodent sample by use of a series of overlapping primer sets to cover the 
length of the genome but for the very 5’ and 3’ ends.  The sequences were edited 
and aligned in the Simmonics v1.7 editing package.  Using UNAfold (Markham 
and Zuker, 2008) with NDR randomisation, secondary structure predictions 
were made along the length of the genome from position 58 to 7318; 776 
fragments of 300 nucleotides were analysed at intervals of 9 nucleotides; the 
sequence was scrambled using the NDR randomisation.  Table 4.3 shows the 
average MFED across the entire genome of the 10 viruses.  The threshold for 
definition of a GORS virus is generally considered to be 5-6 %.  All viruses are 
predicted to be GORS viruses, although some may be considered borderline e.g. 
WR960.   
 
  MNV1 MNV2 MNV3 MNV4 Lab12 Lab17 Lab18 Lab22 PSM1 WR960 
Average 
MFED 
6.31% 8.52% 7.68% 7.95% 7.46% 8.17% 7.39% 7.11% 6.38% 5.12% 
Table 4.3  Average MFED values along the length of almost the entire genome based on the 
MFED of 776 fragments of 300 nucleotides at intervals of 9 nucleotides from position 58 to 
7318. 
 
Figures 4.6 A-J show the average MFED of 11 consecutive fragments of nine 
bases i.e. the average of fragments of 99-bases, along the length of the genome; 
the mid-point of every nine-base fragment is therefore plotted against the 
average of its MFED and the five fragments before and fter it on the genome.  
The columns are positioned at the mid-points of each fragment, the first at 
position 245, the last at position 7150.  Figure 4.7 shows a histogram of MFED 
against nucleotide position for all fragments.  All viruses analysed showed 
predicted structures along the length of their genomes, so may be characterised 




























































































   
MNV-1
 
Figure 4.6 A  Distribution of MFEDs along the length of genome of MNV-1; mean MFED of 






























































































Figure 4.6 B  Distribution of MFEDs along the length of genome of MNV-2; mean MFED of 






































































































Figure 4.6 C  Distribution of MFEDs along the length of genome of MNV-3; mean MFED of 































































































Figure 4.6 D  Distribution of MFEDs along the length of genome of MNV-4; mean MFED of 





































































































Figure 4.6 E  Distribution of MFEDs along the length of genome of MNV from laboratory 





























































































Figure 4.6 F  Distribution of MFEDs along the length of genome of MNV from laboratory 





































































































Figure 4.6 G  Distribution of MFEDs along the length of genome of MNV from laboratory 






























































































Figure 4.6 H  Distribution of MFEDs along the length of genome of MNV from laboratory 









































































































Figure 4.6 I  Distribution of MFEDs along the length of genome of MNV from the pet shop 






























































































Figure 4.6 J  Distribution of MFEDs along the length of genome of MNV from the wood mouse, 







































































































































































































































































































































































































































































































































































































































4.3.4 Effect of serial passage 
A laboratory strain of MNV-3 was serially passaged, at low and high moi to 
assess the effect of cell culture adaptation on GORS.  At 10 and 20 passages, the 
viral RNA was extracted and the L1 and L2 regions amplified by PCR and 
sequenced and compared to the sequence of the original virus.  After passage 33, 
P0 and P33 were sequenced along the length of almost the entire genome and 
the base mutations recorded.  Table 4.4 shows the position of single base 
mutations identified in MNV-3 after 33 passages, the c ange in nucleotide and 








Change in side-chain properties 
608 G-C Lys-Asn No change 
1200 G-A Ala-Thr Non-polar neutral to polar neutral 
5960 C-T Thr-Ile Polar neutral to non-polar neutral 
6152 T-C Val-Ala No change 
6595 T-A Phe-Ile No change 
6690 A-G Thr-Ala Polar neutral to non-polar neutral 
6796 T-G Phe-Cys No change 
Table 4.4  Showing single base mutations after 33 passages of MNV-3 at high moi, the resulting 
change in amino acid sequence and the alterations of the amino acid properties 
 
Of these seven point mutations present after passage 33, two are in the non-
structural region (608, 1200), four are in the VP1 gene (5960, 6152, 6595) and 
the other two are in the VP2 gene (6690, 6796).  In no e of these changes in 
amino acid sequence is the charged side chain of the amino acids involved 
altered; and of all these changes only those between alanine-threonine and 
threonine – isoleucine represent a changes between non-polar neutral and polar 
neutral.  Changing the polarity of the amino acids in the sequence could have an 




MNV has been detected in laboratory mice since its discovery in 2003 (Karst et 
al., 2003).  Its prevalence has since been determined i  various strains of 
laboratory mice in research institutions in North America and Germany.  In 
2005, a study of 12,639 mouse serum samples from laboratory mouse colonies 
in the United States and Canada revealed a seroprevalence of 22.1 % (Hsu et al., 
2005).  Another study in the United States of sentinel mice in multiple research 
facilities discovered seroprevalence rates in five acilities of 2 %, 29 %, 49 %, 
67 % and 83 %; with 28.5 % cages containing PCR positive faeces (Perdue t 
al., 2007).  A 2007 study in Germany of 76 faecal samples collected from two 
laboratory mouse colonies in Berlin, comprising 28 different mouse lines, 
showed that MNV was present in 18 mouse lines (64.3 %) and that the 
prevalence within each mouse line was 83.7 % (Müller et al., 2007).  We have 
shown that screening of faecal samples taken from cages of 39 laboratory mouse 
lines in the University of Edinburgh revealed 26 positive samples, a prevalence 
of 67 %.  This prevalence is comparable to previously published studies.  The 
description of MNV-2, MNV-3 and MNV-4 as persistent viruses i.e. viruses 
were still detectable in mesenteric lymph node and faeces up to 8 weeks post 
infection (Hsu et al., 2006) and sub-clinical infection may explain the igh 
prevalence rates in laboratory mice.  As far as we are aware, this is the first 
study into the prevalence of MNV in wild mice (Mus musculus) as well as three 
other wild rodent species wood mouse (Apodemus sylvaticus), bank vole 
(Myodes glareolus) and field vole (Microtus agrestis).  The low prevalence of 
MNV determined in these studies, a single positive result in an Apodemus 
sample, is somewhat surprising as there is a consiste tly high prevalence in 
laboratory mice.  There may be several explanations f r this.  The first is that the 
prevalence is in reality higher but that the PCR is insufficiently sensitive to 
detect small amounts of virus.  In order to detect novel viruses, the primers used 
were necessarily degenerate to maximise the possibility of finding positive 
samples.  A dilution series of an MNV plasmid was crried out using MNV 
capsid primers and degenerate norovirus primers.  The result is shown in figure 
4.8.  The MNV capsid primers were able to detect MNV plasmid at a 
concentration of 5 x 10-7 ng / µl (~4 copies / µl); the degenerate norovirus 
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primers detected plasmid at 5 x 10-6 ng / µl (~40 copies / µl) so were only 











Figure 4.8  PCR of dilution series of pMNV using MNV caps and degenerate norovirus primers; 
-2 to -9 represent ten-fold dilutions from original plasmid at concentration 500 ng / µl (~4 x 1010 
copies / µl) 
 
 Another factor that may play a part in the discrepancy between the prevalence 
in laboratory and wild mice is the fact that laborat y strains of mice have 
deficiencies of the IFN effector molecule Mx (Staeheli et al., 1988; Staeheli and 
Sutcliffe, 1988).  Mx1 was first discovered in a strain of mouse unusually 
resistant to influenza A virus (Lindenmann et al., 1962).  Subsequent work on 
Mx1 and Mx2 in human, mouse and rat cells has shown that Mx1 is localised to 
the nucleus and confers resistance to viruses that replicate in the nucleus; cells 
expressing rat Mx2 in the cytoplasm show antiviral activity against vesicular 
stomatitis virus (VSV), and the bunyaviruses Rift Valley fever virus (RVFV) 
and LaCrosse virus (LACV) (Sandrock et al., 2001; Stertz et al., 2007).  There 
have been no reports on the relationship between Mx and MNV, but the 
difference in prevalence between laboratory and wild mice opens a line of 
further investigation. 
 
A 2006 paper by Zheng and colleagues describes classific tion and 
nomenclature of noroviruses.  This paper describes the classification of 
noroviruses into genogroups, clusters (also known as genotypes) and strains 
based on nucleotide or amino acid sequences.  Figures 4.1, 4.3, and 4.4 show 
phylogenetic trees constructed from nucleotide sequences, whole genome, and 
-2            -3           -4            -5            -6          -7            -8           -9 -2           -3            -4          -5           -6           -7            -8             -9
MNV caps primers Degen noro primers
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~750 base fragments of the non-structural and structural regions respectively.  
They show that the MNVs detected in the laboratory faecal samples and the pet 
shop mice cluster together with the previously published MNV sequences.  The 
sample from the wood mouse though is clearly not as closely associated with the 
other sequences.  These relationships are repeated in trees made from amino 
acid sequences.  Figure 4.2, a tree made from the almost complete amino acid 
sequence of four novel MNVs discovered in laboratory mice, the pet shop mice 
and the wild mouse, has an almost identical pattern o the tree made from 
nucleotides sequences.  Figure 4.5 is a phylogenetic tr e constructed from the 
amino acid sequence of the VP1 protein of every genetic cluster/genotype of 
norovirus throughout the 5 genogroups, including the novel MNVs sequenced in 
this study.  The wood mouse MNV appears to be separate from the other MNVs 
on the tree, but perhaps just as significantly it does fall within the MNV 
genogroup, genogroup V, demonstrating that this PCR positive sample from the 
wood mouse faeces was not a contaminant from a human, porcine or bovine 
norovirus that the wood mouse had consumed.  It is likely, therefore, that this 
novel MNV was infecting the wood mouse.  The classification scheme 
described in Zheng et al., 2006 is based on the amino acid sequence of the major 
capsid protein VP1, encoded by the sub-genomic ORF2.  The most divergent 
region of the norovirus genome, and consequently the amino acid sequence, is 
found in the fourth segment of the of P2 domain (Zheng et al., 2006).  This is to 
be expected as this is the antigenic region of the capsid and therefore will be 
under the greatest evolutionary pressure from the interaction of virus and host 
immunity.  The classification scheme described is baed on the uncorrected 
distance method of the complete capsid amino acid sequence as is as follows: 
 Strain  - 0 – 14.1 % 
 Cluster  - 14.3 – 43.8 % 
 Genogroup- 45.0 – 61.4 % 
Table 4.1 shows the p distances all the 6 novel MNVs to have been almost 
entirely sequenced along all other complete MNV sequences published on 
GenBank.  The status of the MNV from the wood mouse is of most interest as 
its position on the phylogenetic trees, separate from the other MNVs, raises the 
possibility that it may be a new member of a new genetic cluster within 
norovirus genogroup V.  In table 4.1, the left-hand most column, in bold, 
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contains the p distance values of the wood mouse MNV as compared to every 
other MNV.  The values range from 22-23 %, whereas the p distance between 
all the other MNVs range from 0 – 13 %.  Table 4.2 shows the p distances based 
on the amino acid sequence of the capsid VP1 protein of the 6 novel MNVs 
identified in this study, along with 12 other previously published MNVs.  The 
wood mouse MNV is again represented in the left-hand column in bold.  The p 
distances between the wood mouse MNV and the others range from 14 -16 %, 
whereas the values between all the other MNV range from 0 – 7%.  According 
to the classification scheme proposed by Zheng et al., this MNV identified in the 
wood mouse faecal sample may well represent the first member of the new 
genetic cluster of the MNV genogroup of noroviruses, genogroup V.  A much 
wider study of wild rodents and additional positive samples that could be 
sequenced and analysed phylogenetically would be nec ssary to determine if 
there is indeed a second cluster of MNV present in wild rodents.  This discovery 
certainly makes that likely. 
 
Prediction of secondary structure by an energy miniisation algorithm was 
carried out on four published MNV sequences, MNV-1, MNV-2, MNV-3 and 
MNV-4, as well as four newly sequenced MNVs identified by us in laboratory 
mouse faecal samples, the pet shop mouse faecal samp e nd wood mouse faecal 
sample.  Figures 4.6 A-J and 4.7 demonstrated the presence of predicted 
structure throughout the length of the genomes of all the MNV sequences 
analysed, the defining feature of GORS.  The average MFED of all the viruses 
analysed was above 6 %, a threshold above which viruses may be considered to 
be a GORS virus, except for the wood mouse MNV, which was just below that 
value at 5.12 %.  The definition of viruses as GORS or non-GORS by average 
MFED is somewhat arbitrary and the presence of predict  structured regions 
throughout the length of the genome is probably of greater significance.  As 
structural prediction programs continue to advance it may be possible to more 
accurately detect specific RNA structures such as stem-loops and pseudoknots 
more accurately.   It is interesting that throughout the genomes are certain areas 
where there is no predicted structure, but these unstr ctured regions are not 
necessarily at the same location of the genome across all the MNVs analysed 
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Recent work by Davis et al., (Davis et al., 2008) characterises the physical 
nature of GORS and supports the thermodynamic predictions.  In this study 
biotin-labelled oligonucleotide probes, designed to hybridise to viral genomic 
RNA transcripts along the length of the genomes, were used in an accessibility 
study.  This study demonstrated that GORS virus genom s are less accessible to 
probes, and that non-GORS transcripts are significatly more accessible to the 
probes.  One of the viral RNA transcripts used in that study was MNV; the 
pattern of probe binding was that the majority of the genome was inaccessible 
but for occasional areas of accessibility.  The secondary structure predictions in 
this study are consistent with that finding.  Davis and colleagues also 
demonstrated, by inserting the L segment of bunyamwera virus (BV), a non-
GORS virus, into HCV, a GORS virus, that the BV segm nt was still accessible 
to probes, whereas the flanking HCV genome was still inaccessible to its probes.  
The interpretation was that GORS consists of a sequence of discrete secondary 
structures along the length of the genome and is less likely to be a global RNA 
structure dependant on tertiary structure.  The predict  structured regions along 
the MNV genomes in this study are therefore probably similar in nature, and are 
likely to be a series of discrete secondary structue motifs such as stem-loops.  
The presence of extensive secondary structure in the wood mouse MNV is also 
consistent the observed distribution of GORS.  GORS appears from all studies 
so far to be conserved within genera or virus groups, although virus families 
may contain GORS and non-GORS genera.  Within the family Caliciviridae, the 
genus Norovirus contains five distinct genogroups.  Human noroviruses are 
predicted to be non-GORS viruses and infection causes an acute and quickly 
resolved illness.  MNV is a GORS virus which is persistent in its natural host.  
The classification of the wood mouse norovirus as an MNV, meant that its 
classification also as a GORS virus was expected. 
 
The association of GORS with persistence led to the hypothesis that it confers 
an evolutionary advantage to those viruses that are GORS by, in some way, 
protecting the virus from being cleared by the host’s immune response.  As 
viruses undergo adaptations in cell culture the passage study was designed to 
assess the impact of multiple passage on the presenc  of GORS in MNV.  The 
result was that after 33 passages at high moi there were only seven base 
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mutations, a mutation rate of 0.1 %.  This was not considered significant enough 
to warrant bioinformatics analysis as it was considere  unlikely that this degree 
of sequence drift would alter the secondary structure predictions.  The 
hypothesis was that in cell culture, with no pressure from a fully intact immune 
system in an animal, that the advantage that viruses gain from maintaining 
extensive secondary structure in their RNA genomes would be lost, and that a 
GORS virus would lose its widespread structure.  One interpretation of the result 
of this study is that the RAW 264.7 cells, in which MNV is propagated, do not 
constitute an environment in which the pressure to maintain GORS has been 
lost.  The base mutations that were observed lead to non-synonymous changes in 
the amino acid sequence, and three of those changes three were changes that 
included an alteration in polarity if the side chain.  RNA viruses replicate their 
genomes using RNA dependant RNA polymerases which have no proof-reading 
capacity, so throughout the course of multiple passage it is likely that many 
mutations occur that are detrimental to the virus, so are never passed on.  The 
changes observed have been selected by the conditions present in the cell culture 
system.  The nature of the evolutionary pressure operating on viruses in cell 
culture is different from those found in animals.  In order to investigate this 
further it would be necessary to repeat this study in cell lines in which various 
parts of the innate immune system had been knocked-out or knocked-down or 
otherwise inhibited.  The relationship between GORS and innate immunity will 
be discussed later, but a recent study has shown that MNV-1 is detected in 
dendritic cells by MDA-5 (McCartney et al., 2008).  It is not known if the same 
is true of MNV infection of macrophages, the primary cell type that MNV 
replicates in, although dendritic cells are related to macrophages.  A study in 
which the various parts of the MDA-5 cascade in IFN-β induction were knocked 
out of RAW 264.7 cells, a murine macrophage cell line, and the effect on 
mutation rate and degree of secondary structure in MNV may help to shed light 
on the biological relationship between the presence of GORS in viral genomes 
and the ability of GORS viruses to persist in their natural hosts. 
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Chapter 5   A Study of the Interactions of GORS 
and non-GORS RNA Transcripts With Cellular 
RNA Stability Mechanisms and Innate Cellular 
Immunity 
 
5.1  Introduction 
 
5.2  Objectives 
 




5.5  Future work 
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Chapter 5  A Study of the Interactions of GORS and non-GORS RNA 




The observation that viruses that have GORS are able to establish persistent 
infections led to speculation about possible mechanisms by which the presence 
of extensive secondary structure throughout the RNA genome might lead to 
persistence.  In the original study describing the discovery of GORS (Simmonds 
et al, 2004) potential mechanisms are discussed in relation to the interactions 
between RNA and the cellular innate immune machinery.  Eukaryotic cells and 
viruses have been co-evolving throughout the history of life on earth and there 
are many mechanisms that cells have evolved to counter viruses, and viruses 
have evolved as many means of avoiding those mechanisms.   
 
Plants and many invertebrates use RNA interference (RNAi) as an innate 
antiviral mechanism.  Infection by RNA viruses results in the production of long 
dsRNAs, e.g. the replicatory intermediate.  The RNAi mechanism first described 
by Napoli et al. in 1990(reviewed by Umbach and Cullen, 2009) consist of these 
long dsRNAs being cleaved by Dicer resulting in a pool of small, ~22 base pair, 
dsRNAs.  One strand of these RNAs, called siRNA duplexes, is loaded onto the 
RNA-induced silencing complex (RISC).  RISC then bids via the RNA to 
complementary mRNA, viral and/or cellular, resulting i  degradation.  Plant and 
invertebrate viruses have evolved mechanisms to counter the RNAi system e.g. 
tomato bushy stunt virus p19 protein binds 21 base pair dsRNA to prevent its 
being associated with RISC (Scholthof, 2006).   
 
The most important innate immune system in mammalian cells is the IFN 
response and whether RNAi is used as an antiviral mechanism is unclear.  
dsRNA produced by viruses during infection is the most important pathogen 
associated molecular pattern (PAMP) to induce IFN (Marcus, 1983).  The 
pattern recognition receptors (PRRs) responsible for detecting dsRNA are 
TLR3, which detects intraendosomal dsRNA (Alexopoulou et al., 2001); and the 
cytoplasmic receptors RIG-I and MDA-5 (Yoneyama et al., 2004; Andrejeva et 
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al., 2004).  These receptors feed into two transductions cascades that act through 
NF-κB and IRF-3 which act on the IFN-β promoter resulting in the expression 
of IFN-β (as discussed earlier and reviewed by Randall and Goodbourn, 2008).  
Of the IFN induced antiviral effectors, PKR and 2’5’-OAS are also stimulated 
by dsRNA.  Stimulation of 2’5’-OAS leads to the activa ion of the 
endoribonuclease RNase L (Zhou et al., 1993).  RNase L has a role in antiviral 
immunity by cleaving viral and cellular RNAs, creating short RNAs. It has been 
reported that these short RNAs, especially of cellular origin, are then detected 
by RIG-I or MDA-5 leading to further IFN induction (Malathi et al., 2007). 
 
The mechanisms by which the GORS leads to persistence have been speculated 
to be to shield the viral RNA in some way from the cell’s PPRs.  Many viruses 
are able to establish persistent infections by evasion of innate and/or adaptive 
immunity by producing proteins that inhibit various parts of the IFN response; 
from inhibition of IFN induction to inhibition of IFN stimulated enzymes.  
Evasion of immunity does not necessarily lead to persistence though, as many 
non-persistent viruses have evolved strategies to avoid the effects of the various 
antiviral cellular mechanisms.  dsRNA can be degraded or sequestered during 
several viral infections (see table 1.2), reducing the degree of IFN induction.  
We speculated that the evolution of GORS in those virus genera that have it, 
gives those viruses an advantage as this feature of their RNA genomes would 
enable them to evade detection, perhaps by mimicking cellular RNAs that also 
have structured elements.  We hypothesised that upon viral infection of a cell 
and uncoating of the genome, genomic RNA from GORS viruses would induce 
a weaker IFN response than genomic the RNA from non-GORS viruses.  The 
main challenge in testing this hypothesis is that GORS is a phenomenon that 
exists in some genera of positive sense RNA virus families, but not others, 
across several families.  In order to investigate a biological role of GORS we 
needed to select a panel of RNA viruses that were predicted to be GORS and 
non-GORS.  Studying active infections by viruses from different families, which 
may have different replication strategies and grow in different cell lines, makes 
a direct comparison between a GORS group and non-GORS group difficult.  In 
order to study the effect of GORS alone, RNA transcripts were made of the 
genomes of a panel of predicted GORS and non-GORS viruses.  These 
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transcripts, which were replication incapable, were th n used in studies in 
various cell lines: the mouse fibroblast, NIH3T3; and the human type II 
pulmonary epithelial cell, A549.  In this way the effect of all the viral RNA 
transcripts on the cell e.g. IFN induction, can be measured simultaneously under 
the same conditions.  The effect on the RNA of being introduced into the 
cellular environment could also be studied.  Using replication incapable RNAs 
removes potentially complicating factors such as RNA replication and 
translation of protein during virus infections. 
 
The following viral RNA transcripts were made by Dr Matthew Davis from 
infectious clones kindly provided by others (see materi l and methods for 
acknowledgements). 
 
GORS Genus Family 
GBVirus-C (GBV-C) GBV-C like Flaviviridae 
Hepatitis C virus (HCV) Hepacivirus Flaviviridae 
Murine norovirus (MNV) Norovirus Caliciviridae 
Pea enation mosaic virus 2 
(PEMV2) 
Umbravirus  
   
Non-GORS   
Bunyamwera virus (BV) Orthobunyavirus Bunyaviridae 
Poliovirus (PV) Enterovirus Picornaviridae 
Rubella virus (RV) Rubivirus Togaviridae 
Semliki Forest virus (SFV) Alphavirus Togaviridae 
Theilers murine encephalitis 
virus (TMEV) 
Cardiovirus Picornaviridae 
Table 5.1 Table of viruses used in this study 
 
Short notes on virus entry and uncoating, and genom structure of those viruses 
not previously discussed will be given here, as these are the events that would 
lead to the potential exposure of genomic viral RNA to the cellular PRRs during 
infection.  The viruses of the family Flaviviridae are enveloped, positive-sense, 
singe-stranded RNA viruses.  HCV is classified in the genus Hepacivirus 
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whereas GBV-C is classified in an unnamed genus within the family.  HCV 
enters cells, predominantly hepatocytes, and is internalised through clathrin-
mediated endocytosis; the genome is then uncoated although the mechanism is 
still unclear; replication then occurs in a membrane-bound replication complex 
(Moradpour et al., 2007; Brass et al., 2009).  GBV-C has a tropism for human 
lymphoid cells and although little is known about its replication it is likely to be 
similar to that of other flaviviruses.  The genomes of HCV and GBV-C are 
similar though, being ~9.6 kilobases in HCV and 9.1- .3 kilobases in GBV-C.  
The 5’ ends of the genomes consist of highly conserved UTRs that fold into 
complex secondary structures consisting of stem-loops and pseudoknots that act 
as an IRES.  The genomes are arranged with the structural genes at the 5’ end 
and the non-structural proteins at the 3’ end.  The last non-structural protein 
adjacent to the 3’ UTR, NS5B, is the RNA dependant RNA polymerase.  HCV 
genome replication occurs associated with the plasma embrane of the 
endoplasmic reticulum (Lindenbach and Rice, 2001, Fundamental Virology ed. 
Knipe and Howley; Reshetnyak et al., 2008; Nakamura et al., 2008). 
 
The family Togaviridae consist of two genera, Alphavirus and Rubivirus; they 
are enveloped, positive-sense, single-stranded RNA viruses.  The alphavirus 
genome is ~11 kilobases whereas rubella virus (the only member of the genus 
Rubivirus) has a genome of 9.8 kilobases.  Their genomes are arranged with the 
non-structural genes occupying the 5’ two thirds of the genome and the 
structural genes the 3’ third.  The structural proteins are translated from a sub-
genomic RNA.  The 5’ end of the genome is linked to a 7-methylguanosine cap 
and the 3’ end has a poly-A tail (Kuhn, Fields Virology 5th Edition, Ed Knipe 
and Howley, 2007).  Four conserved regions of the genome have been identified 
as cis-acting replication elements (Ou et al.,1981; 1982; 1983).  Semliki Forest 
virus is a member of the Alphavirus genus.  Alphaviruses have a broad host 
range (reviewed by Strauss et al., 1994), due to either the presence of binding 
sites to multiple receptors or the presence of a ubiquitous receptor in many cell 
types across a broad range of species.  Alphaviruses enter cells via an endocytic 
pathway (Marsh et al., 1983), the endosome is acidified causing fusion between 
viral and cellular membranes resulting in the release of the genomic RNA into 
the cytoplasm.  The protein NS1 has an affinity for the lipids found in plasma 
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membranes leading to the location of replication complexes associated with 
cytoplasmic vacuoles (Kujala et al. 2001).  Rubella virus is also thought to enter 
cells via receptor-mediated endocytosis followed by acidification and release of 
the genome (Katow and Sugiura, 1988). 
 
The genomes of viruses of the family Bunyaviridae consist of three segments of 
single-stranded, negative or ambi-sense RNA.  The thr e segments are 
designated small (S), medium (M) and large (L).  Bunyaviruses enter the cell via 
receptor-mediated endocytosis.  Acidification of the endosome leads fusion of 
viral and cellular membranes resulting in the release of genomic RNA into the 
cytoplasm.  The negative sense RNAs are transcribed into mRNA and the 
replication complexes are formed in tubular structures made from Golgi 
elements (Fontana et al., 2008).  The principle site of replication of 
orthobunyaviruses within the body is the skeletal myocyte, but viraemic spread 
results in the viruses entering the central nervous system where they replicate in 
neurones and glial cells (Schmaljohn and Nichol, Fields Virology 5th Edition, Ed 
Knipe and Howley, 2007). 
 
Pea enation mosaic virus 2 (PEMV-2) is a member of the genus Umbravirus, its 
family classification is uncertain.  Umbraviruses are plant viruses; they have a 
single-stranded, positive sense RNA genome, they ar r ther short genomes, 
PEMV-2 has a genome length of 4253 nucleotides.  The genome consists of 
three ORFs but there is little information on the mchanisms of replication 
(Taliansky and Robinson, 2003). 
 
Details of the genomes and replication strategies of caliciviruses and 
picornaviruses have already been given in chapters 1 and 3 respectively.  It is 
notable that all of the viruses discussed share similar strategies in the early 
stages of their life cycles.  After viral entry there is an uncoating event which 
allows the viral RNAs to be translated.  The majority of the viral replication then 
takes place within replication complexes that incorporate organelle membranes, 
lipids and viral proteins.  The studies presented in th s chapter involved the 
electroporation or transfection of RNA transcripts into the cytoplasm of cells in 
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order to mimic the presence of genomic viral RNA after it’s uncoating and 
exposure. 
 
The RNA used in these studies were made replication incapable either by 
cutting of the plasmid with restriction enzymes to remove part of the genome 
(the picornaviruses and flaviviruses were truncated at their 3’ ends to obliterate 
their RNA dependant RNA polymerase genes); by use of plasmids that 
contained only part of the genome (the SFV clone contained only the non-
structural genes); or in the case of bunyamwera virus, only using one of the 
three genomic RNA strands.  Table 5.2 shows the restriction enzymes used and 









GBV-C MluI 8862/9395 533 8862 
HCV EcoRV 9236/9678 442 9236 
PV PvuII 7055/7440 385 7055 
TMEV RsrII 6724/8101 1377 6724 
RV BamHI 9174/9762 588 9174 
BV N/A N/A N/A 6875 
MNV N/A N/A N/A 7400 
SFV N/A N/A N/A 7400 
PEMV2 N/A N/A N/A 4200 
Table 5.2  Table showing truncated viruses, the restriction enzymes used, point of truncation and 


















1.  Study of RNA stability in GORS and non-GORS viruses 
The rate of RNA creation and degradation is one of the most important means of 
regulation of gene expression in the cell (reviewed by Garneau et al., 2007).  
Cellular mRNAs have 5’ 7-methylguanosine caps and 3’ poly(A) tails, and their 
degradation is normally carried out by exonucleases from either end.  We 
hypothesised that GORS viruses would be less susceptible to ribonuclease 
degradation, allowing the genomes to exist for longer in the cytoplasm so that 
replication could be continuous in a persistent infection.  In this study, 500 ng of 
the full length or truncated transcripts of 3 GORS viruses and 3 non-GORS 
viruses were electroporated into NIH3T3 cells and their degradation measured 
over 72 hours by quantitative PCR. 
 
2. Study of IFN-β induction in GORS and non-GORS viruses 
The hypothesis is that GORS viral RNA transcripts induce IFN-β less strongly 
than non-GORS viral RNA transcripts.  To test this hypothesis the full 
length/truncated transcripts were transfected into cells and the level of IFN-β 
induction measured 18 hours post-transfection by two methods: quantitative 
real-time PCR and by a luciferase reporter assay.  All studies using the 





5.3.1  Stability of GORS and non-GORS RNA transcripts in NIH3T3 cells 
Full length or truncated RNA transcripts were made by in vitro transcription 
from infectious clones as shown in table 5.2 from three viruses predicted to be 
GORS viruses and three non-GORS.  The predicted GORS viruses were: GBV-
C, HCV and MNV; the non-GORS viruses were BV, PV and TMEV.  In order 
to measure the degradation of RNA it was necessary to create a standard curve 
for use in the real-time PCR.  Series of ten-fold dilutions were made of each 
RNA transcript before undergoing reverse transcription under the same 
conditions.  These series of cDNA were then used as standard curves during the 
real-time PCR of each virus, which are presented in figure 5.1 along with melt 
curve analysis deomstrating each PCR produced a single specific product at a 
satisfactory reaction efficiency.  The full length or truncated transcripts were 
made as described from infectious clones of each virus by in vitro transcription; 
their concentrations were measured by spectroscopy and their concentration 
normalised to 100 ng / µl.  The RNA transcripts underwent overnight treatment 
with Turbo DNAse (Megascript kit, Ambion) and the restriction enzyme HaeIII 
(New England Biolabs) to remove residual DNA, ensuring the PCR would 
detect only the RNA electroporated into the cell during the experiment.  A 12-
well plate was seeded with 1 x 105 cells 24 hours pre-electroporation.  The time 
of the electroporation of 500 ng of each transcript into NIH3T3 cells was 
considered 0 hours, the mass of the RNA transcripts was measured at 4, 24, 48 
and 72 hours.  The degradation of the transcripts wa recorded as percentage 
decline from 4 hours on a logarithmic scale, which is shown in figure 5.2.  The 
transcripts were stable for the first 24 hours; they then declined at a similar rate 
over the next 48 hours.  Although the six viruses do not degrade identically, 
there is no difference in the rate of degradation between GORS and non-GORS 
viruses and the lines on the graph follow a similar course. 
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Figure 5.1 A(a))  Standard curve of GBV-C cDNA; made from serial dilutions of RNA, from 1 













Figure 5.1 A(b)  Melt curve analysis of GBV-C qPCR; single prominent peak indicates a single 
specific PCR product 
 
 
Reaction efficiency (*) 0.80667 (* = 10^(-1/m) - 1) 
M -3.89287 
B 0.35811 
R Value 0.99598 
R^2 Value 0.99198 
 





















Figure 5.1 B (a)  Standard curve of HCV cDNA; made from serial dilutions of RNA, from 1 












Figure 5.1 B(b)  Melt curve analysis of HCV qPCR; single prominent peak indicates a single 
specific PCR product 
 
 
efficiency (*) 1.5173 (* = 10^(-1/m) - 1) 
M -2.49417 
B 1.75876 
R Value 0.96397 
R^2 Value 0.92923 
 




















Figure 5.1C (a)  Standard curve of MNV cDNA; made from serial dilutions of RNA, from 1 














Figure 5.1 C(b)  Melt curve analysis of MNV qPCR; single prominent peak indicates a single 
specific PCR product 
 
 
Reaction efficiency (*) 1.02593 (* = 10^(-1/m) - 1) 
M -3.26132 
B -2.4031 
R Value 0.99928 
R^2 Value 0.99857 
 




















Figure 5.1 D(a)  Standard curve of BV cDNA; made from serial dilutions of RNA, from 1 ng/µl 













Figure 5.1 D(b)  Melt curve analysis of BV qPCR; single prominent peak indicates a single 
specific PCR product 
 
 
Reaction efficiency (*) 0.9189 (* = 10^(-1/m) - 1) 
M -3.53291 
B -0.76528 
R Value 0.99843 
R^2 Value 0.99686 
 




















Figure 5.1E (a)  Standard curve of PV cDNA; made from serial dilutions of RNA, from 1 x 10-1 













Figure 5.1 E(b)  Melt curve analysis of PV qPCR; single prominent peak indicates a single 
specific PCR product 
 
 
Reaction efficiency (*) 0.95017 (* = 10^(-1/m) - 1) 
M -3.4474 
B -6.02105 
R Value 0.99964 
R^2 Value 0.99928 
 




















Figure 5.1F (a)  Standard curve of TMEV cDNA; made from serial dilutions of RNA, from 1 x 














Figure 5.1 F(b)  Melt curve analysis of TMEV qPCR; single prominent peak indicates a single 
specific PCR product 
 
 
Reaction efficiency (*) 1.11492 (* = 10^(-1/m) - 1) 
M -3.07414 
B 0.12921 
R Value 0.99842 
R^2 Value 0.99684 
 






















Figure 5.2  Graph showing % decline of 6 viral RNA transcripts; GBV-C, HCV and MNV (blue 
points) are GORS viruses; BV, PV and TMEV (green points) non-GORS viruses; each sample 






 4 h 24 h 48 h 72 h 
BV 33.00% 298.85% 4.99% 0.67% 
GBVC 32.37% 18.83% 1.03% 1.19% 
PV 21.58% 8.37% 5.48% 1.36% 
HCV 69.12% 72.35% 1.92% 0.57% 
MNV 14.06% 10.90% 7.99% 2.30% 
TMEV 21.34% 57.38% 76.45% 2.58% 
Table  5.3  Standard deviations of % changes at each time point for each virus 
 





















































































5.3.2 IFN-β induction by full length/truncated RNA transcripts of GORS 
and non-GORS viruses in NIH3T3 cells and A549 cells 
IFN-β induction was conducted in murine and human cell lines so real-time 
PCR standard curves where prepared for both murine and human IFN-β genes.  
18SrRNA was used as a housekeeping gene in both sets of xperiment, and as 
the region amplified has an identical sequence in both species the same set of 
standards were used for both.  An initial round of PCR was conducted with each 
primer set and the PCR product purified by use of the QIAquick PCR 
purification kit.  The concentrations of these products were then determined by 
the NanoDrop 100 Spectrophotometer (Thermo Fisher Sci ntific) and serial ten-
fold dilutions of cDNAs made according to mass or cpy number.  Figure 5.3 
shows the standard curves for the real-time PCRs of murine IFN-β, human IFN-
β and 18SrRNA along with melt curve analysis deomstrating each PCR 
produced a single specific product at a satisfactory reaction efficiency.  During 
quantitative PCR reactions, standard curves made of five points in the same 
concentration range as the samples were used.  Results were expressed as copies 



















Figure 5.3 B(a)  Standard curve of human IFN-β; ten-fold dilutions from 5.8 x 109 copies / µl to 














Figure 5.3 B(b)  Melt curve analysis of human IFN-β qPCR; single prominent peak indicates a 
single specific PCR product 
 
 
Reaction efficiency (*) 1.01862 (* = 10^(-1/m) - 1) 
M -3.2781 
B 1.1734 
R Value 0.99942 
R^2 Value 0.99885 
 




















Figure 5.3C (a)  Standard curve of 18SrRNA; ten-fold di utions from 5.8 x 109 copies / µl to 5.8 














Figure 5.3 C(b)  Melt curve analysis of 18SrRNA qPCR; single prominent peak indicates a 
single specific PCR product 
 
 
Reaction efficiency (*) 1.06811 (* = 10^(-1/m) - 1) 
M -3.16883 
B 30.00549 
R Value 0.99948 
R^2 Value 0.99896 
 




















Figure 5.3A (a)  Standard curve of murine IFN-β; ten-fold dilutions from 6.1 x 108 copies / µl to 













Figure 5.3 A(b)  Melt curve analysis of murine IFN-β qPCR; single prominent peak indicates a 
single specific PCR product 
 
 
Reaction efficiency (*) 0.87036 (* = 10^(-1/m) - 1) 
M -3.67749 
B 13.03386 
R Value 0.99873 
R^2 Value 0.99745 
 
Figure 5.3 A(c) Efficiency data of murine IFN-β qPCR 
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12-well plates were seeded at a density of 1.0 x105 cells per well.  
Approximately 24 hours later, 500 ng of each long (full length or truncated, see 
table5.2) viral RNA transcript was transfected into NIH3T3 cells; poly I:C was 
used as a positive control and mock cells were untreated.  18 hours post-
transfection the cells were collected for analysis by real-time PCR.  In the 
luciferase studies, 24-well plates were seeded with 5.0 x 104. Approximately 24 
hours later, the IFN-β promoter-controlled firefly luciferase (p125-Luc) and, as 
an internal control, renilla (pRL-CMV), reporter plasmids were transfected into 
the cells, 24 hours post-transfection of the plasmid , the transcripts were 
transfected into the cells.  The cells were lysed 18 hours post-transfection for 
analysis; mock cells were untreated, and wells were transfected with the 
luciferase plasmids alone.  Both experiments gave a r markably similar result, 
the GORS viruses induced IFN-β only mildly above mock; the non-GORS 
viruses were variable in their strength of induction, BV, PV and TMEV all 
induced strongly, whereas RV and SFV did not induce at all.  The real-time 
PCR result is shown in figure 5.4, luciferase reporter assay result in figure 5.5. 
 
The same experiments were repeated, with 500 ng of the long transcripts 
transfected into A549 cells with a similar result.  The GORS viruses HCV and 
MNV induced IFN-β weakly, while GBV-C and PEMV2 did not induce a 
significant response above mock; of the non-GORS viruses, BV, PV and TMEV 
induced strongly, RV very weakly and SFV did not induce.  The real-time PCR 
result is shown in figure 5.6, luciferase result in figure 5.7. 
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Figure 5.4  IFN-β induction in NIH3T3 cells following transfection of predicted GORS (blue 
bars) and non-GORS (green bars) viral RNA transcripts measured by quantitative real-time 
PCR; transcripts were tested in duplicate; error bars are standard deviations of the mean. 
 


































Figure 5.5 Expression of luciferase reporter in NIH3T3 cells following transfection of predicted 
GORS (blue bars) and non-GORS (green bars) viral RNA transcripts; transcripts were tested in 
triplicate, error bars are standard deviations of the mean.  BV, PV and TMEV are significantly 
increased over mock, whereas GBV-C, HCV, MNV, PEMV, R  and SFV are not (P < 0.05, 
















































































Figure 5.6  IFN-β induction in A549 cells following transfection of predicted GORS (blue bars) 
and non-GORS (green bars) viral RNA transcripts measured by quantitative real-time PCR; 
transcripts were tested in duplicate; error bars are standard deviations of the mean. 
 
 

































Figure 5.7 Expression of luciferase reporter in A549 cells following transfection of predicted 
GORS (blue bars) and non-GORS (green bars) viral RNA transcripts; transcripts were tested in 
triplicate; error bars are standard deviations of the mean.  All transcripts induced a significant 
response above mock but for GBV-C and SFV; but BV, P  and TMEV induced a significantly 
greater response than all other transcripts (P < 0.05, unpaired t test 
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5.3.3 IFN-β induction by GORS and non-GORS viral RNA transcripts pre- 
and post-phosphatase treatment. 
The PRRs responsible for the cytoplasmic detection of dsRNA are RIG-I and 
MDA-5.  Although both these receptors have been shown t  respond to poly I:C 
(Rothenfusser et al., 2005; Yoneyama et al., 2005; Gitlin et al., 2006), a 
synthetic dsRNA analogue, the specific ligands in nature for each receptor are 
different. The ligand recognised by RIG-I has recently been shown to be the 5’ 
triphosphate group (Hornung et al., 2006; Pichlmair et al., 2006).  There is still 
uncertainty about the precise nature of the ligand for MDA-5, but it has been 
shown to detect dsRNA of length greater than 1 kilobase, whereas RIG-I detects 
shorter RNAs.  In order to investigate the possible ro s of RIG-I and/or MDA-5 
the full length/truncated viral RNA transcripts they were treated with Antarctic 
Phosphatase (New England Biolabs).  
 
The IFN-β induction experiments were repeated: in NIH3T3 cells, IFN-β 
induction was measured by real-time PCR and in A549 cells by luciferase 
reporter assay.  All methods and conditions as previously described.  The real-
time PCR result is shown in figure 5.8, the luciferase reporter assay result in 
figure 5.9.  In both experiments, both dephosphorylated transcripts and untreated 
transcripts were used so a direct comparison could be made between the two 
groups.  In both studies the effect of dephosphorylation was that none of the 
transcripts induced an IFN-β response.  It may be noted that the untreated 
transcripts produced the same pattern of induction as previous experiments with 
none of the GORS transcripts inducing strongly and of the non-GORS 
transcripts, BV, PV and TMEV induced strongly but RV and SFV did not 
induce an IFN-β response. 
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Figure 5.8  IFN-β induction in NIH3T3 cells following transfection of predicted GORS (blue 
bars) and non-GORS (green bars) viral RNA transcripts, hosphorylated (dark blue or green 
bars) and dephosphorylated (light green and blue bars) measured by quantitative real-time PCR; 
transcripts tested in duplicate; error bars are standard deviations of the mean 
 











































Figure 5.9 Expression of luciferase reporter in A549 cells following transfection of predicted 
GORS (blue bars) and non-GORS (green bars) viral RNA transcripts, phosphorylated (dark blue 
or green bars) and dephosphorylated (light green and blue bars) transcripts tested in triplicate; 
error bars are standard deviations of the mean.  Phosphorylated transcripts as in figure 5.7.  No 
dephosphorylated transcripts induced a significant response above mock (P < 0.05, unpaired t 
test).  Dephosphorylated BV induced significantly less strongly than BV, although there was no 
significant difference between TMEV pre- and post- dephosphorylation (P < 0.05, unpaired t 




5.3.4  IFN-β induction by GORS and non-GORS transcripts in A549 and 
A549 NPro cells 
Bovine viral diarrhoea virus, a pestivirus of the family Flaviviridae, produces 
the protein NPro which inhibits the production of IFN by blocking the activity 
of IRF-3 (Hilton et al., 2006).  In an A549 cell line expressing this protein the 
IFN induction experiment was repeated with a single GORS and non-GORS 
virus, GBV-C and TMEV, with poly I:C as a positive control.  This cell line was 
used to investigate if the IFN-β response seen in our studies so far was via the 
IRF-3 pathway.  The experiment was conducted with A549n cells 
simultaneously with A549 NPro cells; the degree of IFN-β induction measured 
by real-time PCR.  Figure 5.10 shows that whereas the A549n cells responded as 
before i.e. weak induction by GBV-C and strong induction by TMEV, there was 
no IFN-β induction at all in the A549 NPro cells, even with the positive control 
poly I:C. 
 


































































































n A549n GBVC 1
A549n TMEV 1
A549n Poly I:C 1
A549n Mock 1
A549 NPro GBVC 1
A549 NPro TMEV 1
A549 NPro Poly I:C 1
A549 NPro Mock 1
 
Figure 5.10  IFN-β induction in A549n and A549 NPro cells following transfection of a 
predicted GORS (blue bars) and non-GORS (green bars) viral RNA transcript, phosphorylated  
measured by quantitative real-time PCR. 
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5.3.5  IFN-β induction by 4 kb GORS and non-GORS transcripts 
The longer transcripts used in these studies up to this point had given a 
consistent result in two cell lines and by two different methods conducted 
independently.  The differing strengths of IFN-β induction across the panel of 
viruses was an interesting finding, although the failure of RV and SFV to induce 
a strong response meant that there was not a simple corr lation between strength 
of induction and the presence of GORS (to be discussed in more detail later).  
One potential factor that may have caused the long transcripts to behave 
differently was transcript length, the transcripts are of different lengths from 
4200 – 9236, so that the same mass of RNA that was transfected in each 
experiment i.e. 500 ng, would contain different copy numbers of RNA 
molecules.  The exact nature of the form that GORS RNA takes as opposed to 
non-GORS RNA remains somewhat uncertain, although atomic force 
microscopy studies suggest that GORS RNA transcript adopt tightly bound 
globular structures whereas non-GORS transcripts appear extended (Davis et al., 
2008).  With these factors in mind, it was not certain that these other variables 
were not having an effect on the strength of IFN-β induction.  Another potential 
factor was the possibility of translation.  None of the transcripts was replication 
competent as those that were truncated were missing the 3’ end of their 
genomes.  Some of the viruses, the flaviviruses (GBV-C, HCV) and 
picornaviruses (PV, TMEV), have a 5’ UTR that contains an IRES so could, 
possibly, undergo translation and produce viral proteins, which could have an 
effect on IFN-β induction e.g. HCV NS3 inactivates Cardif/VISA/MAVS.IPS-1 
(Li et al., 2005).  For these reasons transcripts were made of 4 kilobases (kb) in 
length from regions of the genome that did not include the 5’ UTRs of the 
flaviviruses or picornaviruses.  1 x 1011 copies, or ~ 220 ng, of each 4 kb 
transcripts was transfected into NIH3T3 cells.  Figure 5.11 shows a preliminary 
experiment involving transfection of the long transcripts and 4 kb transcripts of 
GBV-C and TMEV in NIH3T3 cells, measured by real-time PCR.  The long 
GBV-C and TMEV transcripts behave similarly to experiments already 
described i.e. little/no induction with GBV-C and strong induction with TMEV.  
The result with the 4 kb transcripts is similar in that GBV-C still does not induce 
and TMEV does, but the response appears weaker, although not statistically 
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significant as the large mock value in this particular experiment prevents 
meaningful analysis. 
 







































































Figure 5.11  IFN-β induction in NIH3T3 cells following transfection of predicted GORS (blue 
bars) and non-GORS (green bars) viral RNA transcripts, long transcripts (dark blue/ green bars) 
and 4 kb transcripts (light green/blue bars) measured by quantitative real-time PCR. 
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This experiment was repeated with the panel of viruses in NIH3T3 cells and 
A549 cells using the luciferase reporter assay.  Figure 5.12 shows IFN-β 
induction with long and 4 kb transcripts in NIH3T3 cells.  The long transcripts 
induced in the same pattern as seen in all previous experiments, i.e. significant 
induction by BV, PV and TMEV, but by none of the other transcripts.  The 4 kb 
transcripts of BV and PV are the strongest inducers, but the induction is 
significantly weaker than in the long transcripts.  Only the 4 kb transcript of BV 
induces IFN to a comparable degree to that of the long transcript.  There is little 
difference between the long and 4 kb transcripts in those viruses that do not 
induce a strong response in with either long or 4 kb transcripts.   
 
Figure 5.13 repeats the experiment in A549 cells, and while the long transcripts 
have the same pattern as in previous studies, the 4kb transcripts do not.  All of 
the 4 kb transcripts have induced a response higher t an mock with the 
exception of PEMV2  With the exception of BV, there is little difference in the 
level of luciferase reporter expression between any of the viruses, GORS or non-
GORS.  The 4 kb transcripts of RV and SFV have even produced a higher signal 
than their longer counterparts. The 4 kb transcripts were also treated with 
phosphatase, the transfection repeated and IFN induction measured by luciferase 
assay, the result is shown in figure 5.14.  As in the long transcripts, phosphatase 
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Figure 5.12  Expression of luciferase reporter in NIH3T3 cells following transfection of 
predicted GORS (blue bars) and non-GORS (green bars) viral RNA transcripts, long transcripts 
(dark blue/ green bars) and 4 kb transcripts (light green/blue bars); transcripts tested in triplicate; 
error bars are standard deviations of the mean.  Long transcripts of BV, PV and TMEV induced 
a significant response over mock, the other transcript  did not (P < 0.05, unpaired t test); 4 kb 
transcripts of BV, PV and TMEV induced a significant response over mock, the other transcripts 
did not (P < 0.05, unpaired t test); the response to the 4 kb transcripts was significantly lower 
with the 4 kb transcripts of PV and TMEV compared to long (P < 0.05, unpaired t test). 
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Figure 5.13  Expression of luciferase reporter in A549 cells following transfection of predicted 
GORS (blue bars) and non-GORS (green bars) viral RNA transcripts, long transcripts (dark 
blue/ green bars) and 4 kb transcripts (light green/blue bars); transcripts tested in triplicate; error 
bars are standard deviations of the mean.  All long a d 4 kb transcripts induced a significant 
response over mock except for PEMV, 4 kb and long, a d SFV long. (P < 0.05, unpaired t test); 
4 kb transcripts of RV and SFV induced a significantly greater response than long (P < 0.05, 
unpaired t test); long transcripts of BV, PV and TMEV induced a significantly stronger response 
than other long transcripts, but there was no significant difference in degree of induction across 
the 4 kb transcripts(P < 0.05, unpaired t test). 
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Figure 5.14  Expression of luciferase reporter in A549 cells following transfection of 4 kb 
transcripts predicted GORS (blue bars) and non-GORS (green bars) viral RNA transcripts, 
phosphorylated (dark blue/ green bars) and dephosphorylated transcripts (light green/blue bars); 
transcripts tested in triplicate; error bars are standard deviations of the mean.  All 
phosphorylated 4 kb transcripts induced a significant response above mock but for PEMV (P < 
0.05, unpaired t test); dephosphorylated transcripts of GBV-C, MNV and BV induced a 
significant response above mock, the others did not (P < 0.05, unpaired t test); there was a 
significant difference between the strength of signal by phosphorylated and dephosphorylated 
transcripts in HCV, MNV, BV and SFV, but not the others (P < 0.05, unpaired t test). 
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5.3.6  IFN-β induction: dose response to long and 4 kb RNA transcripts 
With the pattern of IFN-β induction consistent throughout the panel of GORS 
and non-GORS viral RNA transcripts used in this study, the next step in this 
study was to perform a dose response experiment of both the long and 4 kb 
transcripts.  For this experiment, the amount of long transcripts transfected into 
the cells was based on copy number rather than mass.  The previous experiments 
had used 500 ng of each transcript transfected per well, which was equivalent to 
1 x 1011 copies of the GBV-C transcript.  Taking 1 x 1011 copies as a starting 
point, the following copy numbers of each transcript were transfected into 
NIH3T3 cells: 2.2 x 1011, 1 x 1011, 4.4 x 1010, 2 x 1010 and 8.8 x 109 copies.  
Figure 5.15 shows that the BV transcript copy numbers that induce the most 
strongly are ,1 x 1011 and 4.4 x 1010, higher and lower copy numbers induces 
less strongly; copy number has little effect on the degree of IFN induction by 
GBV-C i.e. there is little or no induction.  Figure 5.16 shows the first three copy 
numbers inducing strongly, but the strength of the signal declines thereafter.  A 
similar dose response study was conducted with the 4 kb transcripts.  Figure 
5.17 shows a dose response from 1 x 1011, 4.4 x 1010 and 2 x 1010 copies of 
GBV-C, MNV and BV measured by real-time PCR; figure 5.18 shows a dose 
response from 5 x 1010, 3.8 x 1010, 2.5 x 1010, and 1 x 1010 copies measured by 
luciferase assay.  The results are similar to those seen in the longer transcripts in 
that as the copy number is reduced, so is the levelIFN-β induction from by the 
transcript previously shown to be an inducer.  There is no effect by altering the 
copy number on the ability to induce an IFN response i  those transcripts that 
have never previously shown that capability. 
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Figure 5.15  IFN-β induction in NIH3T3 cells – dose response to long transcripts of GBV-C 
(blue bars) and BV (green bars) RNA transcripts measured by real-time PCR; each time point 
was analysed in triplicate; error bars are standard eviations of the mean.  The first, second and 
fifth copy numbers of GBV-C induced a significant response above mock, but there is no 
apparent pattern according to copy number; BV induce  a significant response at all copy 
numbers but was significantly higher than GBV-C from 1 x 1011 to 2 x 1010 (P < 0.05, unpaired t 
test). 
 























































































































Figure 5.16  IFN-β induction in NIH3T3 cells – dose response to long transcripts of MNV (blue 
bars) and TMEV (green bars) RNA transcripts measured by real-time PCR; each time point was 
analysed in triplicate; error bars are standard deviations of the mean.  Only the highest copy 
number of MNV induced a significant response above mock, whereas all copy numbers of 
TMEV did and was significantly higher than MNV from 1 x 1011 to 2 x 1010 (P < 0.05, unpaired 






Figure 5.17  IFN-β induction in NIH3T3 cells – dose response to 4 kb transcripts of GBV-C, 
MNV (blue bars) and BV (green bars) RNA transcripts measured by real-time PCR; ; each time 
point was analysed in triplicate; error bars are standard deviations of the mean.  GBV-C and 
MNV only induced a significant response at 4.4 x 1010 copies, whereas BV induced a significant 
response at all copy numbers and induced a significa tly greater response than GBV-C or MNV 
at all copy numbers (P < 0.05, unpaired t test). 
 






















































































Figure 5.18  Expression of luciferase reporter in NIH3T3 cells – dose response to 4 kb 
transcripts of GBV-C (blue bars) and BV (green bars) RNA transcripts; transcripts tested in 
quadruplicate; error bars are standard deviations of the mean.  GBV-C did not induce a 
significant response at any copy number, whereas BV induced a significant response at every 
copy number and induced a significantly greater respon e than GBV-C at all copy numbers 
except 1 x 1010 (P < 0.05, unpaired t test). 
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5.4  Discussion 
RNA plays a vital role in biology; eukaryotic cells contain their genetic 
information in dsDNA, but RNAs are essential in the transcription and 
translation of those genes into proteins.  It has also been shown in recent years 
that the regulation of RNA production and degradation is an important factor in 
the regulation of gene expression (reviewed by Garneau et al., 2007).  RNA also 
makes up the genetic makeup of many viruses that par sitize cells.  The RNA 
genomes, if they are positive sense, can be translated directly by host ribosomes; 
negative sense genomes have to undergo a round of transcription to create a 
positive sense RNA molecule.  Cellular mRNAs have 5’ caps by which they 
interact with ribosome, and while some RNA viruses also have 5’ caps, others 
interact with ribosomes through conserved secondary structures such as the 
IRES and CRE.  These structures generally consist of stem-loops of 200 -500 
nucleotides of extensive internal base-pairing (Belsham and Sonenberg, 1996)  
During their replication, RNA viruses also generally go through stages where 
dsRNA is generated in forms such as replicatory intermediates.  dsRNA is 
foreign to cells and is the most important of the PAMPs that viruses generate 
(Marcus, 1983).   
 
The discovery of GORS (Simmonds et al., 2004) revealed the presence of 
extensive secondary structure throughout the genomes of some genera of 
positive sense RNA viruses, and an observation was made that this phenomenon 
was associated with viruses able to establish persist nt infection in their natural 
hosts.  The studies presented here are an investigation into the possible 
mechanisms by which GORS leads to persistence.  We focused on the 
interaction of RNA transcripts of GORS and non-GORS viruses with the 
mechanisms of cellular RNA stability and the induction of IFN-β.  We 
hypothesised that the presence of GORS would lead to greater RNA stability in 
transcripts than those transcripts without GORS; and that GORS viral genomes 
would induce IFN-β less strongly than non-GORS viruses.  IFN-β induction 
studies were carried out independently by two methods, by real-time 
quantitative PCR and by a luciferase reporter assay; the findings of these studies 
are summarised below: 
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Summary of findings 
• There is no significant difference in the intra-cellular stability of GORS 
and non-GORS viral RNA transcripts 
 
• Of the panel of long transcripts of GORS and non-GORS viruses used in 
IFN-β induction studies, none of the GORS viruses (GBV-C, HCV, 
MNV, PEMV2) induced IFN-β strongly; but there was variable 
induction from the non-GORS viruses, BV, PV and TMEV inducing 
strongly but SFV and RV inducing very weakly or notinducing at all. 
 
• Dephosphorylation of the RNA transcripts greatly reduced or eliminated 
the IFN response 
 
• Transfection of transcripts into A549 NPro cells resulted in no IFN-β 
induction 
 
• Transfection of translation incapable, 4 kb RNA transcripts into NIH3T3 
cells revealed the same pattern of induction across the same panel of 
viral transcripts, although there was a reduced degree of IFN-β induction 
compared to the longer transcripts. 
 
• Transfection of translation incapable, 4 kb RNA transcripts into A549 
cells revealed that only BV induced significantly more strongly than the 
other viruses, and that there was little difference in the strength of 
induction between the other viruses. 
 
• There was a dose response in IFN-β expression according to copy 
number of RNA transcripts transfected 
 
 175 
Viral RNAs may encounter degradation by the RNase L system, an IFN 
stimulated response in which viral and cellular RNAs are degraded.  They may 
also encounter the cellular exonucleases that have a role in cellular RNA 
stability and regulation of gene expression.  These cellular exonucleases are 
likely to be the more significant enzymes that target viral genomic RNAs 
immediately after uncoating, before the IFN response produces large amounts of 
RNase L.  The avoidance of RNA decay machinery by viral RNAs can be split 
into two strategies: modulation of the host decay mechanisms and physical 
avoidance of the decay mechanisms (Sokolski et al., 2006).  During replication, 
RNA viruses often incorporate cellular elements and viral ribonucleoprotein 
(RNP) into replication complexes.  These complexes may be sufficient to shield 
replicating viruses from cellular exonucleases.  Just as significantly, they may 
shield viruses from intracytoplasmic detectors of dsRNA which induce an IFN 
response; and the IFN-stimulated 2’5’OAS activates RNase L which degrades 
cellular and viral RNAs.  Before establishing replicat on complexes, virus must 
uncoat their genomes, thus exposing their genomic RNAs to the intracellular 
environment.  The study presented here seeks to determine whether structured 
RNAs are more stable than unstructured RNA after elctroporation into NIH3T3 
cells.  The result is that there is no difference in the rate of decay of the three 
GORS viral transcripts (GBV-C, HCV, MNV) and the three non-GORS 
transcripts (BV, PV, TMEV).  These six viruses belong to different virus 
families and naturally infect different cell type in different hosts, but what this 
study shows is that in the same cell type, under th same conditions, the degree 
of secondary structure alone confers no protection against cellular RNA decay 
mechanisms.  The cellular exonucleases would seem to be unaffected by the 
presence of stem-loops or the more globular structue of the GORS transcripts 
as observed by atomic force microscopy (Davis et al., 2008).  During natural 
infections by the viruses tested in this study other factors come into play 
concerning the capacity to avoid RNA degeneration.  The 3’ UTR of HCV binds 
to the cellular protein HuR, resulting in protection against exonucleases 
(Spanberg et al., 2000).  Based on this study, it seems unlikely that secondary 
structure has a large role to play in RNA stability. 
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The observation that GORS viruses establish persistent infections in their 
natural hosts is one of the most intriguing aspects of the in original description 
of GORS.  GORS itself appeared to be a conserved feature of genomes across 
virus families, and the association with persistence was likewise maintained 
across virus families.  Initial speculation as to the mechanism behind this ability 
to persist focused on the innate cellular immune system i.e. type I IFNs.  dsRNA 
has been known to be the most important viral inducer of IFN for many years 
(Marcus, 1983) so it was hypothesised that the presence of GORS would in 
some way limit the exposure of viral RNA to reduce th level of IFN induction.  
The induction of IFN-β by viral RNA transcripts in these studies produced a 
consistent result in repeated experiments using two different experimental 
methods to measure IFN-β induction.  The transcripts were made to be 
replication incapable so that the effect was limited to the RNA molecules 
transfected.  None of the long GORS viral transcripts (GBV-C, HCV, MNV, 
PEMV2) induced IFN-β strongly; whereas of the non-GORS transcripts, BV,
PV and TMEV consistently induced a strong IFN-β response, but RV and SFV 
did not.  This result is interesting as, although is does not confirm the 
hypothesis, it raises more interesting questions.  Firstly, it is still possible that 
the presence of GORS does have a protective effect but that the RV and SFV 
transcripts have other properties that prevent them fro  inducing a strong IFN 
response.  The inclusion of PEMV2, a GORS virus that did not induce IFN, is 
that it is a plant virus, its natural host with whic  it has co-evolved is a plant, 
and it is able to parasitize plant cells.  The main mechanism of innate immunity 
in plants is RNAi, so there is no reason to suppose that a plant virus would have 
evolved any mechanism at all to evade the IFN system of mammalian cells; but 
there was still no apparent recognition of its RNA as it did not induce IFN.  An 
interesting addition to this study would have been a on-GORS plant virus to 
see if the NIH3T3 or A549 cells would have detected i s RNA as foreign.   
 
The lack of a strong response, or no response at all, with the long RV and SFV 
transcripts in either NIH3T3 cells or A549 cells, when the other non-GORS 
transcripts did induce a strong response was unexpected.  It shows that although 
the panel of transcripts did induce IFN-β to different degrees, there was not a 
simple division between GORS and non-GORS.  It is notable that both RV and 
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SFV are members of the virus family Togaviridae, and it would be interesting to 
repeat this experiment with other members of that family e.g. sindbis virus, 
eastern equine encephalitis virus, western equine enc phalitis virus, Venezuelan 
equine encephalitis virus, chikungunya virus.  This re ult is all the more 
surprising as SVF is known to induce an IFN response which acts to limits its 
spread (Fragkoudis et al., 2007; reviewed by Fazakerley, 2002).  During SFV 
infection it has also been shown that PKR acts to enhance the IFN response 
(Barry et al., 2008).  Alphaviruses, a genus of Togaviridae, are known to infect 
many cell types in many species; and NIH3T3 cells do produce an IFN response 
on infection with SFV (data not shown).  Rubella virus has also been shown to 
induce an IFN response on infection of both adult and foetal human cells 
(Adamo et al., 2007).  In this study, neither the SFV nor RV transcripts were of 
full length, as it was important to avoid RNA translation or viral replication.  
These truncated RNA transcripts may not have behaved s the genome does in 
actual infections, although the SFV and RV transcripts were of comparable 
length to the other transcripts in the panel, although in A549 cells the 4 kb 
transcripts of these two viruses appeared to lead to a greater IFN response.  This 
failure of SFV and RV transcripts to induce an IFN response remains 
unexplained and requires further study, for example by use of SFV virus-like 
particles that contain defective genomes so cannot replicate. 
 
The effect of dephosphorylating the transcripts was to markedly reduce or 
eliminate the IFN response.  As RIG-I is the receptor that detects the 5’ 
triphosphate group present on viral RNAs this result ggests that RIG-I is the 
main pattern recognition receptor detecting the transcripts in this study.  In viral 
infections, those viruses that contain groups other an triphosphate on the 5’ 
end of the genome e.g. the picornavirus or calicivirus VPg; the togavirus 7-
methylguanosine cap, will not be detected by RIG-I at all, but by MDA-5.  By 
necessity, to maintain the same experimental conditi s the different transcripts 
had to be treated equally and each experiment condute  in a single cell type.  
Whilst the result of each experiment enables the comparison of the effect of the 
different transcripts in each cell type, NIH3T3 or A549, they do not allow a 
direct inference to be made to say that the same effect will be occurring during 
natural infection.  In this study, the PV transcripts consistently induced a strong 
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IFN response, both the long truncated transcripts and the 4 kb transcripts, in 
NIH3T3 and A549 cells.  With the dephosphorylated transcripts the effect was 
reduced or eliminated, suggesting a role for RIG-I, but during infection PV as a 
picornavirus is detected by MDA-5. 
 
The experiments with 4 kb transcripts were conducted to control for differences 
in transcript length and the possibility of translation and production of proteins.  
The fact that in general the 4 kb GORS transcripts induced little or no IFN 
response in the NIH3T3 cells indicates that that lack of induction by the longer 
GORS transcripts in this cell line had not been a protein effect, and that the 
difference in IFN induction between the transcripts was almost certainly an 
RNA effect.  In NIH3T3 cells, the viruses whose longer transcripts had induced 
the most strongly still produced the strongest signals with the 4 kb transcripts, 
although the level of IFN expression was generally lower.  The difference in the 
response to longer and 4 kb transcripts may be a result of different level of 
access to the binding site of RIG-I.  The RIG-I binding site has been recently 
described by Cui and colleagues.  The C-terminal domain of RIG-I contains a 
regulatory domain (RD) which contains a zinc-binding domain which is the 
ligand binding site.  The other RLRs have a similar structure, but in RIG-I there 
is a lysine residue at the centre of the binding site which is required for 
triphosphate binding, in MDA-5 in this position there is a threonine or 
isoleucine residue.  The binding site of RIG-I is unable to detect 
dephosphorylated RNAs.  RD is a flat domain, it has a concave and convex side, 
it has dimensions of 45 Ǻ (4.5 nm) x  35 Ǻ (3.5 nm) x 30 Ǻ (3.0 nm) (Cui et al., 
2008)  Atomic forces microscopy has revealed that te transcripts of predicted 
GORS viruses GBV-C and HCV have a prolate spheroid shape.  Their 
dimensions were, for GBV-C and HCV respectively, radii of 32 nm and 30 nm 
along the x and y axes, and mean heights of each transcript molecule of 3.9 ± 1.0 
nm (Davis et al., 2008).  With GORS transcripts forming tight cluster , it may 
be that the triphosphate groups are shielded from the binding site on the RIG-I 
RD.  Figure 5.14 show the effect of dephosphorylation on 4 kb transcripts in 
A549 cells, and interestingly there is a small degre  of IFN induction by the 
dephosphorylated transcripts which had not been see in the NIH3T3 cells.  
Perhaps in this cell type there is a slightly contribution by MDA-5. 
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In A549 cells the 4 kb experiments had a different outcome.  As can be seen in 
figures 5.13 and 5.14, in this cell line the there is no significant difference 
between the strength of induction across the panel of viruses.  This is in contrast 
to the result in this cell line using the longer transcripts which is more similar to 
the result seen in NIH3T3 cells (see figures 5.4, 55 .6, 5.7).  There may be a 
difference in the exact nature of the innate defences present in these two cell 
lines.  Although the pathways of the IFN system may be shared by different cell 
types, it may be that different cell types within the body have evolved defence 
mechanisms that have been modified by exposure to viruses throughout 
evolution and have adapted to respond accordingly.  Future work in this area 
could investigate the impact of different RNAs on all kinds of cell types, and 
reveal more valuable information about the relationship between cells and RNA 
viruses. 
 
The dose response experiments have shown that the level of IFN induction is 
dose dependant.  In many persistent infections the viruses continue to replicate 
at a low level, without lysing the cell and often are clinically silent.  It would be 
interesting to establish the viral RNA copy numbers detectable during the actual 
infection by each of the viruses from this study.  According to this study, below 
~1 x 1010 viral copies per well (~5 x 104 copies per cell) there was a barely 
significant IFN response.  The transfection efficieny of Lipofectamine 2000 in 
these cells lines could have an effect on the outcome.  Transfection efficiency is 
expressed as the percentage of cells to have been transfected, although it is not 
an indication of the exact mass of RNA to be delivered into the cell cytoplasm.  
These RNA copy numbers may be also misleading as the exp riments were 
carried out in two cell types, NIH3T3 and A549, whereas in their natural hosts 
each viruses may have evolved a very particular replication strategy and innate 
immunity evasion strategy. 
 
This study has investigated some of the complex relationships that exist between 
viral RNAs and cellular mechanisms.  It is difficult to investigate the biological 
properties of the phenomenon of GORS as it exists across virus families that 
infect different hosts and different cell types.  In attempting to control for these 
 180 
variables in their design, the experiments are necessarily artificial.  It is difficult 
to infer from these studies in cell culture what the mechanism is by which the 
presence of GORS in the genome leads to persistence during natural infection.  
It is an interesting finding that there was a consistent pattern of IFN induction 
across the panel of predicted GORS and non-GORS viral transcripts, and that 
none of the long GORS viruses induced.  This could be the first indication of a 
mechanistic role for GORS in persistence, although the failure of long RV or 
SFV transcripts to induce remains unexplained.  Further investigation is required 
to highlight where within the innate immune system the transcripts are acting 
and which pathways are involved.  Future studies should broaden the scope of 
the viral transcripts used and the cell types.  Cells with various specific parts of 
the innate immune system knocked out/down could be used to assess the effect 
on RNA induced IFN.  There was also no direct relation between strength of 
IFN induction and other parameters such as genome GC content or the 
dinucleotide UA or CG ratios.  There is much to learn bout the interaction 
between viral RNA and cells, but the work presented in this chapter shows that 
that relationship is complex, and that GORS may be one part of the picture. 
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5.5 Future work 
A study for which some preliminary work was carried out, was designed to 
quantify the dsRNA in cells during infection.  A panel of predicted GORS and 
non-GORS viruses would be used to infect cells.  At the same point on their 
respective growth curves the cells would fixed and, using the anti-dsRNA 
antibody, J2 (Scicons), fluorescence-activated cellsorting (FACS) would be 
used to quantify the level of dsRNA present.  Viral copy number in cells 
infected at the same time would then be determined so that for each virus the 
level of dsRNA per virus copy number could be determined.  The hypothesis 
would be that GORS virus infection would produce less detectable dsRNA per 
viral RNA copy than non-GORS viruses. 
 
The panel of viruses chosen for the study were, the following GORS viruses: 
canine calicivirus (CaCV) (an isolate of which was kindly provided by Dr Erwin 
Duizer of the National Institute for Public Health and the Environment, 
Netherlands), ERAV and MNV; and the following non-GORS viruses: 
echovirus 11 (E11), Semliki Forest virus (provided by Prof John Fazakerley, 
University of Edinburgh) and Theilers murine encephalomyelitis virus.  Each 
virus isolate was titrated by the end-point method an titres expressed as TCID50 
/ ml.  Seven wells of a 12-well plate were seeded with the following cell types 
for each virus: 
 
CaCV - MDCK cells 
ERAV - Vero cells 
MNV - RAW 264.7 cells 
E11 - RD cells 
SFV - NIH3T3 cells 
TMEV - NIH3T3 cells 
 
Each well was infected with the appropriate virus and the cells were collected 
and frozen at 2, 4, 6 ,8 ,10, 12 and 24 hours post-infection, and stored at -80°C.  
Total cellular RNA was extracted by the RNEasy kit (Qiagen); the RNA was 




Standard curves for quantitative real-time PCR were pr pared as described 
previously.  Briefly, RNA extracted from each virus was reverse transcribed and 
a PCR carried out.  The PCR product was purified anthe concentration 
determined by spectroscopy.  Ten-fold dilution series were made according to 
copy number and used as the standard curves.  Growth curves for each virus, 
based on intracellular viral copy number were made nd are shown on figure 
5.19 A-F.  The plan was to infect two sets of cells; at the same point on each 
growth curve to measure the intracellular viral copy number in one group and to 
quantify the level of dsRNA in the other. 
 
The anti-dsRNA, J2 (Scicons) has been used to demonstrate the presence of 
dsRNA in viral infection.  dsRNA has been detected in infections with positive-
sense, single-stranded RNA viruses, double stranded RNA viruses and DNA 
viruses, but not with negative strand RNA viruses (Weber et al., 2006).  The 
plan was to use the J2 antibody in FACS analysis to quantify dsRNA.  Some 
preliminary immunostaining of MDCK cells infected with CaCV and RD cells 
infected with E11 was carried out and multifocal, punctate bodies were seen 
(data not shown), but unfortunately the remainder of the planned experiment 
was not able to be carried out.  This experiment, had it been successful, would 
not have relied upon IFN-β expression, which as has been discussed before, may 
vary considerably between cell lines; but would have ttempted to quantify the 
















Figure 5.19 (A)  24 hour growth curve of canine calicivirus; measuring intracellular copy 
















Figure 5.19 (B)  24 hour growth curve of equine rhinitis A virus; measuring intracellular copy 
















Figure 5.19 (C)  24 hour growth curve of murine norovirus; measuring intracellular copy 








































































































Figure 5.19 (E)  24 hour growth curve of Semliki Forest virus; measuring intracellular copy 


















Figure 5.19 (F)  24 hour growth curve of Theilers murine encephalitis virus; measuring 
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Chapter 6  Final discussion 
 
Genome-scale ordered RNA structure (GORS) was first de cribed in 2004 by 
Simmonds et al.  GORS was characterised by the presence of extensive 
predicted secondary structures along the lengths of the entire genomes of certain 
single-stranded, positive-sense RNA groups or genera.  Viruses from the 
families Picornaviridae and Flaviviridae were included in the study, which 
analysed their RNA genomes by bioinformatic analysis, and it was shown that 
of the genera within those two families, some were predicted to be GORS and 
others non-GORS.  It was considered that GORS could play not fundamental 
role in virus replication as replication strategies are generally conserved within 
virus families (Simmonds et al., 2004).  Many RNA viruses have specific, 
conserved regions of secondary structure involved in replication e.g. IRES, CRE 
(Pelletier and Soenberg, 1988; Good fellow et al., 2000), but the presence of the 
extensive secondary structure in GORS appeared to be unrelated to these well 
characterised structures.  The observation was also made that there was a 
relationship between viruses that contained GORS and the ability to establish 
persistent infections e.g. HCV, GBV-C, FMDV.  It was speculated that GORS 
may be an evolutionarily maintained phenomenon as it confers an evolutionary 
advantage by contributing to viruses’ ability to become persistent.  The 
mechanism behind the contribution of GORS to persistence were unclear, but it 
was speculated that by adopting elaborate RNA secondary structures throughout 
the genome that the viruses would be able to evade recognition by cellular 
innate immunity (Simmonds et al., 2004).  Subsequent work includes further 
bioinformatic predictions of GORS, including viruses from Togaviridae and 
Caliciviridae.  It was shown that of the caliciviruses, the genus Norovirus 
contains genogroups which are predicted to be GORS (genogroup V containing 
MNV)) as well as non-GORS (other genogroups).  As part of the same study, 
the physical nature of GORS was investigated by a probe hybridization 
accessibility assay of RNA transcripts.  It was shown that the transcripts of 
predicted GORS viruses were markedly less accessibl to the probes than 
predicted non-GORS viruses.  Atomic force microscopy also revealed that 
GORS viral transcripts formed a tightly packed, conde sed shape, whereas non-
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GORS transcripts were pleomorphic and there were often protrusion of apparent 
single-stranded RNA (Davis et al., 2008) 
 
This thesis present work carried out in the investigation of GORS and its role in 
viral persistence.  There were two main paths of enquiry: the study of a GORS 
virus in cell culture and an investigation into the interaction between a panel of 
RNA transcripts of GORS and non-GORS viruses and the cellular mechanisms 
of RNA stability and innate immunity. 
 
The aim of studying a virus whose genome contains GORS was to investigate 
the association between GORS and persistence in theatural host.  The purpose 
was to identify viruses by PCR from animals with a n turally occurring 
persistent infection, which could then be analysed bioinformatically for 
secondary structure.  Laboratory strains of viruses often become cell culture 
adapted and through mutations may lose features of wild-type viruses.  The 
study of GORS viruses is somewhat complicated by the fact that some of them a 
not very convenient to work with the laboratory e.g. FMDV and HCV require 
category 3 containment facilities.  ERAV is the only other member of the genus 
Aphthovirus apart from FMDV and is predicted to be a GORS virus. It causes a 
relatively mild upper respiratory tract infection and has been shown to be 
persistently shed for several weeks post-infection (McCollum and Timoney, 
1992). We have shown the seroprevalence of ERAV in Scottish horse to be 56 
%, which is comparable to similar studies in other countries (Kriegshauser t al., 
2005; De Boer et al., 1979; Holmes et al., 1978; Steck et al., 1978).  
Unfortunately, it was not possible to isolate a wild type ERAV from an infected 
horse which could then have formed the basis of further work; and isolates 
kindly provided by the Animal Health Trust were the same strain as the 
published laboratory strain. 
 
MNV, a norovirus of the family Caliciviridae, is the ideal virus to study GORS: 
the mean MFED of the first four published MNV sequences are 6.3 – 8.5 %; it 
establishes subclinical, persistent infections in immunocompetent mice (Hsu et 
al., 2006); uniquely among noroviruses there is a cell culture system available 
(Wobus et al., 2004) and there are infectious clones making it amenable to 
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reverse genetics (Chaudhry et al., 2007).  This thesis has revealed a prevalence 
of MNV, by PCR screening of faecal samples, of 67 %; a similar value to other 
research facilities in the United States, Canada, Germany and Japan (Koto et al., 
2009; Kitajima et al., 2009).  Screening of faecal samples of wild mice revealed 
a surprisingly low prevalence, just one positive sample from a wood mouse 
(Apodemus sylvaticus) from a total of 56 samples (15 house mice (Mus 
musculus), 11 wood mice (Apodemus sylvaticus), 8 field voles (Microtus 
agrestis), and 12 bank voles (Myodes glareolus).  A much wider prevalence 
study in wild rodents would provide a more accurate figure for the prevalence of 
MNV in wild rodents.  As GORS has been associated with persistence, it would 
be expected that GORS viruses would be reasonably prevalent in wild animal 
populations, particularly if the viruses is able to replicate at a low level without 
causing a debilitating disease.  A possible reason for the prevalence in 
laboratory mice being higher than that in wild mice s the absence of Mx in 
many laboratory mouse strains (Staeheli et al., 1988).  Mx is one of the IFN 
induced genes that plays a role in the antiviral stte, and the lack of Mx may 
make it easier for persistent infections to become established; wild animals will 
have fully competent immune systems.  It is also true that MNV infection in 
immunocompetent mice is clinically silent, and its di covery by Karst et al. in 
2003 was as the cause of widespread disease in a seriously 
immunocompromised, RAG/STAT-/- mouse.  It is likely that MNV has existed 
in research facilities for some time before its discovery.  The effect of the 
presence of MNV in laboratory mice in other studies s a current line of 
investigation, and has been shown to have little or no effect on experiments with 
murine cytomegalovirus (Doom et al., 2009) or on the adaptive immunity to 
vaccinia virus or influenza A virus (Hensley t al., 2009).  Laboratory mice are 
also bred and live together in enclosed environments, allowing easier spread of 
pathogens; wild mice may not live in such density.  It is interesting that the pet 
shop mouse samples were also positive for MNV as they are bred and raised in 
captivity and may live at a higher population density than wild mice.  
Phylogenetic analysis of the novel MNVs showed thate laboratory mouse and 
pet shop mouse MNVs were closely related to all previously published MNVs.  
The wood mouse MNV identified in this study may well be the first identified 
member of a new genetic cluster/genotype of norovirus genogroup V.  Current 
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published norovirus classifications (Zheng et al., 2006) state that while the other 
norovirus genogroups contain different cluster, theMNVs made up a single 
cluster in genogroup V.  This study demonstrates that there are likely to be more 
noroviruses in wild rodent species, and that maybe norovirus genogroup V has 
further undiscovered clusters; the data presented in this thesis provide the first 
evidence of that. 
 
Bioinformatic analysis of the complete / almost complete genomes of these 
novel MNVs revealed them to be GORS viruses.  The fact that the wood mouse 
virus can be classified as a member of genogroup V, and it genome also contains 
GORS agrees with previous observation on the distribution of GORS within the 
genus.  The presence of GORS in the novel laboratory m use MNVs also agrees 
with the description of MNV as a clinically silent, persistent infection in 
immunocompetent mice.  The passage study of MNV-3 was designed to assess 
the impact of cell culture adaptation on GORS.  The fact that, after 33 passages, 
there were so few mutations means that there was likely to be very little effect 
on the degree of secondary structure.  The changes were non-synonymous so 
there must have been a degree of selection pressure during the passage series.  It 
is unclear what those adaptations may have been.  This study could be greatly 
expanded in the future study of the effect of GORS in viruses.  Cell lines with 
various parts of the innate immune system knocked out c uld be generated, the 
hypothesis being that removing pressure from the immune system would make it 
less of an advantage for the virus to maintain that degree of genomic secondary 
structure.  It is already known that mice the RAG/STAT-/- are susceptible to 
MNV-1, a challenge study of knockout mice deficient in various immune genes 
could provide an insight into the mechanism of persistence by tracking the 
course of infection.  It is certainly easier to consider experiments of this kind in 
mice with MNV than in horses with ERAV, cattle with FMDV or chimpanzees 
with HCV for example. 
 
The relationship between viruses and the immune system is particularly 
complex.  Many viruses, over the course of their co-ev lution with their hosts, 
have developed a panoply of means to evade aspects of the immune system in 
order to survive.  Eukaryotic cells have likewise developed innate and adaptive 
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immune system in order to counteract the actions of invading pathogens.  
dsRNA is the most important pathogen associated molecular pattern (PAMP) 
produced during viral infections.  It was speculated that the mechanism behind 
the ability of GORS viruses to establish persistence was as a result of the 
genome-scale structure to evade detection by cellular receptors by mimicking 
the structured elements of cellular RNAs.  It must be pointed out that many 
viruses have evolved mechanisms to evade certain aspects of the innate or 
adaptive immune systems (see Chapter 1), but that not all of them are persistent; 
although in order to become persistent, viruses must prevent themselves from 
being destroyed by the host.  The work presented in this thesis investigates the 
effect of transfecting RNA transcripts of GORS and non-GORS viruses into 
cells and measuring the rate of decay of those transc ipts, and their capacity for 
IFN-β induction.  This experimental design is necessarily rtificial in that these 
transcripts from a panel of viruses, which naturally infect a broad range of cell 
types in different hosts, were transfected into twocell types, NIH3T3 and A549.  
The experiments were carried out in this way to eliminate others variables so 
that the only variable feature was the degree of secondary structure present in 
the transcripts.  In natural infections, the importance of the presence of GORS in 
the viral genomes is likely to be most significant fter uncoating; at this time the 
viral RNA is released into the cytoplasm where it goes on to interact with 
ribosomes to be translated.  Production of the viral proteins and the 
establishment of replication complexes associated with cellular organelle 
membranes is likely to restrict the access of the cytoplasmic dsRNA receptors 
RIG-I and MDA-5.  Other points in the viral life cyle that involve dsRNA 
include the production of replicatory intermediates and production of new 
progeny RNA genomes that go on to encapsidation, but again, there is likely to 
be shielding from cytoplasmic receptors during these processes.  The 
transfection experiments presented, in which RNA is delivered to the cytoplasm, 
most resembles the situation after genome uncoating.  The hypothesis of the 
study states that GORS genomes would induce IFN-β less strongly than non-
GORS genomes; but the results are interesting in that while the GORS virus 
transcripts did indeed induce IFN weakly, the non-GORS transcripts were gave 
a variable response.  It raises the question of the role of structure in the nature of 
the response, as well as what other factors may be involved in explaining the 
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differences observed.  The plant virus PEMV2, a predict  GORS virus, failed 
to induce an IFN-β response.  As a plant virus it will never have needed to 
evolve any other mechanism to avoid IFN as plant cells used RNAi as their 
mechanism of innate immunity (reviewed by Umbach and Cullen) – so the 
degree of secondary structure may have been the feature that prevented it from 
inducing a response in the mammalian cells, the RNA would certainly have been 
foreign to them.  The failure of the SFV and RV transcripts is particularly 
surprising as i) they are both predicted non-GORS viruses and ii) they are both 
known to induce an IFN response in their natural infections and in cell culture 
(Fazakerley, 2002; Adamo et al., 2007).  The reason for this is still unclear, but
they both belong to the same family, Togaviridae, and there may be feature of 
togavirus RNA that has prevented these two transcripts from inducing IFN 
under these experimental conditions.  While it was necessary for these studies to 
perform the experiments with all the viral transcripts simultaneously in the same 
cell line, it does not accurately reproduce the conditions during natural infection 
by each of these viruses in their own host cells.  On the other hand, GORS is a 
feature that is observed across virus families and genera and is invariably 
associated with persistence, so the mechanism behind t e role of GORS in 
persistence may common to all GORS viruses.  Further work to investigate the 
interaction between GORS and non-GORS containing RNAs will be necessary 
to further elucidate the mechanisms behind the associated of GORS and 
persistence.  The different reaction of NIH3T3 cells and A549 cells to the 4 kb 
transcripts also raises more questions.  By making the 4 kb transcripts many 
variables could be removed from the experiment to focus the experiment 
uniquely on the effect of RNA secondary structure; but in nature the relationship 
between viral genomes and cells could be much more c mplicated and the 
presence of GORS may be only be part of a bigger picture.  The longer 
transcripts are more likely to be representative of the situation during natural 
infection, and the division between those transcripts that induced IFN strongly 
and those that induced weakly or not at all was more marked in the long 
transcript experiments. 
 
An experiment planned but unfortunately not completed, would have quantified 
intracytoplasmic dsRNA by means of FACS analysis using the anti-dsRNA 
 192 
antibody, J2, during infection by a panel of GORS and non-GORS viruses.  This 
could have given an indication as to the potential of each viruses to induce an 
IFN response; IFN could not be measure directly as m ny cell culture lines have 
deficiencies in parts of the innate immune system e.g. IFN deficiency in Vero 
cells. 
 
This thesis set out to investigate the presence of GORS in positive-sense RNA 
viruses and its role in viral persistence.  The investigation into MNV has 
confirmed that it is a common, subclinical infection f laboratory mice, is 
present in pet shop mice, and that a potentially new g netic MNV cluster exists 
in wild rodents; all of which have GORS; also that multiple passage in RAW 
264.7 cells had little effect on the genome sequence.  It has shown that GORS 
and non-GORS viral transcripts do not degrade at different rates after 
electroporation into cells.  It has also shown, intriguingly, that transfection of a 
panel GORS and non-GORS viral RNA transcripts produce a marked variability 
in IFN-β induction, which while not confirming out original hypothesis, does 
not rule out a role for GORS in the evasion of innate immunity as a possible 
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Sequence of MNV3 – Passage 33, high moi: position 4-7351 
 
 
AAATGAGGATGGCAACGCCATCTTCTGCGTCCTCCGTGCGCAACACAGAGAACGC
AAAAACAAAAAGGCTTCATCTAAGGCTAGCGTCTCCTTTGGAGCACCTAGCCTTCTC
TCTTCGGAGAGTGAAGATGAAGTTAACTACATGACCCCTCCTGAGCAGGAAGCTCA
GCCCGGCACCCTTGCGGCCCTCCATGCCGACGGGCCGCACGCCGGGCTCCCGTGA
CGCGAAGTGATGCACGCGTGCTGATCTTCAATGAGTGGGAGGAGAGGAAGAGTCC
GAGCCGTGGCTACGGCTGGACATGTCTGATAAGGCCATCTTCCGCCGCTTCC CCAT
CTGCGGCCCAAGGAAGATAAGCCTGACGCGCCCTCCCTTGTGGAGGACGCTA GGA
TGCAAGGGAGCCCGTGATCGGGTCTATCCTTGAGCAGGATGACCACAAGTTCTACC
ACTATTCTGTCTACATCGGCAACGGCCAGGTGATGGGTGTCAACAATCCTGCGCC
GCCGTCTGCCAGGCTGTGATTGATGTGGAGAAACTCCACCTGTGGTGGAGACCAGT
CTGGGAGCCCCGCCAACCTCTCGACCCGGCTGAGTTGAGGAACTGCGTTGGCATGA
CTGTCCCTTACGTGGCAACTACTGTTAACTGCTACCAGGTTTGCTGCTGGATTGTTG
GGATCAAGGACACCTGGCTGAAGAGGGCGAAGATTTCCAGAGACTCGCCCTTCTAC
AGCCCTGTTCAGGACTGGAACATTGATCCCCAGGAACCCTTCATCCCCTCCAAGCTT
AGGATGGTCTCTGATGGTATCCTGGTGGCCCTTTCAACGGTGATTGGTCGGCCGATC
AAGAACCTGCTGGCATCTGTGAAGCCGCTCAACATCCTCAACATCGTGTTGAGCTGT
GATTGGACTTTCTCGGGGATAGTCAACGCCCTGATTCTCCTTGCTGAGCTCTTTGAC
ATCTTTTGGACCCCCCCCGATGTCACCAACTGGATGATCTCCATTTTTGGGAGTGG
CAGGCCGAAGGGCCCTTCGACCTTGCTCTGGATGTTGTGCCCACCCTCCTTGGCGGG
ATTGGCATGGCCTTCGGTCTGACATCTGAGACCATTGGGCGCAAGCTTGCCT CACC
AACTCGGCCCTCAAGGCCGCCCAGGAGATGGGCAAGTTTGCGATTGAGGTT CAA
ACAAATCATGACATGGATCTGGCCCTCTGAGGACCCGGTGCCCGCTCTGCTT CCAA
CATGGAGCAGGCTGTCATCAAGAACGAGTGCCAGCTTGAGAACCAACTCACGACCA
TGTTGCGGGACCGCAACGCTGGAGCTGAGTTCTTGAAGGCACTCGACGAAGAAGAG
CAAGAGGTCCGGAAAATTGCAGCCAAGTGTGGAAACTCTGCCACCACGGGCACAAC
CAACGCCCTGTTGGCCAGGATTAGCATGGCTCGCGCAGCCTTTGAGAAGGCT GCG
CTGAGCAGACTTCCCGGGTTCGCCCCGTAGTGATTATGGTCTCTGGCAGGCC GGGA
TCGGGAAAACTTGTTTTTGCCAGAACCTAGCAAAGAGAATTGCTGCCTCCCTCGGG
GATGAGACCTCAGTCGGCATCATACCGCGCGCCGACGTGGACCACTGGGATGCCTA
CAAGGGCGCCAGGGTGGTCCTCTGGGATGATTTTGGCATGGACAATGTGGTGAAGG
ATGCACTGCGGCTGCAGATGCTTGCTGACACATGCCCCGTCACGCTCAACTGTGACA
GGATTGAGAACAAGGGGAAGATGTTTGATTCTCAAGTTATCATCATCACCACGAAC
CAGCAGACCCCAGTGCCTTTGGATTATGTCAACCTTGAGGCGGTCTGCCGCCGCATA
GACTTCCTGGTCTATGCCGAGAGCCCCGTGGTCGACGCTGCCCGAGCCAGGTCACC
GGGCGACGTGGCCGCTGTCAAGGCCGCTATGAGGCCAGACTACAGCCATATCAATT
TCATCTTGGCACCGCAGGGTGGCTTTGACCGGCAGGGCAACACCCCCTACGGCAAG
GGCGTCACTAAGATCATCGGCGCCACCGCGCTCTGTGCAAGGGCGGTCGCTTGTC
CATGAGCGTCATGATGATTTTGGCCTCCAGAACAAAGTCTATGATTTTGATGCTGGC
AAGGTTACCGCCTTCAAGACCATGGCGGCTGATGCCGGCATCCCCTGGTACAGAT
GGCAGCGATTGGCTACAAGGCCATGGGCTGCACCTGCGTGGAGGAAGCCATGAACC
TACTCAAGGACTATGAGGTGGCCCCGTGCCAGGTGATCTACAACGGAGCCACCTAC
AATGTCAGCTGCATCAAGGGGGCGCCCATGGTTGAGAAAGTCAAGGAGCCTGAGCT
GCCCAAAACCCTAGTCAATTGTGTCAGGAGGATCAAGGAGGCCCGCCTCCGCTGCT
ATTGCAGGATGGCCACAGATGTCATCACCTCCATCCTGCAGGCGGCTGGGACAGCC
TTCTCTATCTACCACCAGATTGAAAAGAAAACCAGACCCTCTTTCTACTGGGACCAT
GGCNACACCTACCGTGATGGCCCGGGTGCCTTTGACCTCTTTGAGGACGAC---
AATGATGGATGGTACCATTCTGAGAGCAAGAAGGGTAAGAACAAGAAGGGCCGAG
GGCGGCCCGGTGTCTTCAAATCCCGTGGGCTCACGGATGAGGAGTACGATGA TTC
AAGAAGCGCCGCGAGTCCAAGGGCGGCAAGTACTCCATTGATGATTACCTCGCTGA
CCGCGAGAGGGAAGAGGAACTCCAGGAGCGTGATGAGGAGGAGGCCATCTTCGGG
GATGGCTTTGGCCTGAAGGCCACACGCCGCTCCCGCAAAGCAGAGAGGGCCAGGCT
TGGCCTAGTCTCGGGTGGTGACATCCGCGCCCGCAAGCCAATTGACTGGAATGTGG
TTGGCCCCTCCTGGGCTGATGATGACCGCCAAGTTGACTACGGTGAGAAGATCAGC
TTCGAGGCCCCAGTCTCCATTTGGTCCCGCGTCGTACAGTTCGGCACGGGATGGGGC
TTTTGGGTTAGCGGCCATGTGTTCATCACCGCTAAACATGTGGCGCCACCCAAGGGC
ACCGAGGTGTTCGGGCGCAAGCCCGAGGAATTCACCGTCACCTCCAGTGGGGACTT
CCTGAAATACCACTTCACCAGTGCCGTCAGGCCTGACATTCCTGCCATGGTTCTTGA
 260 
GAATGGCTGCCAGGAGGGCGTTGTTGCCTCGGTCCTCGTTAAGAGGGCCTCGGTG
AGATGCTCGCCCTGGCGGTCAGGATGGGCTCGCAGGCAGCCATCAAGATCGGCAAC
GCTGTGGTGCACGGACAGACTGGCATGCTTCTGACTGGTTCCAATGCCAAAGCCCA
AGACCTCGGGACCATCCCGGGCGATTGTGGTTGCCCCTATGTCTACAAGAAAGGAA
ACACCTGGGTTGTGATTGGGGTGCACGTGGCGGCCACTAGATCGGGCAACACGTG
ATCGCCGCCACTCATGGAGAGCCCACCCTTGAGGCTCTGGAGTTCCAGGGACCTCC
CATGCTCCCTCGCCCCTCCGGCACCTATGTAGGTCTCCCCATTGCCGACTACGGTGA
TGCCCCTCCCCTGAGTACTAAGACCATGTTCTGGCGCACCTCGCCAGAGAAGCTCCC
CCCCGGGGCTTGGGAGCCAGCTTACCTGGGCTCCAAGGATGAGAGAGTGGACGGCC
CCTCCCTGCAACAGGTCATGCGGGACCAGCTCAAGCCCTACTCAGAGCCGCGTGGC
TTACTCCCCCCCCAGGAGATTTTGGATGCGGTTTGTGATGCCATCGAGAACGCCTT
GAGAACACCCTTGAACCGCAGAAGCCCTGGACATTTAAGAAGGCCTGCGAGAGTCT
GGATAAGAACACCAGCAGTGGGTATCCTTACCATAAGCAAAAGAGCAGGGACTGG
ACAGGGACTGCCTTCATTGGTGAGCTCGGTGATCAAGCCACCCATGCCAACAACAT
GTATGAGATGGGTAAGTCCATGCGGCCCGTTTACACGGCTGCCCTCAAGGATGAGT
TGGTTAAACCAGACAAGATCTACAAGAAGATAAAGAAAAGGCTTCTGTGGGGCTCT
GACCTTGGCACCATGATTCGCGCTGCTCGCGCTTTTGGCCCCTTCTGTGATGCTTTGA
AGGAGACTTGTGTTCTCAACCCTGTCAGAGTGGGCATGTCAATGAACGAGGATGGG
CCCTTCATCTTCGCGAGACANGCCAACTTCAGGTACCACATGGATGCAGACTACAC
CAGATGGGACTCCACTCAGCAGAGGGCCATCTTGAAGCGCGCTGGTGATATCATGG
TGCGCCTCTCCCCCGAGCCAGAACTGGCCCGGGTGGTAATGGATGACCTCCTGGCC
CCCTCGCTGCTGGACGTTGGCGACTACAAGATCGTCGTCGAAGAAGGACTTCCGTCT
GGTTGCCCCTGCACCACACAGCTGAATAGTTTGGCCCACTGGATTTTGACCCTCTGC
GCAATGGTTGAAGTGACCCGAGTTGACCCTGACATTGTGATGCAAGAGTCTGAATT
TTCTTTCTATGGTGATGACGAGGTGGTCTCGACCAACCTCGAATTGGACATGACCAA
GTACACCATGGCTCTGAAGCGGTACGGTCTCCTCCCGACTCGTGCGGACAAGGAGG
AGGGGCCCCTGGAGCGTCGTCAGACGCTGCAGGGCATCTCCTTCCTACGCCG GCG
ATAGTCGGTGACCAGTTTGGCTGGTACGGTCGCCTCGATCGTGCTAGCATTGACCGC
CAGCTTCTCTGGACTAAAGGACCCAACCATCAGAACCCCTTTGAGACTCTTCCCGGA
CACGCCCAGAGACCCTCCCAATTGATGGCCCTGCTCGGTGAGGCTGCCATGCATGG
TGAAAAGTATTACAGGACTGTTGCTTCCCGGGTCTCCAAGGAAGCAGCCCAGAGTG
GGATAGAAATGGTGGTCCCACGCCACCGGTCTGTTCTGCGCTGGGTGCGCTT GGA
ACAATGGATGCTGAGACCCCGCAGGAACGCTCAGCAGTCTTTGTGAATGAGATGA
GTGATGGCGCAGCGCCAAAAGCCAACGGCTCTGAAGCCAGCGGCCAGGATCTTGTT
CCTACCGCCGTTGAACAGGCCGTCCCCATTCAGCCCGTGGCTGGCGCGGCTCTTGCC
GCCCCCGCCGCCGGGCAAATCAACCAGATTGACCCATGGATCTTCCAAAATTTTGTC
CAATGCCCCCTTGGTGAGTTTTCCATTTCACCCCGAAACACCCCAGGTGAATACTG
TTTGATTTGGCCCTCGGACCGGGGCTCAACCCCTACCTCGCCCACCTCTCAGCCATG
TACACCGGCTGGGTTGGGAACATGGAGGTTCAGCTGGTCCTCGCCGGCAATGCCTTT
ACTGCTGGCAAGGTGGTTGTTGCCCTTGTACCACCCTATTTTCCCAAAGGGTCACTC
ACCACTGCTCAGATCACATGCTTCCCACATGTCATGTGTGATGTGCGCACCTGGAG
CCCATTCAACTTCCCCTTCTTGACGTGCGTCGAGTTCTTTGGCATGCTACCCAGGATC
AGGAGGAATCTATGCGCCTGGTTTGCATGTTGTACACGCCACTCCGCACAACAGC
CCGGGTGATGAGTCTTTTGTGGTCTCTGGCCGCCTTCTTTCTAAGCCGGCGGCTGAT
TTCAACTTTGTATACCTGACCCCCCCCATCGAGAGGACCATCTACCGAATGTCGAC
CTGCCCGTGTTGCAGCCGCGGCTGTGCACGCACGCTCGTTGGCCAGCCCCGGTCTAT
GGCCTCTTGGTTGACCCGTCCCTCCCGTCCAACCCCCAATGGCAGAATGGAAGAGT
GCACGTTGATGGAACCCTTCTTGGCACAACACCTGTCTCTGGTTCCTGGGTT CCTG
CTTTGCAGCAGAAGCCGCCTACGAGTTCCAGTCTGGGATTGGTCAGGTGGCGACCTT
CACCATGATTGAGCAGGACGGGTCTGCCTACGTCCCTGGTGACAGGGCGGCC CCC
TTGGCTACCCCGATTACTCCGGGCAACTGGAGATTGAGGTGCAGACTGAGACCACC
AAAGCAGGTGACAAGCTGAAAGTGACCACCTTTGAGATGATCCTTGGTCCCACTAC
CAACGCGGACCAGGCTCCCTACCAGGGTAGAGCGTATGCGAGCTTAACGGCTGCAG
CCTCACTCGACCTGGTAGACGGGAGGGTTAGGGCGGTCCCCCGCTCTATCTACTCCT
TCCAGGACGTGCTCCCAGAGTACAATGATGGTCTTTTGGTCCCCCTTGCCCCACCCC
TGGGTCCCTTCCTTCCCGGTGAGGTCTTGTTGAGGTTCCGAACCTACATGC CAGC
TTGACACCGCTGACGCCGCGGCGCAGCCGATTGACTGTGCCTTGCCCCAGGA TTC
GTCTCTTGGTTCGCAAGCAACAGCTTCACGGTCCAGTCGGACGCGCTCCTGGTTAGG
TACCGGAACACCTTGACCGGCCAGCTCCTGTTCGAGGCTAAGCTCTATAGTGAAGG
CTACATTGCTGTGTCTTATTCAGGATCTGGCCCCCTCACTTTTCCCGCCGACGGCATC
 261 
TTCGAGGTCGTTAGTTGGGTCCCCCGCCTCTTTCAATTGGCCTCTGTGGGAAGCTTG
GCAACAGGCCGAACACTCAAACAATAATGGCTGGTGCTCTTTTCGGAGCGATTGGA
GGTGGCCTGATGGGCATAATTGGCAATTCCATCTCAACAGTTCAGAACCTTCAGGC
AAATAAACAATTGGCTGCACAACAATGTGGCTACAATTCCTCTTTGCTTGCAACGCA
AATTCAGGCCCAGAAGGATCTCACACTGATGGGGCAGCAATTCAACCAGCAGCTCC
AAGCCAACTCTTTCAAGCACGACCTTGAGATGCTTGGCGCCCAGGTGCAAGCCCAG
GCGCAGGCTCAGGAGAACGCCATCAACATCAAATCGGCGCAACTCCAGGCCGCAG
GCTTCTCAAAGTCCGACGCCATACGCCTGGCCTCAGGGCAGCAACCGACGAGGGCC
GTCGACTGGTCGGGGACGCGGTATTACACCGCTAACCAGCCGGTTACGGGCTTCTC
GGGTGGCTTCACCCCAAGTTACACTGCAGGTAGGCAAATGGCAGTCCGCCCTGTGG
ACACATCCCCTCTGCCGGTCTCGGGTGGGCGCATGCCGTCCCTTCGTGGAGGTTCCT
GGTTTCCGCGTGATTACACGCCGCAGACTCAAGGCACCTACACGAACGGTCGGTTT
GTGTCCTTCCCAAAGATCGGGAGTAGCAGGGCATAGGTTGGAAGAGAAATCTTTCT
GTGAAAATGATTTCTGCTTACTGC 
  
 
